Temperature-dependent efficacy of the IFN-alpha/beta response against chikungunya and other arboviruses by Lane, Whitney
 TEMPERATURE-DEPENDENT EFFICACY OF THE IFN-α/β RESPONSE AGAINST 
CHIKUNGUNYA AND OTHER ARBOVIRUSES 
 
 
 
 
 
 
 
 
by 
Whitney Christine Lane 
B.S. in Biology, Purdue University-Fort Wayne, 2012 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
The School of Medicine in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy in Molecular Virology and Microbiology 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2018 
 
 ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Whitney Lane 
 
 
 
It was defended on 
July 10, 2018 
and approved by 
William Klimstra, PhD, Associate Professor of Immunology 
Neal DeLuca, PhD, Professor of Microbiology and Molecular Genetics 
Robert Binder, PhD, Associate Professor of Immunology 
Amy Hartman, PhD, Assistant Professor of Infectious Diseases and Microbiology 
John Williams, MD, Professor of Pediatrics 
Doug Reed, PhD, Associate Professor of Immunology 
 Dissertation Advisor: William Klimstra, PhD, Associate Professor of Immunology 
 
 
 iii 
Copyright © by Whitney Lane 
2018 
 iv 
 
Chikungunya virus (CHIKV) is a mosquito-transmitted arbovirus in the genus Alphavirus that 
has reemerged in recent years to cause explosive epidemics of acute and chronic arthritic disease 
across the globe. Like other arboviruses, CHIKV has evolved to replicate efficiently in both its 
arthropod vector and its vertebrate hosts, which represent two very different thermal 
environments. Arthritogenic alphaviruses such as CHIKV preferentially replicate and cause 
disease in distal small joints that are lower in temperature than the body core. The type-I 
interferon (IFN-α/β) system is a critical innate immune response for controlling arbovirus 
infection. Recent evidence suggests that IFN-α/β is less effective in controlling virus infection at 
temperatures below the body core temperature. Therefore, we hypothesized that arboviruses such 
as CHIKV may exploit a weakened innate immune environment in low-temperature joint tissues 
to fuel exacerbated viral replication and disease at these sites. 
To address this hypothesis, we examined the efficacy of IFN-α/β induction and antiviral 
efficacy against CHIKV and other arboviruses at different temperatures within the normal 
physiological range. In vitro, we found that mild hypothermia significantly compromised both 
the induction and effector arms of the IFN-α/β response compared to normal or febrile-range 
temperatures against diverse arboviruses. We narrowed this effect to delayed and reduced 
transcription of effector genes, as upstream signaling pathways were not attenuated by 
hypothermia, and demonstrated differential temperature-sensitivity profiles of interferon-
stimulated gene (ISG) induction versus some lipopolysaccharide (LPS)-inducible genes. Finally, 
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mice with reduced core temperatures suffered exacerbated CHIKV replication and disease 
compared with normal mice during the acute phase of infection, and this phenotype was 
dependent upon a functional IFN-α/β system. Reduced core temperature during the first few days 
of CHIKV infection also resulted in higher persistent viral signal at chronic time points, and 
temperature reduction >30 days post infection resulted in significantly increased viral protein 
production at persistently-infected sites. Together, these data indicate that reduced tissue 
temperature results in attenuated IFN-α/β and ISG gene transcription, leaving these tissues more 
vulnerable to arboviral infection than warmer sites. CHIKV can take advantage of this dynamic 
to infect and persist in low-temperature tissues in vivo.  
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1.0  INTRODUCTION 
1.1 ARBOVIRUSES 
The term arbovirus is an abbreviation used to refer to viruses transmitted biologically between 
vertebrate hosts by a hematophagous arthropod vector (arthropod-borne virus). The World 
Health Organization defines arboviruses as “viruses which are maintained in nature principally, 
or to an important extent, through biological transmission between susceptible vertebrate hosts 
by haematophagous arthropods; they multiply and produce viremia in the vertebrates, multiply in 
the tissues of arthropods, and are passed on to new vertebrates by the bites of arthropods after a 
period of extrinsic incubation” (1). This definition excludes arthropod-transmitted plant viruses 
as well as viruses that may be vectored by an arthropod but that do not replicate within the 
vector, a mode of transmission deemed mechanical rather than biological (2). However, the term 
arbovirus does not represent a taxonomic distinction, and in fact, arboviruses comprise a highly 
diverse group, with arthropod transmission evolving convergently among phylogenetically 
distant viruses belonging to several taxa. The clinically important arboviruses fall into one of 
four taxonomic groups; family Togaviridae, genus Alphavirus, family Flaviviridae, genus 
Flavivirus, several genera in the order Bunyavirales (formerly, family Bunyaviridae) and several 
in the Reoviridae family, however arboviruses of other vertebrates that rarely infect humans are 
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also found in the Rhabdoviridae (genus Vesiculovirus) and Orthomyxoviridae (genus 
Thogotovirus) families (3, 4). 
One shared feature of all arboviruses is their ability to replicate efficiently across a broad 
temperature range due to their adaptation to both vertebrate hosts and invertebrate vectors, which 
represent two very different thermal environments. Many arboviruses, including all species 
known to infect humans, are transmitted between endothermic mammalian and/or avian hosts, 
whose core body tissues are actively maintained at a very high temperature, typically 37-39°C 
for mammals and 39-41°C for birds (5). By contrast, the arthropod vectors are ectotherms, and 
their temperatures are dependent on the ambient temperature of their environment. Within a 
human host, arboviral pathogenesis begins in the skin, at the site of the arthropod’s bite, and 
from there the virus can use the lymphatics and bloodstream to disseminate systemically, 
traversing tissues in the body core and periphery and thus encountering variable tissue 
temperatures. In addition, while many arboviruses inhabit tropical and subtropical regions where 
transmission can occur year-round, others are subject to seasonality in more temperate climates, 
which may further impact their hosts’ thermal environments, particularly during the transitions 
toward or away from peak (summer) transmission. It is currently unknown how arbovirus 
pathogenesis and disease are influenced by the thermal environment within a human host, but 
several lines of evidence suggest various components of innate and adaptive immunity are 
sensitive to temperature variation, which could, in turn, impact the course of an arbovirus 
infection. In this section, I will introduce some of the most medically and agriculturally 
impactful arboviruses and their associated diseases and describe the features of arbovirus 
ecology and pathogenesis that are common to most species. 
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1.1.1 Major characteristics of arbovirus genera and associated diseases 
1.1.1.1 Genus Alphavirus 
The alphaviruses are a genus of positive-sense single-stranded RNA (ssRNA) viruses in the 
family Togaviridae. The 60- to 70-nm, spherical alphavirus particle consists of a nucleocapsid 
core surrounded by a host cell plasma membrane-derived lipid envelope studded with 
glycoprotein spikes (6). The genomic RNA is contained in the nucleocapsid protein shell. 240 
copies of the capsid protein are arranged around the genome in T=4 icosahedral symmetry (7-9). 
The viral envelope glycoproteins, E1 and E2, form trimers of heterodimers that protrude from the 
lipid envelope as 80 spike structures, such that 240 total copies each of E1 and E2 interact with 
the 240 copies of capsid (8, 10-12). The alphavirus genome measures between 11 and 12 kb in 
length (6) and bookended with a 5’ type-0 7-methyguanosine cap and a 3’ poly-A tail along with 
5’ and 3’ untranslated regions (UTRs) (13-16). The nonstructural proteins, nsPs 1 through 4, are 
encoded as a single open reading frame in the 5’ proximal end of the RNA, while the structural 
proteins, capsid, E3, E2, 6K/TF, and E1, are expressed off a subgenomic promoter 3’ to the 
nonstructural proteins (6, 17). The Alphavirus genus (commonly, alphaviruses) comprises over 
30 species, the vast majority of which are known to be arthropod-vectored (18). These species 
can be subdivided further into seven antigenically similar complexes, Barmah Forest, eastern 
equine encephalitis, Middleburg, Ndumu, Semliki Forest, Venezuelan equine encephalitis, and 
Western equine encephalitis serocomplexes (19). Most alphaviruses are transmitted between 
mammalian or avian hosts by mosquito vectors, but some are thought to be mite- or louse-borne 
(6, 20). Beyond antigenic complexes, alphaviruses historically have been grouped based on both 
geographic range and human or veterinary disease phenotype. Alphaviruses found predominantly 
on the continents of Australia, Africa, Europe, and/or Asia tend to cause a febrile illness 
 4 
associated with joint pain and rash, and have thus been designated the Old World, arthritogenic 
alphaviruses (19, 21). Analogously, alphaviruses geographically restricted to the Americas 
primarily cause acute encephalitis, and thus became known as the New World, encephalitic 
alphaviruses (19, 22). However, these geographic designations do not accurately reflect the true 
distributions of all alphaviruses.  
Members of both the Old World and New World alphaviruses are known to cause disease 
in humans and livestock. Eastern, western, and Venezuelan equine encephalitis viruses (EEEV, 
WEEV, and VEEV) are medically and agriculturally important New World alphaviruses while 
CHIKV, Ross River virus (RRV) and Sindbis virus (SINV) are the Old World alphaviruses most 
commonly associated with human infections. Most alphaviruses in fact do not infect humans and 
instead exhibit a very broad vertebrate host range, with various non-human primates, equids, 
rodents, birds, and fish serving as hosts for different alphaviruses (6, 23, 24). EEEV, VEEV, and 
WEEV are encephalitic alphaviruses that typically cause a low incidence of human disease but 
EEEV and VEEV have been known to cause large epizootic outbreaks in horses (25-27). VEEV 
has also been known to cause infrequent but explosive outbreaks of human disease in South 
America (28). The severity of human encephalitis caused by these viruses can range from 
subclinical to lethal. North American strains of EEEV, for example, have case-fatality rates 
between 35 and 75% (22, 29, 30). Nonfatal encephalitic cases of any of these viruses can result 
in mild to severe neurological sequelae (31). Most WEEV and VEEV cases in humans do not 
progress to encephalitis and are either asymptomatic or acute and mildly symptomatic, 
presenting with flu-like symptoms and fever and resolving within 1 to 2 weeks (22, 32). Unlike 
the encephalitic alphaviruses, the arthritogenic species are associated with low mortality but very 
high morbidity in humans. SINV, RRV, and CHIKV are examples of arthritogenic alphaviruses 
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commonly associated with human disease, especially CHIKV, which has reemerged on a 
pandemic scale in the last 15 years (33). These viruses cause an acute febrile illness and severe, 
debilitating joint pain that can persist for years after infection (21). 
1.1.1.2 Genus Flavivirus 
Viruses in the genus Flavivirus, family Flaviviridae, are, like the alphaviruses, enveloped, 
positive-sense ssRNA viruses. They are slightly smaller than alphaviruses, with particle 
diameters near 50 nm and a genome length of approximately 11 kb (34). Genomic RNA is 
contained within the nucleocapsid, encased by a coat of capsid proteins. Surrounding the 
nucleocapsid core is a host cell-derived lipid envelope in close association with the viral 
membrane protein (35). The surface of the flavivirus virion is covered completely with the 
envelope protein, which forms homodimers that lie parallel to the virion surface, giving mature 
flavivirus particles a smooth appearance (36, 37). The flavivirus genome is organized oppositely 
of that of the alphaviruses, with the structural proteins encoded 5’ of the nonstructural proteins 
on a single ORF (38). The genomic RNA is capped at the 5’ end but lacks a poly-A tail, and 
contains both 5’ and 3’ noncoding regions (39). Phylogenetic analysis has revealed that 
divergence from the ancestral virus occurred along two primitive lineages according to 
transmission vector, yielding sister taxa of tick-borne and mosquito-borne flaviviruses (40). The 
mosquito-borne flaviviruses further diverged according to usage of Culex versus Aedes species 
mosquitoes (40, 41). Today, there are over 60 recognized species of flaviviruses, many of which 
are pathogens of humans and livestock (42). 
Many flaviviruses commonly associated with human disease are mosquito-borne species 
that cause exotic tropical fevers, such as Dengue virus (DENV), yellow fever virus (YFV) and 
Zika virus (ZIKV). However, other flaviviruses such as Japanese Encephalitis virus (JEV) and 
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West Nile virus (WNV) reside in more temperate regions as well as the tropics and subtropics 
(43). In addition, the tick-borne encephalitis viruses (TBEVs) cause frequent human infections 
throughout Europe and Asia (44). This diversity has given flaviviruses a near worldwide 
distribution. Human flavivirus diseases are typically either neurological/encephalitic or 
visceral/hemorrhagic (45). Acute flavivirus infection usually elicits fever, fatigue, body aches, 
and other nonspecific, flu-like symptoms, and many cases are asymptomatic (46).  
1.1.1.3 Order Bunyavirales 
The order Bunyavirales contains over 350 viral species divided into nine families (47). Of these 
families, only one, the Hantaviridae, is not a family of arthropod-transmitted viruses (48). The 
other eight families contain a huge diversity of arboviruses as well as arthropod-vectored viruses 
of plants and invertebrates. Bunyaviruses are vectored by a plethora of different arthropods 
including mosquitoes, ticks, sand flies, and thrips, among others, and, as mentioned above, 
display incredible host diversity (48). Despite this variety, all bunyaviruses share common 
structural and genomic characteristics. Bunyavirus particles are enveloped and typically measure 
between 80 and 120 nm in diameter, with either spherical or pleiomorphic morphology (48-51). 
The nucleocapsid contains a tripartite genome of negative-sense or ambisense ssRNA, the large 
(L), medium (M), and small (S) segments, each encoding a single transcriptional unit flanked by 
5’ and 3’ non-translated regions (48). The S segment encodes the nucleocapsid protein, which is 
responsible for packaging viral genomic RNA into virions, and, in many but not all 
bunyaviruses, the nonstructural protein NSs, which is involved in modulation of the host cell and 
innate immune evasion, making it a major virulence factor for pathogenic bunyaviruses (52, 53). 
The M segment encodes the two viral glycoproteins in a single ORF, along with NSm proteins in 
some genera, which may be involved in viral assembly (54, 55). The L segment of all 
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bunyaviruses codes for the RNA-dependent RNA polymerase (RdRp) without accessory 
nonstructural proteins (48). Aside from these shared features, the virion morphologies and 
protein coding strategies of bunyaviruses are as diverse as their vector and host ranges. 
 Many arthropod-borne bunyaviruses such as Rift Valley fever virus (RVFV), a 
phlebovirus, Crimean-Congo hemorrhagic fever virus (CCHFV), a nairovirus, and La Crosse 
virus (LACV), an orthobunyavirus, are of great public health and agricultural significance. 
RVFV is endemic to Africa and has recently expanded into the Middle East (56, 57). It infects 
various domesticated animal species such as goats, sheep, and cattle, as well as humans, and can 
be transmitted through direct contact with infected bodily fluids (58, 59) or by a large variety of 
mosquito genera including Culex and Aedes species (60). In humans, symptomatic cases can 
range from a mild febrile illness to rare cases of severe hemorrhagic fever syndrome or 
meningoencephalitis, with a case-fatality rate up to 20% (61). In livestock, RVFV infection is 
usually more serious and can result in higher fatality rates. It also induces 70-100% fetal loss in 
pregnant animals and 20-30% mortality in adult animals, which can be devastating for 
agricultural economies affected by a large outbreak (61). CCHFV can cause a similar 
hemorrhagic disease to RVFV, but it is transmitted by ticks, which also serve as the natural 
reservoir, in addition to body fluids (62). It is found in much of Europe, Africa, the Middle East, 
and Asia and can cause outbreaks of human disease that can reach a 30% case-fatality rate (62, 
63). Unlike RVFV, domesticated ungulates that become infected with CCHFV do not experience 
disease (64). LACV is an encephalitic bunyavirus endemic to the United States that is 
transmitted between deciduous forest-dwelling rodents by the mosquito Aedes triseriatus (65). 
Human infection is associated with nonspecific summertime fevers that usually resolve within a 
 8 
week, but a small subset of patients, typically children, progress to encephalitis characterized by 
seizure, paralysis, coma, and rarely, death (66, 67). 
1.1.1.4 Family Reoviridae 
The Reoviridae are a hugely diverse family of segmented, double-stranded RNA (dsRNA) 
viruses with a host range encompassing vertebrates, invertebrates, plants, protists, and fungi. 
There are two subfamilies of reoviruses containing 15 genera. Of these, four genera contain 
arboviruses; Cardoreovirus, Coltivirus, Orbivirus, and Seadornavirus, of which the latter three 
contain human pathogens. Rotavirus is probably the most-well known human reovirus, causing a 
common diarrheal disease in children, but it is transmitted via the oral-fecal route rather than by 
an arthropod vector. All reoviruses are nonenveloped and possess a single, double, or triple-
layered virion structure with concentric inner and outer protein layers, and virions measure 
approximately 70 nm in diameter (68). The inner capsid is arranged as a T=2 icosahedron while 
the outer layer typically possesses T=13 icosahedral symmetry. The reovirus genome comprises 
10-12 segments of dsRNA contained within the nucleocapsid, each encoding 1-3 proteins (68). 
Colorado tick fever virus (CTFV), a coltivirus, is one of the most important human reovirus 
transmitted by an arthropod, with 200-400 cases in the United States per year (69). It is 
transmitted to humans by the tick Dermacentor andersoni, which is endemic to the Rocky 
Mountains and the western United States (69). About 50% of human cases are symptomatic, 
characterized by biphasic fever, headache, muscle pain, and weakness, and disease is usually 
self-limiting (70). Rare severe complications such as encephalitis, hemorrhage, and pericarditis 
are sometimes observed in children, but associated mortality is very low (69). 
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1.1.2 Common features of arbovirus transmission and ecology  
Most arbovirus transmission cycles involve a zoonotic reservoir or amplification in vertebrate 
hosts in addition to an arthropod vector, although some, such as dengue virus (DENV), Zika 
virus (ZIKV) and chikungunya virus (CHIKV), are capable of sustained human-mosquito-human 
spread in an urban transmission cycle in the absence of an intermediate zoonotic host (71, 72). 
Many characteristics of arbovirus existence – geographic range, ecological niche, potential for 
emergence in human populations, and epidemiology, to name a few – thus depend heavily on the 
lifestyles of its primary vectors and enzootic host(s). Birds are common enzootic reservoirs for 
arboviruses, and the avian arboviruses are transmitted by ornithophilic (bird-feeding) arthropods, 
frequently Culex and Culiseta species mosquitoes. The distribution of avian arboviruses such as 
the flaviviruses JEV and WNV is often subject to the migratory patterns of their host birds, and 
thus may exhibit very large or seasonal geographic ranges (71). The power of migratory birds to 
spread an emerging arbovirus was demonstrated recently with the single introduction of WNV 
into New York in 1999. Within only five years, WNV had established endemicity throughout the 
United States, southern Canada, Central and South America in large part due to the rapid 
infection of and dissemination through naïve migratory bird populations (73-76). In addition, 
many Culex mosquito species are anthropophilic (human-feeding) as well as ornithophilic, so 
humans living near arbovirus-infected bird populations are at risk of infection by the virus’ 
primary vector species (71). 
In contrast, arboviruses with mammalian reservoirs tend to be less naturally mobile than 
bird-borne arboviruses. Forest-dwelling rodents and nonhuman primates host various arbovirus 
species that are commonly transmitted by arboreal Aedes species mosquitoes in a sylvatic 
transmission cycle. Tick-borne viruses in temperate areas such as CTFV transmit in a similar 
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cycle between rodents and ticks that bite humans opportunistically. Historically, the risk of 
emergence of mammalian arboviruses in human populations has been relatively low, but 
recently, human encroachment into tropical forest habitats combined with the advent of rapid and 
prolific international air travel has greatly increased that risk (77-80). Interestingly, human 
interference in sylvatic arboviral transmission in Africa during the slave trade is responsible for 
bringing YFV and DENV and their principal vector Aedes aegypti to South America from Africa 
on ships (81-84), so humans have a rich history of aiding the spread of mammalian-borne 
arboviruses even before the age of air travel.  
For mammalian arboviruses to cause an epidemic or epizootic outbreak, a spillover event 
out of their sylvatic cycle must occur. Most arboreal Aedes mosquitoes are not anthropophilic, so 
spillover into human or domesticated animal populations often occurs via a bridge or epizootic 
vector (85). For some arboviruses such as CHIKV and DENV, human epidemic spread can be 
maintained by direct human-mosquito-human transmission in an urban cycle by distinct, 
anthropophilic epidemic vectors such as Aedes aegypti or Aedes albopictus (85). Importantly, 
because most arboviruses evolved in an enzootic cycle that does not involve humans, human 
infections are typically not required for sustained viral transmission, and humans rarely establish 
a high enough viremia to reinfect a mosquito (except during urban CHIKV or DENV infections). 
Other factors beyond serum viremia, such as some heretofore unidentified aspects of human 
physiology or the feeding preferences of competent vector species, may also block human-to-
vector transmission for some arboviruses. Thus, humans are usually dead-end hosts for 
arboviruses (71). However, lack of coevolution with arboviruses means that humans are more 
likely to become ill upon infection compared to an enzootic host, which typically replicates the 
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virus to high titer to enable transmission but does not develop disease (71). For some 
arboviruses, human infection can result in very severe disease and even death. 
 
Figure 1: Example arbovirus transmission cycles (adapted with permission from (85)) 
1.1.3 Features of arbovirus pathogenesis and immune response in humans 
Arbovirus infections of humans share many pathogenic features due to their similar routes of 
transmission. All arbovirus infections begin in the skin, at the site of the infected arthropod’s 
bite. Many arboviruses replicate locally at the site of infection and then in secondary lymphoid 
organs, and from there disseminate systemically via the bloodstream. End-game organs vary by 
arbovirus and determine the presentation characteristics of severe disease. Encephalitic 
alphaviruses, flaviviruses, and bunyaviruses target tissues in the central nervous system 
including neurons, microglia, and astrocytes, depending on the virus (86, 87). 
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Meningoencephalitis is a common outcome of symptomatic encephalitic arbovirus disease. 
Arthritogenic alphaviruses exhibit preferential tropism for joint-associated musculoskeletal 
tissues in the distal limbs of patients, where they cause arthritis, arthralgia, and myalgia (88). 
Hemorrhagic arboviruses such as YFV and CCHFV infect a variety of the deep visceral organs 
like the liver and induce a strong inflammatory response associated with internal bleeding and 
eventual multiorgan failure (89, 90). CTFV targets hematopoietic cells in the bone marrow and 
can persist in the blood stream in erythrocytes that became infected as erythroblasts for months 
after infection (91, 92). 
 It bears repeating that the majority of arboviral infections of humans result in 
asymptomatic or mild disease, therefore, humans possess the immune capabilities to control and 
clear arbovirus infections. Type-I interferon (IFN-α/β) has been identified as a critical innate 
immune response for initial control of a plethora of arboviral infections. Evidence supporting the 
vital role of IFN-α/β against arboviruses comes from mouse models lacking various components 
of the IFN-α/β induction or effector pathways. Peripheral infection of adult wild-type mice with 
many arboviruses results in subclinical or mild nonlethal disease and viral replication is quickly 
controlled coincident with IFN-α/β induction. By contrast, arboviral infection of mice deficient 
in the IFN-α/β receptor or various components of its associated signaling pathways is often 
rapidly fatal with uncontrolled viral replication and systemic tissue invasion. This is true of the 
arthritogenic alphaviruses CHIKV (93, 94), o’nyong’nyong virus (ONNV) (95), Semliki Forest 
virus (96), and SINV (97, 98), the flaviviruses DENV (99-101), YFV (102), ZIKV (103, 104), 
TBEV (105), and Murray Valley encephalitis virus (106) and the bunyaviruses CCHFV (107) 
and LACV (108, 109). The encephalitic alphaviruses EEEV and VEEV, flaviviruses WNV and 
JEV, and the bunyavirus RVFV do cause fatal disease in adult IFN-α/β-competent mice, but 
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mean time-to-death is significantly shortened in its absence (110-114). Interestingly, mice with 
attenuated but not abrogated IFN-α/β responses have shown increased susceptibility to various 
arboviruses without the fatal outcome, indicating that the relative strength of the IFN-α/β 
response can determine pathogenic outcomes of arbovirus infections (115). Similarly, modest 
changes in IFN-α/β efficacy have been shown to influence the cellular tropism of highly IFN-
α/β-sensitive arboviruses, such as SINV (98).   
Additional support for the importance of the type-I IFN response against alphaviruses 
comes from the multitude of virally-encoded mechanisms to counteract the IFN-α/β response. 
For example, most alphaviruses are able to inhibit host cell macromolecular synthesis and 
thereby attenuate the cells’ ability to produce IFN-α/β and its antiviral effectors (116). EEEV, by 
contrast, completely avoids replication in myeloid cells, which would otherwise be responsible 
for producing high levels of IFN-α/β (117, 118). Alphavirus and flavivirus proteins can also 
directly antagonize various components of the IFN-α/β signaling pathway (119-123). CCHFV 
encodes a protease that can directly cleave cellular ubiquitin and the antiviral effector protein 
ISG15 to suppress IFN-α/β responses (124) and LACV NSs can inhibit IFN-α/β production 
(125). Importantly, mutations that abrogate these activities result in greatly attenuated viruses. 
Together, these findings underline the role of type-I interferon as a critical first-line defense 
against most if not all arbovirus infections, and suggest that even modest variations in its efficacy 
can have meaningful impacts on arbovirus pathogenesis and disease. 
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1.2 CHIKUNGUNYA VIRUS 
Chikungunya virus (CHIKV) is an Old World arthritogenic alphavirus that has recently extended 
its geographic range from sub-Saharan Africa and southeast Asia to include southern Europe, 
South and Central America, the Caribbean, and some areas of the southern Unites States. 
CHIKV causes an acute febrile syndrome in humans characterized by a debilitating 
polyarthritis/polyarthralgia, which can persist in the distal joints of the limbs and extremities for 
months or years after the initial infection has been cleared (21). It is well established that an 
effective IFN-α/β response, in concert with production of neutralizing antibody, is paramount to 
the control and clearance of the virus in the acute stage (126), but the mechanisms driving the 
chronic disease manifestations, including whether or not viable CHIKV persists in distal joint 
tissues, remain unknown and hotly debated. Among arboviruses, CHIKV is somewhat unique in 
its preferential infection of, and potentially, persistence in, cold peripheral musculoskeletal 
tissues. If reduced tissue temperature confers greater viral fitness, possibly through attenuation of 
IFN-α/β, then the cooler temperatures in distal joint tissues may facilitate CHIKV infection and 
disease at these sites. While this interaction would most likely manifest during the acute 
infection, indirect consequences of inefficient viral clearance from distal joint tissues due to 
weakened IFN-α/β may present a risk factor for chronic CHIKV arthritis. Alternatively, there is 
mounting evidence of chronic type-I interferon activity during persistent RNA virus infection, 
potentially due to continual stimulation of pattern recognition receptors by persistent viral RNA, 
which may contribute to chronic inflammatory phenotypes (127), but may also be necessary for 
long-term control of the virus. In this section, I will introduce the molecular and pathogenic 
characteristics of CHIKV, with a focus on its acute and chronic disease mechanisms in humans 
and in animal models. 
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1.2.1 Cellular replication 
The major features of the CHIKV virion and genome are akin to those of the other alphaviruses, 
as described above. Viral attachment to host cells is mediated by the viral envelope glycoprotein 
E2. Though known to have a proteinaceous component, the identity of the cellular receptor(s) 
that bind to and promote infection by CHIKV, or indeed any alphavirus, has/have remained 
largely a mystery. Several candidate molecules including glycosaminoglycans have been 
proposed as attachment and/or entry factors (128-130), but none have been confirmed as 
universal receptors. It is clear that c-type lectins can facilitate the attachment of alphaviruses to 
immune cells such as dendritic cells via engagement of the high mannose carbohydrate 
modifications of mosquito-derived viruses (131), however, the role of lectins in mediating entry 
is unclear. As CHIKV displays a broad host and tissue tropism, it is likely that the cellular 
receptor is either a broadly conserved and widely expressed protein and/or carbohydrate 
modification, or that CHIKV uses different receptors depending on the host and cell type being 
infected, with the latter hypothesis most likely. Very recently, the cell adhesion molecule Mxra8 
was identified in a CRISPR-Cas9 screen as a specific infection-promoting receptor for CHIKV 
and several other arthritogenic alphaviruses, but not for encephalitic alphaviruses or other, 
unrelated RNA viruses, both in relevant cell types in vitro and in a mouse model of CHIKV 
infection (132). After receptor binding, CHIKV is internalized by clathrin-mediated endocytosis, 
and uncoating and release of the viral genome into the cytoplasm occurs upon acidification of the 
endosomal compartment (133-137). A pH-dependent conformational change in the E1 
glycoprotein exposes a fusion loop that enables viral envelope fusion with the endosomal 
membrane and release of the nucleocapsid core (136). 
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The alphavirus genomic RNA is recognized as an mRNA by host cell ribosomes and 
immediately translated, producing the nonstructural polyproteins P123 or P1234 via readthrough 
translation of an opal stop codon between nsP3 and nsp4 (6). Autoproteolytic processing through 
the protease activity of nsP2 frees nsP4, the RdRp, which, together with P123, forms an active 
replicase complex (6, 138, 139). Full-length negative strand synthesis is initiated by this 
replicase complex and is associated with membranous structures formed at the plasma 
membrane, termed spherules, which are thought to be the major sites of genome replication (140-
144). These small, vesicular structures become large cytopathic vacuoles within the cytoplasm of 
the host cell as the infection proceeds and may serve as sites of viral assembly before egress 
(140-142). Further proteolytic processing of P123 by nsP2 results in a conformational change in 
the replicase complex that switches its activity from negative strand to positive strand synthesis, 
using negative strand genomes as a template for both full-length genomic RNA and the 26S 
subgenomic RNA that encodes the structural proteins (138, 141, 145). 
The structural proteins are translated as a second polyprotein consisting of capsid (C), E3, 
E2, 6K, TF, and E1. C is released immediately from the polyprotein upon its completed 
translation by autoproteolytic processing, which enables it to associate with viral genomic RNA 
and begin the encapsidation process (146-149). The rest of the polyprotein is translated as E3-
E2-6K-E1, but low-frequency ribosomal frameshifting also results in a secondary product, E3-
E2-TF (150, 151). Host proteases cleave the viral structural polyprotein into pE2 (E3-E2 fusion), 
free 6K and TF, which share an N-terminus but have disparate C-termini due to ribosomal 
frameshifting (TF stands for transframe protein (151)), and E1 (138). E3 is a leader peptide fused 
to the N-terminus of E2 and is responsible for trafficking the other structural proteins through the 
secretory pathway and protecting the nascent spike heterodimer of E2/E1 from premature 
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membrane fusion in the low pH of the early secretory pathway (138, 152, 153). pE2 and E1 
traverse the secretory pathway as a non-covalently-linked hetero-oligomer and acquire several 
post-translational modifications including palmitoylation and N-linked glycosylation (154-156). 
A host furin-like protease in the trans-Golgi cleaves E3 from pE2, leaving mature E2, which can 
then form mature heterodimers with E1 at the plasma membrane (157-159). Nucleocapsid cores 
containing a single copy of the genomic RNA bud into regions of plasma membrane studded 
with E1/E2 spikes, and emerge from cells as enveloped, infectious particles (138, 160, 161).  
1.2.2 Distribution and ecology 
CHIKV first evolved in sub-Saharan Africa at least several hundred years ago from an ancestral 
arbovirus that was likely transmitted between primate hosts, by Aedes species mosquitoes (33). 
Since its initial divergence from its closest relative, ONNV, CHIKV has further diverged along 
several distinct lineages. First, the ancestral West African lineage gave rise to the 
East/Central/South African (ESCA) genotype in sub-Saharan Africa (162). A third lineage 
evolved from an ESCA strain that was imported into India and Southeast Asia between 1879 and 
1956 (163) and became the Asian genotype. Then, in 2004, an explosive outbreak involving 
another ESCA strain began in coastal Kenya and spread throughout the Indian Ocean basin, 
affecting millions of people (163, 164). These CHIKV strains comprised the newest lineage, the 
Indian Ocean Lineage (IOL), which is sometimes considered a sublineage of the ESCA 
genotype. Remarkably, the divergence of the IOL strains was associated with a mutation in the 
viral E1 protein that conferred enhanced fitness and transmissibility in a new vector species, A. 
albopictus, which was found to be the principal vector in the 2004 Indian Ocean outbreak, where 
A. aegypti is not common (165-167). The IOL outbreak also occurred in the era of unprecedented 
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increases in rapid air travel, and traveler-associated cases seeded autochthonous transmission in 
Italy and southern France (168, 169). Spread to the Americas was recognized in 2013 on the 
Caribbean island of St. Martin, ground zero for another massive outbreak that swept Central and 
South America and the Caribbean through 2014 (170, 171). Interestingly, the viruses circulating 
in the Americas were members of the Asian lineage, not the IOL, and transmission occurred via 
A. aegypti (172, 173). Subsequently, an ESCA-derived virus was imported to and established 
autochthonous spread in Brazil in 2014 (174). 
 
 
Figure 2: Distribution of Chikungunya virus and its major epidemic vectors (adapted with 
permission from (33), Copyright Massachusetts Medical Society) 
 
Throughout its natural history, CHIKV has been maintained in two transmission cycles, a 
sylvatic cycle and an urban cycle. Sylvatic CHIKV transmission involves forest-dwelling 
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mosquitoes of the Aedes genus feeding on and transmitting the virus between enzootic, non-
human primate (NHP) amplification hosts. The sylvatic cycle is considered the ancestral method 
of CHIKV transmission, occurring in Africa since CHIKV diverged and continuing there to the 
present day (173). In contrast, there is no evidence of sylvatic CHIKV transmission outside of 
Africa, despite its now worldwide distribution, save for its retention in these geographic areas 
between epidemics (173, 175). In areas of Asia and South America where sylvatic NHPs are 
endemic, the possibility of spillback into an enzootic cycle, as occurred with YFV in South 
America (83), is strong. In Asia and the Americas, CHIKV is known to be maintained in the 
urban cycle, which can also operate in Africa alongside sylvatic transmission. Originally, urban 
CHIKV transmission would occur as the result of a spillover event of the virus into a human 
population from the sylvatic cycle (176). That spillover event could be either a sylvatic mosquito 
vector biting a human or an anthropophilic mosquito biting an enzootic host, acquiring the virus, 
and then biting a human. The risk of spillover is greatly increased with human encroachment into 
or near arboreal habitats, which gives CHIKV vectors access to both humans and 
zoonotic/enzootic reservoirs. Once a human becomes infected, urban transmission can seed an 
epidemic outbreak fueled by human-mosquito-human transmission by the anthropophilic and 
domesticated A. aegypti aegypti subspecies (171). Domestication of A. aegypti, that is, the 
adaptation of this mosquito to live in and around human settlements and breed preferentially in 
standing water trapped in man-made vessels, probably coincided with the development of 
human-mosquito-human transmission and the urban transmission cycle (171). Recently, A. 
albopictus has joined A. aegypti as an urban cycle vector of IOL strains, which, as described 
above, have adapted to efficiently use this vector. 
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The recent establishment of urban transmission of CHIKV in the Americas and Europe 
did not result from enzootic spillover, but rather from importation of an infected human or 
mosquito from an urban transmission cycle elsewhere in the world. A major concern now is 
whether or not spillback into the sylvatic cycle from the urban cycle will occur and allow 
CHIKV to establish endemicity in new regions with robust NHP populations (173). Also 
troubling is the transition of IOL viruses into A. albopictus, as this mosquito inhabits a much 
larger geographic range than A. aegypti, which is confined to tropical and subtropical climates 
(177). A. albopictus is found worldwide from the tropics to much more temperate regions, posing 
a risk of CHIKV in previously risk-free populations should the IOL strains continue to expand 
geographically or additional lineages evolve to use this vector. There is also evidence that 
American strains of A. albopictus are more competent for transmission of CHIKV of any lineage, 
which adds another layer of risk to the expansion of CHIKV in the Americas (178). However, as 
NHPs are the major reservoirs for endemic CHIKV, it is unlikely that CHIKV would be able to 
establish endemicity in temperate climates in the absence of NHPs. Another possibility is that 
climate change may facilitate geographic expansion northward and southward for A. aegypti, 
which could pose its own risk for the introduction of CHIKV into new areas (179).   
1.2.3 Pathogenesis and disease in humans 
CHIKV infection of humans begins upon deposition of viral particles into the skin and 
superficial capillaries by an infected mosquito during a bloodmeal. The virus replicates initially 
at the site of infection in dermal fibroblasts, endothelial cells, and possibly macrophages, and is 
transported to the regional lymph node through the draining lymphatics, possibly aided by skin-
resident dendritic cells (DCs) and macrophages (94, 135, 180, 181). Whether or not CHIKV can 
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infect myeloid cells in vivo is controversial, and transport by these cells may occur as a result of 
phagocytosis of infected cell debris (33). In the draining lymph node, CHIKV gains access to 
additional susceptible cells, where it replicates sufficiently to seed a primary serum viremia via 
the thoracic duct, and then utilizes the circulatory system for systemic spread. Major secondary 
sites of infection include musculoskeletal tissues, spleen, and skin, with rare involvement of 
liver, brain, and ocular tissues also possible (94, 181-186). Peripheral viral replication at these 
sites produces a high-titer viremia that can reach >109 genomes/mL (180, 186), allowing for 
direct human-mosquito-human transmission without the need for an intermediate amplifying 
host. Coincident with the high-titer viremia is a spike in circulating proinflammatory cytokines 
such as IFN-α, IL-1β, tumor necrosis factor alpha (TNFα), monocyte chemoattractant protein 1 
(MCP-1), and IL-6 and the onset of clinical symptoms (135, 187-193). Most patients experience 
a high fever (39-40°C) lasting up to 7 days, followed shortly by debilitating polyarthralgia, 
which is usually symmetrical and involving distal joints, although during the acute phase, axial 
and large joints can also be affected (21). A macropapular erythematous rash on the trunk and 
limbs is also a common manifestation of acute CHIKV (33). Incidence of subclinical CHIKV 
disease is very low, with seroconversion in the absence of overt disease occurring in less than 
15% of infected individuals (194). Conversely, the incidence of fever and joint pain can reach as 
high as 90 and 95%, respectively (21). Rash is less common but still a hallmark sign of CHIKV 
infection, with 40-50% of infected individuals presenting with rash (21, 195). Atypical and 
severe manifestations include neurological and ocular involvement, hepatitis, hemorrhage, 
gastrointestinal disease, and myocarditis resulting on rare occasions of viral invasion of these 
tissues (186, 195-198). Severe CHIKV infection occurs almost exclusively in at-risk populations 
such as neonates, the elderly, and those with underlying comorbidities (199). Accordingly, 
 22 
CHIKV infection results in very low mortality, less than 1 in 1000 infected, but very high 
morbidity; however, retrospective studies of CHIKV outbreaks in the Indian Ocean region and 
South America have revealed a higher-than-expected rate of neurological disease (e.g. Guillan-
Barre syndrome) in previously healthy individuals after infection with CHIKV (196, 197, 200). 
This raises the possibility that more severe consequences of CHIKV infection are more common 
than previously thought. 
Acutely-infected joint-associated musculoskeletal tissues contain numerous cell types 
that are targeted for CHIKV infection, including fibroblasts, osteoblasts, muscle satellite cells, 
myocytes, and endothelial cells (94, 180-184, 201-203). As a result, all articular and periarticular 
tissues are subject to infection and subsequent inflammation. Acute arthralgic symptoms can 
result from both direct cellular damage by the cytolytic virus (135, 204) and immune-mediated 
mechanisms. Immune cell infiltrates into infected joints are predominated by macrophages and 
contain neutrophils, natural killer (NK) cells and DCs, which contribute to inflammation and 
edema (180-184). High-titer viremia in patients coincides with elevated levels of several 
proinflammatory cytokines, with IL-6, MCP-1, and IL-1β universally identified as markers of 
acute CHIKV disease in diverse patient cohorts from around the world, and their levels correlate 
with disease severity (192, 205). Interestingly, many of the features of CHIKV-induced arthritis 
are reminiscent of rheumatoid arthritis (RA), an autoimmune disorder marked by elevated levels 
of proinflammatory cytokines such as IL-6, synovial inflammation, focal bone erosions, damage 
to cartilage, and the production of autoantibodies (206). CHIKV arthritis is also associated with 
elevated IL-6 and synovial inflammation, and has been shown to lead to bone loss (207), but 
presence of RA-associated autoantibodies is rarely detected in CHIKV patients (208). However, 
it is not uncommon for patients experiencing chronic CHIKV-related rheumatic symptoms to 
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meet the clinical criteria for seronegative RA (208, 209), and significant overlap in gene 
expression profiles has been noted between a mouse model of CHIKV arthritis and human RA 
patients in affected musculoskeletal tissues (210). Thus, there may be a connection in the 
mechanisms driving RA and post-CHIKV rheumatism. 
 
 
Figure 3: Clinical signs of acute CHIKV disease: swollen joints and erythematous rash (adapted with 
permission from (126)) 
 
Convalescence from the acute infection usually begins between 7 and 10 days after 
symptom onset. Viremia is cleared coincident with rising serum anti-CHIKV IgM, which usually 
appears within 5-7 days after infection (211). IgG is detectable between days 7 and 10 and 
contributes to viral clearance from circulation, if viremia is still present (212-214).  Both CD4+ 
and CD8+ T cells are activated during acute CHIKV infection, but their roles in viral control and 
immune protection are unclear and may even contribute to CHIKV-associated pathology in the 
case of CD4+ T cells (180, 191, 215). A strong neutralizing antibody response is widely 
considered the best correlate of protection against secondary CHIKV infection (21). In most 
patients, acute symptoms resolve within two weeks of onset, and many patients report 
improvement or disappearance of joint and muscle pain (126). Many patients will reach full 
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recovery from joint symptoms within one month; however, between 15 and 87% of patients, with 
an average of 47% will report symptoms of persistent or flaring joint pain associated with the 
chronic phase of CHIKV disease (216).  
Chronic CHIKV disease is characterized by persistent or flaring bouts of arthralgic 
symptoms (pain, swelling, stiffness) lasting for months or years beyond the acute infection. 
Unlike the acute phase, during which patients can experience arthritis/arthralgia in the large 
joints, chronic CHIKV manifests exclusively in the small joints of the extremities, namely the 
wrists, ankles, and phalanges (126, 217-219). Pain at these sites can be severe and debilitating. 
For example, many patients describe the inability to move from the position they were in when 
the pain started, which is indicative of the significant detriment to the affected person’s quality of 
life (33, 220). Many risk factors for chronic CHIKV have been identified in various cohorts, with 
advanced age, acute-phase arthralgia persisting past one-month post-infection, and the presence 
of a pre-existing arthritic condition being universally associated with chronic disease (180, 218, 
220-227). In addition, many studies have found the severity of acute disease, including high viral 
load, extreme joint pain, and atypical disease indicative of severe infection, to be strongly 
predictive of chronic arthralgia (180, 222, 226, 228-231). A few studies have also positively 
correlated female sex (222-224, 230), smoking (223), and chronic comorbidities such as 
cardiovascular disease and diabetes (220, 223) with increased risk of chronic CHIKV disease. 
Notably, one study determined that the most prominent factor associated with chronic CHIKV 
flaring disease (>40% of total) was a change in ambient temperature, indicating that external 
factors may influence disease progression (220). 
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Figure 4: Pathogenesis of Chikungunya virus (adapted with permission from (153)) 
 
The underlying pathology and molecular mechanisms driving persistent and flaring joint 
pain in CHIKV patients have yet to be unraveled. It is generally accepted that much of the 
persistent CHIKV disease is immune-mediated, representing a chronic inflammatory state in the 
periarticular microenvironment, with some similarities to RA, as noted above. In patients with 
chronic CHIKV, the proinflammatory cytokines IL-6, IL-1, and MCP-1 remain elevated versus 
recovered patients, and increased levels of immune cells have been found in biopsies from these 
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patients (153). The possibility that chronic post-CHIKV arthralgia is an autoimmune condition 
has been explored, as it shares many features with RA, however, no autoantigens have yet been 
identified and affected patients are rarely positive for RA-associated autoantibodies (207). In 
contrast, viral genomes and, occasionally, antigens, have been found in both humans and animal 
models during the chronic phase of CHIKV infection, leading to the intriguing possibility that 
persistent CHIKV infection is responsible for driving the chronic inflammation. Specifically, 
CHIKV RNA and protein was detected in synovial and muscular biopsy specimens from one 
patient with chronic arthralgia 18 months post-infection (180). Similar findings have been 
reported in experimentally-infected macaques and mice (181, 202, 215, 232). However, 
infectious CHIKV has not been isolated from chronically infected humans or animals, except for 
persistent, low-level viremia in mice lacking B and T cells that lasted at least 84 days post-
infection (202). No infectious virus has been successfully cultured from joint-associated tissues 
in any model past 6 weeks post-infection, and this was, again, in mice lacking adaptive immune 
responses (202). If the infectious virus was persisting in a cellular reservoir long-term, it would 
likely be at a low level and any infectious particles produced would likely be immediately 
neutralized by circulating antibody. Thus, while the presence of viral genomes at chronic time 
points in no way confirms the presence of an active infection, it warrants further investigation 
into its exact nature, and its relationship to the chronic inflammatory responses driving persistent 
post-CHIKV joint disease. The establishment of a tractable small animal model of chronic and/or 
flaring CHIKV infection will be of great aid in addressing these questions. 
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1.2.4 Adaptive immune response 
The majority of information on the specific mechanisms by which CHIKV is controlled and 
cleared by the adaptive immune system comes from studies in mice, although some data is 
available from patient cohorts. Increasingly, it is becoming clear that adaptive immunity plays 
both protective and pathogenic roles in CHIKV infection, with different immune cell subsets 
contributing differently. As mentioned above, mice lacking B and T cells suffer a greater viral 
burden in several tissues during acute infection and sustain persistent viremia indefinitely, 
highlighting the importance of these adaptive immune cells in control and clearance of the virus 
(202, 215, 233, 234). However, these mice also display decreased musculoskeletal disease (foot 
swelling upon subcutaneous inoculation of CHIKV into the footpad), indicating that some 
subsets of adaptive immune cells may contribute to CHIKV disease. 
1.2.4.1 T cell response 
CD8+ T cells are activated in response to CHIKV infection in humans, with peak 
numbers observed in peripheral blood around the time of symptom onset and a sizeable 
circulating population persists until at least 7-10 weeks post-infection (191, 209). In mice, CD8+ 
T cells migrate into infected musculoskeletal tissues within the first week of infection (233). 
Despite this evidence for an active CD8+ T cell response, it is unclear what role, if any, CD8+ T 
cells play in the control or pathogenesis of CHIKV. In mice, genetic knockout or antibody-
mediated depletion of CD8+ T cells have not resulted in differences in musculoskeletal disease 
or viral burden during the acute or chronic stages of CHIKV infection (233). However, it is 
possible that CD8+ T cells contribute to other aspects of anti-CHIKV immunity or pathogenesis, 
such as cytokine profiles or memory responses, that have not yet been studied.  
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In contrast to CD8+ T cells, distinct roles for effector CD4+ T cells and regulatory T cells 
have been described in mice. Large numbers of IFN-γ-producing CD4+ T cells migrate to 
synovial tissues of infected wild-type mice early after infection and contribute directly to disease 
pathology, as mice deficient in CD4+ T cells or MHC-II experience greatly reduced foot 
swelling compared to wild-type mice (215, 233). This reduction in musculoskeletal disease was 
not associated with any changes in viremia or recruitment of monocyte/macrophages or 
neutrophils to the site of infection, suggesting that effector CD4+ T cells are directly pathogenic 
during acute CHIKV infection (233). The role of CD4+ T cells during the chronic disease phase 
is unknown and has not been studied in mice, although one study of chronically-infected humans 
found a relatively high fraction of activated CD4+ T cells in synovial biopsies, suggesting that 
these cells may contribute to chronic disease manifestations, although no hypothesis for that 
mechanism has yet been posited (180). In contrast to effector CD4+ T cells, regulatory T cells 
appear to play a protective role against CHIKV-associated joint pathology. One study examined 
the effect of expanding the small regulatory T cell population found in the joints of CHIKV-
infected mice by administration of an IL-2/anti-IL-2 complex, and found that increased numbers 
of regulatory T cells reduced foot swelling, proinflammatory cytokine expression, and IFN-γ+ 
CD4+ T cell recruitment and expansion during acute CHIKV infection (235). γδ T cells have 
also been implicated in protection from CHIKV-induced inflammation at the site of infection by 
limiting immune-mediated oxidative damage and proinflammatory cytokine induction (236). 
Thus, regulatory and γδ T cells may limit immune-mediated pathology during acute CHIKV 
infection, although their roles during chronic infection remain unknown. 
No epitopes for CHIKV-specific CD8+ or CD4+ T cells have yet been identified, and the 
antigen presenting cells (APCs) responsible for CD4+ T cell priming have not been defined. 
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However, CHIKV has been shown to infect monocytes and macrophages in humans and NHPs, 
and these cell types dominate immune infiltrates into infected tissues, so it is likely that these cell 
types contribute to antigen presentation (135, 181, 189). Less clear is the role of DCs in antigen 
presentation, as there is no evidence that CHIKV can productively infect these cells. It has been 
suggested, though, that skin-resident DCs may transport CHIKV and other arboviruses from the 
site of infection to the DLN, indicating that these cells may present antigen to T cells in the DLN 
(237). Other, nonclassical APCs such as neutrophils, which are abundant in immune cell 
infiltrates into CHIKV-infected tissues, may also contribute to antigen presentation, but no 
studies have addressed this possibility. B cells are refractory to CHIKV infection (135) and there 
is no evidence that they act as APCs in this context. Overall, additional studies are required to 
define the APC subsets important for CHIKV antigen presentation and how those interactions 
contribute to viral control and/or CD4+ T cell-mediated immunopathology.   
1.2.4.2 B cell response 
It is well-known that neutralizing antibodies are essential for clearance of infectious 
CHIKV from serum and tissues, as administration of neutralizing anti-CHIKV monoclonal 
antibodies is able to achieve viral clearance in B cell-deficient mice and even protect 
immunocompromised mice from lethal infection when given before or soon after infection (202, 
215, 238-244). Most neutralizing antibodies so far identified target the viral envelope 
glycoproteins E2 and E1, which are exposed on the surface of the virion, and the most strongly 
neutralizing antibodies target the A and B domains of E2 and are cross-protective against other 
arthritogenic alphaviruses (245, 246). Different antibodies have been shown to inhibit the virus 
at various stages of infection in vitro, including attachment, entry, fusion at the endosome, virion 
assembly, budding, and cell-to-cell spread (240, 244, 246-249). In addition, antibodies may act 
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in other ways in vivo, including antibody-mediated cellular cytotoxicity, activation of 
complement, and opsonization of extracellular virus particles (250). CHIKV-specific IgM is 
detectable in mice within the first few days after infection and IgM levels fall during the second 
week of infection as class-switching to IgG occurs (251). In human patients, anti-CHIKV IgM 
remains detectable for months after the initial infection and isotype switching to IgG occurs more 
quickly than in mice, within the first week (180, 211). 
Few studies have examined the specific characteristics of the anti-CHIKV IgG response, 
although one study found that the subtype IgG3 predominated the IgG response in both acutely- 
and chronically-infected CHIKV patients (252). These neutralizing antibodies were found to be 
directed against a single linear epitope near the N-terminus of the viral E2 glycoprotein (the 
E2EP3 peptide; STKDNFNVYKATRPYLAH), and immunization of NHPs and mice with this 
epitope reduced viremia and musculoskeletal disease upon CHIKV challenge (212, 253). A study 
in mice mapped the greatest number of antibody epitopes to the C-terminal region of E2, 
although a number of other epitopes were identified throughout the CHIKV structural proteins 
and the other domains of E2 (251). In addition, studies in mice lacking MHC-II expression have 
demonstrated that class switching from IgM to IgG occurs in the absence of T cell help, but the 
response is diminished compared to wild-type mice and predominated by the IgG2c isotype, 
indicating that development of normal antibody responses to CHIKV infection is partially 
dependent on T cells (215).  
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1.2.5 Animal models of CHIKV infection 
1.2.5.1 Neonatal and immunocompromised murine lethal challenge models 
Neonatal mice rapidly succumb to encephalitic disease upon infection with CHIKV, and 
therefore have proven useful in the past for vaccine candidate safety trials, but have little utility 
for more detailed studies of CHIKV pathogenesis or vaccine efficacy due to their immature 
immune systems and atypical disease course (254). However, due to increasing recognition of 
neurological involvement and encephalitis in human CHIKV cases that have been noted in recent 
human outbreaks, the neonatal mouse encephalitis model may prove serendipitously relevant yet, 
and has begun to be used for modeling neonatal human infection (94, 255). Adult mice lacking 
key components of the type-I IFN system also represent a lethal challenge model of CHIKV 
infection that may be somewhat less contrived than the neonatal model. Type-I IFN-deficient 
mice exhibit exacerbated arthritic disease compared to wild-type mice and uncontrolled viral 
replication and dissemination that ultimately results in death, underscoring the criticality of IFN-
α/β in protecting mice from CHIKV (93, 94, 256, 257). Thus, these mice represent a useful 
control group against which to measure the contributions of individual components of IFN-α/β 
signaling or other immune mediators in protection from CHIKV challenge. In addition, these 
mice are useful in safety and efficacy studies of new vaccines and therapeutics (238, 258). 
1.2.5.2 Adult wild-type murine acute arthritic models 
Several related adult mouse models of CHIKV acute arthritis have been well-established. Studies 
in three- to eight-week-old outbred CD-1/NIH Swiss or inbred 129 and C57BL/6 (B6) 
background mice have yielded similar disease courses and findings, but the B6 model has proven 
more popular due to the availability of genetic knockouts in this background (93, 183, 184, 201). 
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Subcutaneous inoculation of CHIKV into the ventral side of the rear footpad of these mice 
results in a marked biphasic swelling of the infected foot and ankle region that resolves around 
day 8 post infection. Many features of human acute CHIKV arthritis are recapitulated in this 
model, including cell infiltrate and cytokine profiles, cellular tropism and musculoskeletal tissue 
involvement, and antibody-mediated clearance of viremia (183, 184). Such similarity to human 
disease has led to a plethora of information about the host and viral factors important for driving 
and controlling CHIKV infection, as well as pathogenic and pathologic details. 
1.2.5.3 Mouse models of chronic CHIKV infection 
In adult B6 mice infected with CHIKV, viral RNA has been detected in joint-associated tissues 
at least four months after infection and was associated with persistent synovitis (202), indicating 
that the B6 acute CHIKV model may also serve as a chronic disease model, if given the time. 
Additionally, several groups have attempted to encourage or exacerbate chronic CHIKV 
infection and disease through the use of various adaptive immune knockout strains, such as 
Rag1/2-/- mice, which lack B and T cells, and µMT mice, which are B cell deficient. The disease 
course in these mice does not differ appreciably from wild-type mice in the acute phase, but they 
do exhibit persistent viremia and elevated viral burden in several tissues at chronic time points 
attributable to the lack of effective clearing antibody responses (202, 215, 233, 234, 251). 
Importantly, infectious virus has been recovered from the ankle joints of Rag1-/- mice as late as 6 
weeks post-infection, indicating that persistent viral replication is possible in mouse models 
(202). However, whether or not alterations in the efficacy of human antibody responses underlie 
chronic disease manifestations is unknown.  
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1.2.5.4 Nonhuman primate models 
Infection of cynomolgus macaques with CHIKV results in a clinical disease profile remarkably 
similar to that seen in humans. Kinetics of viremia and systemic dissemination closely followed 
the time course of human infection, and evidence of viral persistence in lymphoid tissues was 
detected at three months post infection (181). Signature cytokines such as IL-6 and MCP-1 were 
also elevated in macaques, and CHIKV-specific antibody epitopes were similar to those 
identified from human cases (181, 259). Rhesus macaques have also been used to study CHIKV 
pathogenesis and immune response and have provided important mechanistic insights regarding 
the route of dissemination from the site of infection and the kinetics of the adaptive immune 
response (232). This study also compared CHIKV disease in adult rhesus macaques to aged (>17 
years old) animals in an effort to understand why and how elderly humans are more predisposed 
to severe and persistent CHIKV (232). 
1.3 TYPE-I INTERFERON 
The type-I interferon response is a critical component of antiviral innate immunity, and its 
efficacy during acute CHIKV infection is a major determinant of clinical outcome, particularly 
with respect to suppression of disseminated virus replication and morbidity prior to the 
development of effective neutralizing antibody responses (33). It is an ancient system, likely 
appearing very early in vertebrate evolution, as all known extant vertebrate genera possess 
homologous versions of this response (260). In humans and other mammals, nearly all somatic 
cells bear the type-I interferon receptor and are equipped with varying repertoires of antiviral 
genes responsive to these cytokines, allowing uninfected cells to preempt viral infection and 
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infected cells to suppress it (261). In response, viruses have collectively evolved extensive 
arsenals of molecular weapons that subvert or directly antagonize type-I interferon at every level 
of the response, from induction pathways to the actions of individual antiviral effectors (262). 
Substantial work since the discovery of type-I interferon in 1957 (263) has elucidated both its 
major signaling pathways and the finer details of its induction and effector phases, as well as 
mechanisms of action for many of its inducible effectors. Most of these studies have, necessarily, 
relied on genetic manipulation of model systems to knock out various components of the 
response and used the subsequent phenotypic changes to piece the signaling puzzle together. The 
resulting knowledge has proven invaluable to the fields of cell biology, innate immunology, and 
virology, among others, and the importance of these studies cannot be overstated. However, little 
of the research on type-I interferon has so far examined this system in situ, so to speak, or as a 
response of an intact organism, being activated and acting in diverse and spatially separated 
tissues with potentially variable physiological conditions. With mild hypothermia representing a 
near pervasive existence for peripheral and respiratory tissues in humans and other endotherms, 
at least in temperate and cooler climates, and with some viral infections preferentially affecting 
these tissues, the question of how immunity, and specifically type-I interferon, is influenced at 
variable temperatures becomes quite relevant. Importantly, type-I interferons are primary 
cytokines detected in the serum after virus infection and are responsible for systemic innate 
immune signaling and responses in tissues both near to and far from their site of production, 
which is commonly macrophages and DCs located in lymphoid organs (118). 
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1.3.1 Definition and classification 
Type-I interferons (IFNs) are a family of secreted protein cytokines that act in an autocrine and 
paracrine manner to stimulate the production of a large subset of responsive gene products 
involved in its antiviral, antiproliferative, and immunomodulatory functions. They belong to the 
class II cytokine superfamily alongside interleukins -10, -19, -20, -22, -24, and -26, and the type-
II and type-III IFNs (260, 264, 265). Despite modest amino acid sequence identity, these 
cytokines share structural similarity, in the form of a bundle of six α-helices, and functional 
similarity, as they all utilize heterodimeric transmembrane receptors that signal through the Janus 
kinase (JAK) – signal transducer and activator of transcription (STAT) pathway (265). There are 
multiple species within the type-I IFN family, including the IFNs α, β, ε, κ, ω in humans and 
additional types in other mammals, such as limitin/IFN-ζ in mice (266), but only the IFN-α 
subtypes and IFN-β are known to contribute substantially to antiviral innate immunity (261, 
264). There are 13 IFN-α subtypes in humans and 14 in mice (266), which are likely to have 
diverged from the single, ancestral IFN-β-like gene through gene duplication events resulting in 
a type-I IFN gene cluster located on chromosome 9 (260, 265). While these distinct species of 
type-I antiviral IFNs demonstrate some degree of specificity in their stimulation and activities 
[reviewed in (267)], the amount of overlap between them in terms of induction and effector 
pathways is so vast and commonly simultaneous that unless otherwise specified, for the purposes 
of this discussion, they will be considered as one entity, which I will call IFN-α/β.  
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1.3.2 Induction pathways 
IFN-α/β is produced in response to a variety of stimuli, and most body cells are capable of IFN-
α/β induction (261). Induction pathways begin with the sensing of pathogen-associated 
molecular patterns (PAMPs) by membrane-bound or cytosolic pattern recognition receptors 
(PRRs). Three families of PRRs contribute to IFN-α/β induction in infectious contexts; the toll-
like receptors (TLRs), the RIG-I-like receptors (RLRs), and the cytoplasmic DNA sensors. TLRs 
are expressed mainly on immune cells and some fibroblasts and epithelial cells, and exhibit 
specificity for viral, bacterial, or fungal antigens, while the cytoplasmic sensors bind nucleic 
acids and are therefore most important for detection of viruses (268). The diverse ligand 
specificity and broad expression patterns of these sensor molecules mediate innate detection of a 
wide variety of PAMPs and activate both distinct and overlapping signaling pathways tuned to 
elicit the appropriate response to a given stimulus. Though not all PRRs lead to appreciable IFN-
α/β induction, those that do converge on the activation of interferon response factors (IRFs), the 
principal transcription factors for IFN-α/β mRNA upregulation. Translation and subsequent 
processing through the secretory pathway then ready the mature cytokines for export into the 
extracellular space, where they can bind receptors on the same or neighboring cells to exert their 
antiviral effects. 
1.3.2.1 Toll-like receptor signaling 
TLRs are class I integral membrane proteins that serve as sensors for a wide array of PAMPs and 
initiate appropriate cell-intrinsic immune responses through both distinct and overlapping 
signaling cascades. The N-terminal TLR extracellular domain contains between 19 and 25 
leucine-rich-repeats that mediate ligand binding specificity. Intracellular signaling capacity is 
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conferred by the C-terminal cytoplasmic Toll/IL-1R homology (TIR) domain (268, 269).  
Humans possess ten TLRs (TLRs 1-10) with different substrate specificities and cell type 
distributions. Of these ten, TLRs 3, 4, 7, 8, and 9 induce a robust IFN-α/β response upon 
activation (261). TLR4 is expressed on the cell surface and exhibits relatively broad substrate 
specificity. Bacterial lipopolysaccharide is usually cited as the major ligand for TLR4, but 
several other agonists, such as fungal mannans and certain viral envelope proteins, have also 
been identified (268). Conversely, TLRs 3, 7, 8, and 9 are found in endosomal and lysosomal 
compartments and primarily engage nucleic acids including dsRNA (TLR3), ssRNA (TLRs 7 
and 8), and unmethylated CpG DNA (TLR9). Thus, these TLRs are most suited for detection of 
viruses, which generally lack the complex, non-self signatures recognized by the other TLRs and 
often traffic through endolysosomal compartments (268). TLR3 is more widely expressed than 
the other endosomal TLRs, which are largely restricted to plasmacytoid and myeloid dendritic 
cells (pDCs and mDCs) (261, 270). 
Upon ligand binding, TLR dimerization and conformational changes recruit TIR-
containing adaptor molecules to the TLR TIR domain. All TLRs except for TLR3 utilize the 
TIR-containing adaptor myeloid differentiation factor 88 (MyD88) to initiate signaling leading to 
induction of proinflammatory cytokines (268, 271). TLR3 instead recruits TIR domain-
containing adaptor protein inducing IFN-β (TRIF) (272, 273), which then activates TANK-
binding kinase 1 (TBK1) and the inhibitor of kappa B kinase epsilon (IKKε) through TRAF3 
(274, 275). Active TBK1 is responsible for the phosphorylation and activation of IRF3, while 
IKKε frees NFκB from its cytoplasmic inhibitors (276, 277). Polyphosphorylated IRF3 then 
homodimerizes and translocates to the nucleus, where it induces the transcription of IFNs β and 
α4, among other innate immune genes such as IFIT1 and IRF7 (278). IFN gene transcription is 
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enhanced by NFκB activity. Upregulation of IRF7 is a feed-forward mechanism to amplify the 
IFN induction pathway and its activation alongside IRF3 by TBK1 results in increased 
transcription of IFN β and α4 as well as induction of the other IFNα subtypes (279-281). In 
immune cells, IRF7 is constitutively expressed, leading to a more rapid induction of maximal 
IFN-α/β transcription (282). TLR4 is also able to recruit TRIF and uses a similar pathway to 
induce IFN-α/β, but can initiate MyD88-dependent signaling for induction of other 
proinflammatory cytokines (283). In DCs, MyD88 is found in complexes with IRF7 at the 
endosomal membrane and can directly activate it in response to ligation of TLR7 or 9, leading to 
particularly robust IFN-α/β responses in these cells (284). 
1.3.2.2 RIG-I-like receptor signaling 
While TLRs demonstrate a great deal of cell type-restricted expression, the RIG-I-like receptors 
(RLRs) are very widely expressed, allowing nearly any body cell to detect and respond to viral 
infection. The RLRs are a family of cytoplasmic DExD/H-box RNA helicases whose stimulation 
results primarily in the activation of IRF3 and/or IRF7 and IFN-α/β production (285). Humans 
express three RLRs; retinoic acid-inducible gene I (RIG-I), melanoma differentiation associated 
protein 5 (MDA5), and laboratory of genetics and physiology 2 (LGP2). RIG-I and MDA5 both 
contain caspase activation and recruitment domains (CARDs), which are essential for 
downstream antiviral signaling, but LGP2 lacks CARDs and cannot independently stimulate 
IFN-α/β production (286). Accordingly, RIG-I and MDA5 are the primary inducers of IFN-α/β 
in response to cytosolic RNA ligands, while LGP2 has been shown to enhance MDA5 signaling 
but repress RIG-I activity, making it an important regulator of the pathway downstream of these 
molecules (286-290). 
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Although RIG-I and MDA5 are structurally and functionally very similar, their roles as 
viral sensors are not completely redundant. They have demonstrated differential abilities to sense 
certain viral infections and have unique substrate specificities (291). RIG-I preferentially binds 
to short dsRNA and 5’-PPP ssRNA (292-294) while MDA5 recognizes longer, highly structured 
dsRNA (295-298) and possibly AU-rich RNA sequences (299, 300). In addition, both RIG-I and 
MDA5 can respond to viral and cellular cleavage products of the antiviral ISG RNase L (301). In 
the absence of an RNA ligand, RLRs exist in an autorepressed conformation wherein the C-
terminal repressor domain obscures the N-terminal CARDs and prevents them from signaling 
(287). Upon engagement of the central helicase domain with a substrate, a conformational 
change exposes the CARDs, allowing homotypic interaction with CARDs of mitochondrial 
antiviral signaling protein (MAVS) (285). This CARD-CARD interaction induces the prion-like 
aggregation of MAVS, which is central to its activation and propagation of the signal to IKKε 
and TBK1 (302). IKKε and TBK1 then activate NFκB and IRF3, as in the TLR pathways, to 
stimulate IFN-α/β transcription. 
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Figure 5: RNA-sensing type-I interferon induction pathways (adapted with permission from (285)) 
1.3.2.3 IFN gene transcription 
In the absence of stimulation, the type-I IFN genes are near completely silenced by the presence 
of condensed chromatin, including nucleosome occlusion of the promoter and transcriptional 
start site, and constitutively-bound repressors (303). The IFNβ promoter contains four cis-acting 
positive regulatory domains, PRDs I-IV (304).  PRD-I and PRD-III are the binding sites for 
activated IRF dimers, while NFκB and the transcription factor complex AP-1 bind to PRD-II and 
PRD-IV, respectively (304). Upon activation and translocation to the nucleus, IRF3/7, NFκB, 
and AP-1 complex with the high mobility group (HMG) A1 protein to form the complete 
enhanceosome (304). The enhanceosome recruits the histone acetyl transferases (HATs) general 
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control of amino acid synthesis 5 (GCN5) and CREB binding protein (CBP) to the nucleosome, 
where they acetylate lysine residues on histones H3 and H4 (305). The acetylated histones allow 
a nucleosome modification complex to dislodge the IFNβ transcription start site from the 
nucleosome, freeing the promoter for recognition by TFIID and assembly of the transcription 
machinery (305). The promoters for the IFNα genes only contain PRDI and PRDIII-like 
elements and are therefore fully activated by IRF binding alone (306). However, the IFNα 
promoters do exhibit differential affinities for IRF family members beyond IRF3 and 7, 
indicating a potential mechanism for gene-specific regulation, particularly in specific cell types, 
depending on the specific state of chromatin and transcription factor binding efficiency at 
different promoters under different conditions (307-309). 
1.3.3 Effector pathways 
While IFN-α/β inductive pathways concurrently produce some antiviral effectors in addition to 
IFNs, such as antiviral genes directly upregulated by IRF3, the full magnitude of the response, 
especially in uninfected bystander cells, is realized through subsequent autocrine and paracrine 
signaling of IFN-α/β. Binding of IFN-α/β to its cell surface receptor, which is expressed on 
nearly all cell types, initiates several distinct signaling cascades which, together, result in the 
induction of over 300 known effectors called interferon-stimulated genes (ISGs). The collective 
action of ISGs in IFN-α/β-primed cells constitutes the “antiviral state,” which renders uninfected 
cells largely refractory to subsequent viral infection and can greatly suppress viral replication in 
infected cells. The major pathway involved in this mass gene induction event is the JAK-STAT 
pathway, but secondary MAPK, CRK, and PI3K signaling serve to augment or regulate JAK-
STAT-mediated responses to IFN-α/β. 
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1.3.3.1 Canonical JAK-STAT signaling 
Upon engagement of the IFNAR by IFN-α/β, dimerization the IFNAR1 and IFNAR2 receptor 
chains bring the nonreceptor tyrosine kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 
(Tyk2), which are constitutively associated with the receptor subunits, into close proximity (310, 
311). JAK1 and Tyk2 then cross-phosphorylate, which activates their kinase domains and allows 
them to phosphorylate the IFNAR chains at multiple tyrosine residues, creating docking sites for 
signal transducer and activator of transcription (STAT) proteins via their Src homology 2 (SH2) 
domains (312-315) Type-I IFN binding most often recruits STAT1 and STAT2 to the receptor 
complex, which are themselves phosphorylated by JAK1 and Tyk2 at Tyr-701 and Tyr-690, 
respectively (310). Phosphorylated STAT1 and STAT2 then form a heterodimer, which joins 
with IRF9 to form the active transcriptional complex interferon stimulated gene factor 3 (ISGF3) 
(316). Phosphorylation of STAT1 at Tyr-701 exposes a nuclear localization signal (NLS), and 
assembled ISGF3 translocates into the nucleus, where it binds to interferon stimulated response 
elements (ISREs) in the promotors of ISGs (317, 318). STAT1 acquires a secondary 
phosphorylation at Ser-727 (319), which fully maximizes its transcriptional ability (320). Other 
homo- and hetero-dimers of STAT proteins can also be assembled in response to IFN-α/β 
signaling, often in an IFN-α subtype- and cell type-dependent manner, but these bind to another 
ISG promoter element, the IFN-γ-activated site (GAS), rather than ISREs (310, 316, 321-323). 
1.3.3.2 Accessory signaling pathways 
In addition to the JAK-STAT pathway, IFN-α/β stimulates other signaling cascades including 
mitogen activated protein kinase (MAPK) family members, and the CT10 regulator of kinase 
(Crk) and phosphoinositol-3-kinase (PI3K) pathways. Activation of multiple signaling cascades 
is thought to confer some of the diversity of cellular responses to IFN-α/β and allow fine-tuning 
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of the response in different contexts and cell types (324, 325). MAPK signaling pathways are 
quite diverse and involved in many cellular functions. In IFN-α/β signaling, activation of p38 
MAPK is central to its antiviral and antiproliferative functions, with transcription of several ISGs 
shown to be dependent on downstream effectors of p38, including chromatin modifiers and 
histone kinases (325, 326). However, activation of the p38 pathway is not required for activation 
or nuclear translocation of STATs, indicating that this pathway operates independently of the 
JAK-STAT pathway in response to IFNs (327, 328). In addition, CrkL has been shown to 
interact directly with Tyk2 via its SH2 domain and become tyrosine-phosphorylated in response 
to IFN-α/β signaling, which then activates the small GTPase RAP1 through interaction with the 
guanine exchange factor C3G (329). RAP1 is thought to positively regulate p38MAPK signaling 
and contribute to the antiproliferative effects of IFNs (330). Finally, SH2-mediated activation of 
PI3K leads to activation of protein kinase c (PKC) isoforms, especially PKC-δ, which is 
responsible for phosphorylation of STAT1 at Ser727 (331). PI3K also regulates IFN-induced 
apoptosis through activation of AKT and mTOR, which can also selectively regulate ISG 
translation (325). 
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Figure 6: Signaling pathways stimulated by IFN-α/β (adapted with permission from (261)) 
1.3.3.3 ISG transcriptional regulation 
Transcription of ISGs involves a multitude of regulators activated by the pathways described 
above. In the absence of an IFN-α/β signal, the chromatin structure around ISG promoters is kept 
closed by a ternary complex of repressors and higher-ordered nucleosomes (332). However, this 
is offset somewhat by the presence of the nucleosome remodeling complexes BAF and PBAF, 
which constitutively prime ISGs for rapid induction upon IFN-α/β signaling (333-335). When 
that signal occurs, ISGF3-associated IRF9 binds to ISRE regions in ISG promoters, and creates 
binding sites for STAT1 and STAT2, which exert strong pro-transcriptional activity (336). Some 
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ISG promoters contain either ISREs or GAS elements, while others have both, indicating that 
different STAT combinations determine optimal transcription of different ISGs (325). In addition 
to STATs, several other co-activators are required for ISG transcription. STATs in the nucleus 
interact with the HAT family members cAMP-responsive element binding protein (CREB)-
binding protein (CBP)/p300 and GCN5, which further open the chromatin surrounding ISG 
promoters (337-342). STAT1 Ser727 phosphorylation is required for recruitment of these 
proteins, which probably contributes to the transcription-enhancing effects of p-Ser727. In 
addition, STAT-dependent gene induction has also been shown to be dependent on a number of 
other factors, including, paradoxically, histone deacetylases (HDACs) (343, 344), whose activity 
may be required for the recruitment of RNA polymerase II (345). Other coactivators, including 
minichromosome maintenance (MCM) 5 and 3 and N-Myc interactor, also facilitate ISG 
transcription, while several corepressors, including members of the protein inhibitor of activated 
STAT (PIAS) family of proteins act as corepressors (340, 341, 346, 347). 
Beyond this canonical regulation of ISG transcription, numerous noncanonical 
transcription factors and transcriptional regulators have been identified that contribute to 
modulation of ISG expression. These include variants of the ISGF3 complex (348, 349), a CrkL-
STAT5 dimer that binds GAS elements (350), and additional IRFs. IRF1, which is induced by 
IFN-α/β signaling, can bind to certain ISG promoters at a site that partially overlaps the ISRE, 
leading to their activation, while IRF2 can competitively inhibit this binding and negatively 
regulate ISG expression (351-353). IRF3, in addition to its crucial role in IFN-α/β induction, can 
also directly induce a subset of ISGs in an ISRE-dependent manner, as alluded to above (354, 
355). Retinoic acid has also been shown to enhance IFN-α/β responses and ISG induction, and 
most ISG promoters contain retinoic acid response elements (RAREs) (356). It is thought that 
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retinoic acid facilitates binding of other transcription factors and works synergistically with IFNs 
to induce ISGs (356).  
1.3.4 ISG functions and the antiviral state 
ISGs are the functional units of the IFN-α/β response and their combined activities confer onto 
activated cells the ability to combat an existing intracellular infection or prevent the 
establishment of one. This heightened infection-refractory phenotype is known as the antiviral 
state. Over 300 ISGs have been identified, and their functions range from direct interference with 
viral processes and positive regulation of IFN-associated signaling pathways to pro-apoptotic 
mediators and direct inhibitors of IFN signaling. Most PRRs are present at low levels in the cell 
prior to viral infection to minimize the risk of aberrant activation and unnecessary inflammation, 
so their rapid upregulation in response to IFN-α/β greatly enhances the ability of infected and 
bystander cells to sense infection and mount an appropriately potent response (357). Both RLRs 
and TLRs are ISGs, as are the RNA-sensing molecules oligoadenylate synthetase (OAS) and 
double-stranded RNA-dependent protein kinase (PKR). OAS proteins detect foreign RNA 
species and produce 2’-5’-oligoadenylates, which act as second messengers to activate RNaseL, 
which promiscuously cleaves both host and viral RNAs, generating additional PAMPs for 
detection by PRRs and reinforcement of the IFN-α/β response (358). Concurrently, PKR 
activation leads to a global repression of translation in an effort to limit production of viral 
proteins while stabilizing IFN gene mRNAs to selectively enhance their translation (359) In 
addition, many IRFs and STATs are upregulated by IFN-α/β, including IRFs 1, 3, 7, and 9, and 
both STATs 1 and 2, each with crucial roles in enhancing IFN gene and ISG production (357). 
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Besides bolstering the innate and adaptive immune signaling capacity of activated cells, 
ISGs are also responsible for the opposite effect, that is, providing a means for efficient 
resolution of IFN responses and preventing cellular toxicity that can accompany prolonged 
activation. Endocytosis of the IFNAR and the actions of various non-ISG phosphatases also play 
important roles in limiting IFN responses (357). The PIAS proteins mentioned above also inhibit 
STAT function by preventing their interaction with DNA as well as targeting them for 
degradation via SUMOylation (360-362). Of the ISGs that negatively regulate IFN-α/β signaling, 
the suppressors of cytokine signaling (SOCS) family proteins and the ubiquitin-specific 
peptidase 18 (USP18) are the best characterized. SOCS proteins are SH2 domain-containing 
proteins that are induced rapidly by IFN-α/β signaling and inhibit the JAK-STAT pathway in two 
main ways. First, they bind to phosphorylated tyrosine residues on the IFNAR or JAKs, thereby 
preventing STAT binding (363). Secondly, their C-terminal SOCS box domains are involved in 
recruiting ubiquitin ligases to the receptor complex to target it for degradation (364). USP18 
binds directly to the cytoplasmic tail of IFNAR2 and limit its interaction with JAK1 (365). In 
addition, USP18 binding to IFNAR2 appears to alter its extracellular conformation, abrogating 
its binding with IFN-α and reducing its affinity for IFN-β (366, 367). This differential binding 
phenotype has been suggested to be an example mechanism by which distinct IFN species can 
cause diverse cellular outcomes despite usage of the same receptor (357). 
The antiviral ISGs comprise a highly varied set of effectors that are collectively known to 
target every stage of a viral life cycle. Several have been well-characterized and together exhibit 
highly diverse mechanisms of action, but the majority await detailed characterization. 
Additionally, efforts to parse out which ISGs are critical for restricting which viruses – and how 
– continue. Below, I will summarize the functions of a few select ISGs that are well-
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characterized and/or have demonstrated anti-arboviral activity to illustrate the mechanistic 
diversity of this response. 
1.3.4.1 Myxovirus resistance (Mx) 
Mx proteins belong to a family of dynamin-like guanosine triphosphatases (GTPases) and are 
among the most recognizable of the “classical” ISGs. They were so named for their potent 
restriction of influenza virus, an orthomyxovirus. Humans encode two Mx proteins, Mx1 and 
Mx2, and neither of their mechanisms of action have been fully elucidated. Of the two, Mx1 is 
the more broadly-acting and better characterized. Mx1 is known to form oligomeric ring 
structures that are required for its ability to induce conformational changes in its binding partners 
and its antiviral activity (368, 369). Thus, Mx1 oligomers are thought to surround viral 
nucleocapsids at an early stage post-entry and direct them to degradation pathways, although the 
details of how this works are unknow (357). Less is known about Mx2, and it does not appear to 
be active against as many viruses as Mx1, ironically including influenza A. However, it has been 
shown to be a critical effector against HIV infection, but not other retroviruses, by preventing 
translocation of the reverse-transcribed genome into the nucleus and, as a result, integration of 
HIV into the host cell genome (370-372). 
1.3.4.2 Interferon-induced protein with tetracopeptide repeats (IFIT) 
The IFIT family of ISGs are broadly-acting translation suppressors and contain five members in 
humans, IFIT1, IFIT1B, IFIT2, IFIT3, and IFIT5 (373). They are not typically expressed under 
basal conditions in most cell types, but are rapidly and potently induced by both IRF3 and ISGF3 
activation (354, 374). The best-characterized IFIT protein is murine Ifit1b (formerly Ifit1) (375). 
This protein restricts translation of RNA virus genomes that lack 2’-O-methylation on their 5’ 
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guanosine cap (i.e. have a type-0 cap) either by directly binding to the RNA and preventing its 
association with the translational machinery or by preventing its recognition by the eIF3 complex 
(373, 376). Many RNA viruses, including flaviviruses and coronaviruses, subvert Ifit1b 
restriction by adding type-I caps to their genomic RNAs. Alphaviruses, however, have type-0 
caps but evade recognition by Ifit1b due to conserved stem-loop structures in their 5’ UTRs 
(377). The other IFIT family members are also translational repressors and may be involved in 
discrimination of self and non-self RNA, but their activities are not dependent on type-0 cap 
structures (378). 
1.3.4.3 Interferon-inducible transmembrane (IFITM) 
The IFITM family proteins were the first ISGs known to inhibit virus entry into cells. They are 
enriched in endosome and lysosome membranes, and have particularly potent effects on viruses 
that require endocytosis for cell entry (379, 380). Humans express four IFITM proteins, IFITMs 
1-3 and IFITM 5, and each seems to selectively inhibit certain subsets of viruses (357). Although 
most of the viruses shown to be IFITM-sensitive have been enveloped, recently reovirus entry 
was reported to be inhibited by IFITM3 (381). The molecular details of IFITM-mediated viral 
entry restriction are unknown, but it has been proposed that IFITMs modify the physical 
properties of endolysosomal membranes, such as fluidity or curvature, that could impact viral 
escape from these compartments (382). IFITMs may also alter the kinetics of endosome 
maturation, such as acidification, and thereby interfere with the timing of viral processes 
necessary for efficient entry into cells (357, 373). The importance of IFITM3 against arboviruses 
was recently demonstrated in studies of alphaviruses and flaviviruses. In one study, Ifitm3-/- mice 
were significantly more sensitive to CHIKV and VEEV infection than wild-type mice (383) and 
similar results were obtained in a mouse model of WNV (384). 
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1.3.4.4 Zinc finger antiviral protein (ZAP) 
Like the IFITs, ZAP is transcriptionally induced by both ISGF3 and IRF3 (385, 386). It is a 
member of the poly(ADP-ribose) polymerase (PARP) family with activity against several RNA 
viruses including alphaviruses (387), retroviruses (388, 389), and filoviruses (390), and hepatitis 
B virus (391). ZAP is thought to prevent initial translation of incoming viral genomes by directly 
binding to viral RNA and targeting it for degradation by recruiting the RNA processing exosome  
(392). It may also inhibit viral RNA translation through interaction with different eukaryotic 
initiation factors (393). 
1.3.4.5 Interferon-stimulated gene 15 kDa (ISG15) 
ISG15 is a ubiquitin-like protein that is very highly induced by IFN-α/β and exerts pleiotropic 
effects on its vast array of protein targets. ISG15 becomes covalently attached to lysine residues 
of nascent polypeptide chains of both host and viral origin in a process termed ISGylation (394). 
ISGylation can have very different effects on its target proteins, and thus can exert antiviral 
activity in a variety of ways. For example, ISG15 linkage to IRF3 makes IRF3 more resistant to 
ubiquitin-mediated degradation and prolongs its transcriptional activity (395), but attachment to 
cyclin D1 results in destabilization and cell cycle inhibition (396). As the list of targets for 
ISG15 continues to expand, the view that ISGylation may represent a very broad and nonspecific 
mediator of antiviral defense strengthens, and it may be that all proteins are co-translationally 
ISGylated in IFN-α/β-primed cells, with largely undefined effects (397). 
1.3.4.6 Interferon-stimulated gene 20 kDa (ISG20) 
ISG20 is a 3’-5’ exonuclease that can directly degrade ssRNA and ssDNA, with a substantial 
preference for ssRNA and little or no activity against dsRNA (398). ISG20 has reported antiviral 
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activity against a wide range of RNA viruses, including alphaviruses, vesicular stomatitis virus, 
influenza A, YFV, hepatitis A and C viruses, HIV, and several bunyaviruses (387, 399-402) 
Curiously, it is unlikely that ISG20 restricts these viruses by direct degradation of genomic or 
transcribed viral RNAs considering that ISG20 is localized to various intranuclear compartments 
(403). However, viral RNA degradation was demonstrated against hepatitis B virus, which 
transcribes viral RNA in the nucleus and uses it as a template for reverse-transcription of viral 
genomic DNA (404). Thus, direct degradation of viral RNA is an antiviral mechanism of ISG20, 
provided those RNAs are inside of the nucleus. For RNA viruses that replicate entirely in the 
cytoplasm, the mechanism(s) of ISG20-mediated restriction are less clear, but there is emerging 
evidence that ISG20 can globally enhance transcription of other ISGs, thus indirectly 
contributing to the cytoplasmic antiviral state (Weiss et al. 2018. mSphere. Under review).  
1.3.4.7 Virus inhibitory protein, endoplasmic reticulum-associated, IFN-inducible (Viperin)  
Viperin is induced by JAK-STAT signaling as well as activated IRF1 and IRF3 (405-409). It is 
localized to the ER and ER-derived lipid droplets and interferes with lipid-relevant steps in the 
replication cycles of diverse enveloped viruses (357). Mechanistically, viperin has been shown to 
inhibit genome replication of DENV, WNV, and the somewhat related flavivirus (genus 
hepacivirus) hepatitis C virus by binding to components of the viral replicase (410-412). As 
flaviviruses form extensive membranous structures in which to replicate, viperin gains access to 
the viral replicases by virtue of its association with lipid droplets, which are included in these 
structures (357). In addition, viperin has been reported to inhibit the budding process in HIV-1 
and influenza-A infections (413, 414). 
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1.3.5 Effects of IFN-α/β on innate and adaptive immunity 
Beyond the canonical induction of cell-intrinsic immunity, type-I IFNs work in other ways to 
promote innate and adaptive immune responses through action on DCs, B and T lymphocytes, 
and natural killer (NK) cells. In immature DCs, IFN-α/β signaling contributes to the maturation 
process by increasing cell surface expression of the major histocompatibility complexes and the 
costimulatory molecules CD80 and CD86, which are required for efficient antigen presentation 
and activation of T cells (415, 416). In T cells, the effects of IFN-α/β are very context-dependent 
and may be activating or inhibiting, either of which may lead to increased or decreased 
pathology. CD4+ T cell survival and B cell activating ability seem to be enhanced by IFN-α/β in 
response to viral infection (417), and IFN-α/β encourages a TH1, IFN-γ-producing phenotype 
(418). CD8+ T cell responses to IFN-α/β depend on the relative levels of STAT1 versus other 
STATs, as predominant STAT1-mediated signaling leads to antiproliferative effects, while 
STAT3/5 activation promotes clonal expansion (419, 420). CD8+ T cell functionality may be 
regulated in similar manner, with IFN-γ production either repressed or enhanced depending on 
whether or not signaling occurs through STAT1 or STAT4 (421, 422), although cytotoxicity is 
generally positively regulated (423-425). IFN-γ expression in NK cells is also regulated this way 
(421, 426). It is increasingly clear that the effects of IFN-α/β on T cell expansion and function 
depend on the magnitude and timing of the IFN-α/β response itself, as well as the specific 
expression of different signaling intermediates in the target T cells (427-429). B cells, on the 
other hand, seem to be universally positively regulated by IFN-α/β, and display early activation 
and enhanced antibody class switching in response to various viral infections (430-434). 
While there are certainly demonstrable positive effects of IFN-α/β signaling on the 
development of other innate and adaptive immune responses, our understanding of the fine 
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balances involved in these interactions is far from complete. For instance, much of the 
foundational information regarding the role of IFN-α/β on the development of adaptive immunity 
has come from a limited number of infectious models, such as lymphocytic choriomeningitis 
virus (LCMV) infections of mice. However, as specific effects are highly context-dependent and 
nuanced, it is probable that “known” effects of IFN-α/β on immune cells and its requirement for 
certain aspects of immune maturation may be quite different in other infections. For example, the 
IFN-α/β response is not stringently required for induction of adaptive immunity following 
vaccination with the yellow fever virus (YFV) vaccine strain 17D, as vaccinated IFNAR-/- mice 
develop robust CD4+, CD8+, and antibody responses that confer protective immunity against a 
subsequent lethal challenge with wild-type YFV (435). In addition, the relationship between 
IFN-α/β and disease outcomes during chronic viral infections seems to be a detrimental one for 
the host. Simian immunodeficiency virus (SIV)-infected macaques and human 
immunodeficiency virus (HIV) patients with rapid disease progression display higher levels of 
IFN-α/β activation than non-progressors, which may lead to aberrant T cell recruitment or 
expansion and impede viral clearance (261, 436-438). Similarly, blocking of chronic IFN-α/β 
activation during LCMV infection aided CD4+ T cell-mediated viral control by preventing 
induction of inhibitory molecules such as IL-10 and PDL-1 (439, 440). This type of chronic 
immune suppression may very well operate in other chronic infections, but the details of other 
systems, including the potential contribution of IFN-α/β to chronic viral control as well as effects 
on other immune components, remain to be investigated. 
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1.4 PHYSIOLOGICAL TEMPERATURE VARIATION 
The majority of human infectious disease research is conducted, naturally, under conditions 
aimed to recapitulate the homeostatic conditions of the human body. One parameter easily 
controlled during such applications as mammalian cell culture is ambient temperature, with 
37°C, the historical average for the mammalian core body temperature, being the archetypal set 
point. However, other, equally valid physiological temperature states exist both within the 
human body and throughout the living world that may influence the cellular and organismal 
processes usually studied at 37°C. For example, other species may have elevated (birds) or 
depressed (reptiles, fish) core temperature optima, yet each has innate and adaptive immune 
responses that must function in these conditions. In the context of infectious diseases, 
conventional wisdom tells us to let a fever burn and that being out in the cold will make you 
catch a cold. Some studies have begun to explore the validity behind these statements, but our 
understanding of how temperature variation can affect immune system function, in response to 
an infection or otherwise, is far from complete. Of particular interest, and one of the central 
themes of this dissertation, is the extent to which, and by what mechanisms, temperature 
variation in host tissues may impact the fitness and pathogenesis of arboviruses, which have the 
ability to replicate efficiently across a broad temperature range due to their adaptation to both 
vertebrate hosts and invertebrate (arthropod) vectors. Within a human host, these viruses display 
a broad cellular tropism, invading myriad tissues in different thermal compartments, from the 
most superficial skin layers to deepest tissues of the visceral organs and central nervous system. 
In the following section, I will discuss the major mechanisms of human thermoregulation and 
how they result in temperature variation between anatomical compartments. I will also describe 
sources of tissue temperature variation under abnormal circumstances such as fever, and the 
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cellular responses to thermal stress. Finally, I will discuss known effects of temperature variation 
on immune responses that may influence arboviral pathogenesis and disease. 
1.4.1 Mechanisms of thermoregulation for core temperature maintenance 
Maintenance of core body temperature within a narrow, optimal range regardless of 
environmental conditions is among the most critical homeostatic requirements for endothermic 
organisms. Accordingly, humans have evolved a complex and multilayered thermoregulatory 
apparatus that has enabled the successful colonization of widely varied climatic regions across 
the globe. In any climate, successful core temperature maintenance is dependent upon the body’s 
ability to balance metabolic heat production with heat loss to its surroundings. Under resting 
conditions, most metabolic heat is produced by deep organs such as the brain, heart, and liver, 
and delivered to the peripheral and superficial tissues (limbs, skeletal muscle, subcutaneous fat, 
and skin) primarily by convection from the bloodstream (441). Heat dissipation to the 
surroundings at the skin’s surface can occur through evaporation, convection, radiation, and 
conduction with the relative contributions of each mechanism dependent on the magnitude and 
direction of the thermal gradient between the skin and the environment (442). Similarly, heat can 
be gained from the environment through the skin by radiation, and by conduction and convection 
if the temperature of the surroundings is higher than that of the skin. At rest in a thermoneutral 
environment, which in humans has been determined empirically to be between 24 and 28°C for 
air temperature (443-446), heat balance is achieved without dedicated energy expenditure on 
thermoregulatory processes because the rate of metabolic heat production equals the rate of heat 
dissipation and body temperature is maintained. When heat production exceeds dissipation, body 
tissues must store the excess heat, causing temperatures to rise. Conversely, when heat loss 
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occurs more rapidly than it can be replaced, body temperature falls (441). Human tolerance for 
these non-thermoneutral circumstances is borne from both physiological and behavioral 
responses to rising or falling body temperature, with opposing mechanisms (active heat 
conservation versus active heat dissipation) usually stimulated at threshold temperatures within 
just 0.2°C of one another (441, 447). These responses are aimed to curb the effects of the thermal 
stress and maintain deep (core) tissue temperature around 37°C, however, core temperature 
maintenance often comes at the expense of the peripheral tissues. 
1.4.1.1    Physiological and behavioral responses to cold exposure 
When the environmental temperature is lower than the skin surface temperature, 
convective heat loss from the bloodstream predominates skin surface cooling, with contributions 
from radiation and evaporation. Conduction of heat from static tissues to other static materials 
(solid objects or static fluids) usually accounts for very little of the total heat loss in any given 
environment (442). The skin contains a high density of cold-sensitive thermoreceptors, and thus 
autonomic thermoregulatory responses to cold are activated first upon reduction in skin 
temperature and are later reinforced by a subsequent drop in core temperature (441, 448). 
Afferent signals from cold-sensitive neurons in the skin are transmitted to the preoptic anterior 
hypothalamus, which is often described as the body’s “thermostat,” and which can centrally 
integrate thermal signals from all regions of the body (sometimes called “mean body 
temperature” (448)) to effect the appropriate responses (447, 448). Of note, local afferent signals 
can also elicit efferent responses without central integration at the hypothalamus, as different 
efferent responses appear to be activated at different core and skin threshold temperatures (449), 
resulting in localized thermoregulatory mechanisms acting independently of a systemic response 
(450). The sum of these local responses along with hypothalamic integration of thermal signals 
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yields the core body temperature balance point of 37°C, which is the product of the 
thermoregulatory efforts, rather than the standard against which they are measured (441). When 
skin temperature falls below a threshold of about 35°C (451), the body will attempt to limit 
further heat loss by employing cutaneous vasoconstriction. Smooth muscle contraction mediated 
by alpha-adrenergic sympathetic nerves innervating cutaneous blood vessels limits blood flow 
close to the skin surface (452). Thus, convective heat loss from the body core is reduced and the 
insulative effect of the periphery is increased, albeit at the expense of peripheral tissues, which 
continue to decrease in temperature (448). Although this mechanism operates in both non-
glabrous (hairy) and glabrous skin, arteriovenous shunts specifically designed for 
thermoregulatory redirection of blood flow are concentrated in the glabrous (non-hairy) skin of 
acral regions (i.e. palms of hands, soles of feet, fingers, toes, tip of nose and ears) and make these 
regions the major contributors to heat conservation at the skin surface, especially during whole-
body and reflexive vasoconstriction (441, 447, 448). These arteriovenous shunts are 
approximately 100 µm in diameter and close near completely during cold stress, effectively 
shunting 10,000 times more heat-carrying blood away from the skin surface than an equal length 
of constricted 10-µm capillary, making the shunts particularly efficient (447). Importantly, 
arteriovenous shunting under mild to moderate cold stress does not affect nutritional blood flow 
through distal capillary beds, nor does it impact systemic blood pressure, which is maintained by 
larger and more central arterioles (447). However, as these shunts are concentrated in acral 
regions, activation of vasoconstriction at these sites sharpens the temperature gradient between 
proximal and distal body tissues during cold stress and renders these regions particularly prone to 
damage and loss of dexterity due to severely lowered temperatures (441, 447, 453). 
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Peripheral vasoconstriction is the first-line defense against core temperature reduction, 
but is limited in its capacity to prevent hypothermia in the face of severe or prolonged cold 
exposure, as maximal vasoconstriction is reached at a skin temperature of approximately 31°C 
(451). When heat conservation alone is insufficient to maintain core temperature, thermogenic 
mechanisms must supplement vasoconstriction. Nonshivering thermogenesis is activated by 
catecholamine stimulation of beta-3 adrenergic nerves that terminate on brown adipose tissue 
(441). Rich in specialized mitochondria where oxidative metabolism can be uncoupled from 
ATP synthesis in response to cold signals, this tissue generates heat by increasing metabolic rate 
and energy expenditure (441, 454, 455). This mechanism of heat generation is critical in many 
small mammals and human infants, and plays a smaller but established role in thermogenesis in 
older children and adults, although the specific type of adipose tissue involved may be different 
(447, 456). In contrast, shivering thermogenesis is the principal source of autonomic heat 
generation in response to cold stress in humans older than a few years (447). Shivering serves to 
increase the resting metabolic rate 2-3-fold through involuntary, oscillating contractions of 
skeletal muscle (457). As these contractions hydrolyze ATP without coupling it to concurrent 
biochemical processes, that energy is released as heat (441). Shivering is initially stimulated 
upon cold exposure due to falling skin temperature, but is maintained and strengthened in 
response to falling core temperature (458), reaching maximal intensity with involvement of most 
skeletal muscle groups at a core temperature of approximately 34-35°C (459). Piloerection, or 
the contraction of the erector pili muscles at the base of hair follicles, causes hair normally lying 
parallel to the skin’s surface to stand upright in response to cold signals to trap an insulating 
layer of air close to the skin’s surface (441). Although by itself piloerection does little to 
conserve heat in humans versus other mammals due to our comparative lack of hair and 
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predilection for clothing, it has been suggested that this response may augment the effectiveness 
of shivering (442). 
Together, vasoconstriction and shivering thermogenesis act to limit heat loss from the 
skin’s surface and generate additional metabolic heat, which is conserved in the body core due to 
simultaneous peripheral vasoconstriction. The result is that deep body tissue temperature is 
preserved while skin and peripheral tissue temperatures are allowed to fall. However, these 
autonomic thermoregulatory processes are only effective to a point, and upon prolonged or 
severe cold exposure, heat dissipation will exceed heat production and both core and peripheral 
temperatures will continue to drop. Thus, the most effective responses to cold exposure are 
behavioral, motivated by feelings of thermal discomfort in response to afferent signals from the 
skin and processed through multiple brain regions (441). Heat-seeking activities such as finding 
shelter or building a fire combined with heat-conservatory efforts like covering the skin’s surface 
with clothing and taking on a huddled posture are common behavioral responses to cold 
exposure. Voluntarily increasing activity levels through exercising or fidgeting is also effective 
in increasing metabolic heat production. When behavioral responses to cold exposure are 
inadequate or unavailable, or when thermoregulatory mechanisms have been disabled, such as 
due to blood loss from traumatic injury, heat dissipation from the body induces a hypothermic 
state, which is defined as a core temperature below 35°C (460). Continual drop in core 
temperature results in increasingly harmful physiological reactions, depending on the depth of 
the hypothermia, beginning with central nervous system and cardiovascular impairment at core 
temperatures above 33°C, and ending with death by cardiac failure (461). 
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1.4.2 Physiological and behavioral responses to heat exposure 
In addition to cold stress, during which core heat conservation is paramount, humans are 
also regularly confronted with environmental or exertional heat stress, which demands efficient 
heat loss mechanisms to keep the core temperature from rising. When heat production and/or 
absorption by the body exceeds dissipation, heat stored by body tissues causes core and skin 
temperatures to increase. The increased temperature is sensed by heat-sensitive thermoreceptors 
located primarily in deep tissues such as the hypothalamus, spinal cord, viscera, and deep veins, 
but also to a lesser extent in the skin (450), which then activate sympathetic cholinergic nerves 
terminating on eccrine glands in the skin, causing the release of sweat onto the skin’s surface 
(441, 447). Sweat is an ultrafiltrate of plasma comprised mostly of water (447). The ensuing 
evaporative cooling is an important defense against core temperature elevation regardless of 
ambient temperature, but becomes the body’s sole heat loss mechanism when ambient 
temperature is higher than skin surface temperature, as convective and radiant heat loss rely on 
temperature gradients (442). Sweating efficiency is accompanied and enhanced by cutaneous 
vasodilation, which maximizes blood flow to the skin, bringing body heat as close to the skin 
surface as possible to encourage dissipation to the environment (447). Although the exact 
molecular mechanisms governing cutaneous vasodilation have not been confirmed, it is thought 
that the same cholinergic nerves that stimulate eccrine glands concomitantly induce vasodilation 
to rapidly maximize heat dissipation (441). In addition, the acral arteriovenous shunts that close 
in response to cold exposure passively open upon warming due to the absence of a cold signal 
(462, 463), further enhancing convective and evaporative heat loss. Combined, sweating and 
peripheral vasodilation are effective in preventing core temperature elevation under mild to 
moderate heat stress, but excessive heat exposure or physical exertion (especially in warm 
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conditions) requires behavioral responses to avoid overheating. Voluntary responses to heat 
stress can range from shedding of clothing and reduction in overall activity level to discourage 
metabolic heat production and storage, to movement to an area of lower ambient temperature. 
Unsurprisingly, behavioral thermoregulation is far more effective than autonomic mechanisms as 
it works to reduce or eliminate the thermal stress itself, rather than simply mitigating its effects 
(441). 
1.4.3 Temperature variation between anatomical compartments 
Maintenance of a stable core temperature often involves thermal instability in peripheral tissues. 
Even under conditions of thermoneutrality, there still exists a core-to-peripheral temperature 
gradient in which the deep tissues of the head and trunk (the body core compartment) maintain 
an elevated temperature versus the shell compartment (superficial and peripheral tissues of the 
skin and limbs), which is typically about 4°C cooler than the core (441, 464). At rest, most 
metabolic heat is produced in the central, deep organs, whereas heat loss to the environment 
occurs almost exclusively at the skin surface and respiratory passages (441). Thus, a thermal 
gradient exists in which body heat flows from the deep body core outward. Conduction of heat 
through and between adjacent tissues toward the skin surface accounts for very little of body heat 
redistribution, and instead heat redistribution relies most heavily on circulation by the 
bloodstream (442). Distal extremities (hands and feet) are the main sites for cutaneous heat loss 
and are also the last to be perfused with warm blood, after heat transfer to more proximal tissues 
has already occurred (447). Compounded by slow capillary perfusion rates, a high surface area-
to-mass ratio, and little capacity for metabolic heat production, even “deep” tissues in the 
extremities are prone to heat loss and temperature reduction (126). The net result of these factors 
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is a well-documented core-to-peripheral temperature gradient, with the body core compartment 
maintained at 37°C, and peripheral tissues steadily decreasing in temperature as distance from 
the body core increases. 
Many of the studies addressing the core-to-peripheral temperature gradient and heat flow 
and distribution within the human body have come from the field of anesthesiology. Under 
general anesthesia, thermoregulatory mechanisms are hindered or inhibited, resulting in a 
moderate core temperature depression that can be a complicating factor in patient well-being 
during and after surgery (465). Therefore, there has been interest in studying how core body heat 
is redistributed in anesthetized patients to develop strategies to counter or prevent intraoperative 
hypothermia. An ancillary but useful result of these studies has been their contribution to our 
knowledge of precise tissue temperatures within the peripheral thermal compartment, 
particularly the severity of temperature gradients between proximal and distal sites within a 
human limb under normal conditions. In one such study, an extensive series of thermocouples 
inserted at varying tissue depths in the periphery of healthy volunteers revealed that, upon 
induction of general anesthesia, core hypothermia resulted primarily from body heat shunting to 
distal limb compartments, rather than direct cutaneous heat loss (466). This finding reflects the 
capacity of peripheral tissues to gain heat from the body core along the core-peripheral 
temperature gradient when vasoconstrictor activity is abrogated by anesthetization. Importantly, 
this study also revealed that prior to induction of anesthesia, resting limb temperatures, 
calculated as a volume-weighted average of defined segments and tissue depths, were around 
33°C with distal extremity temperatures as low as 31°C under room-temperature (22°C) 
conditions (466). These findings highlight an important point concerning human body 
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temperature in that, under room temperature conditions, tissue temperatures in the peripheral 
thermal compartment can be substantially lower than in the core compartment.  
Other studies have recapitulated the peripheral tissue temperature measurements 
described above using similar methodology (467-469). As a result, attempts to define the exact 
physical volumes occupied by the core and peripheral thermal compartments, and how the sizes 
of those compartments change during general anesthesia, have been made. One study concluded 
that the core thermal compartment, carefully maintained at 37°C, includes tissues extending into 
the upper arm and thigh, with the core-peripheral temperature gradient extending radially from 
the interior of the proximal limbs toward the skin, and the core compartment reaching within 2.5-
7 mm from the skin’s surface (470). Another study examining more distal sites found that the 
core thermal compartment does not reach so close to the skin’s surface, and tissues within 1.8 cm 
of the skin’s surface (in this case, on the foot) display sub-core temperatures and the expected 
temperature gradient (471). Thus, in the extremities and acral regions, tissue depth is insufficient 
for maintenance of the core thermal compartment, and even relatively deep tissues at these sites, 
the muscles, bones, and joints, are fully immersed in the temperature variability of the peripheral 
thermal compartment. Of note, other bodily regions, namely the upper airways and the testes, 
also average tissue temperatures below 37°C. Inhalation of (usually) cooler ambient air results in 
high evaporative heat loss from the upper airways, and 33°C is considered a standard 
approximation of upper airway temperature (472). Testicular temperature between 33 and 35°C 
is optimal for spermatogenesis, and thus human testicles are separated spatially from the body 
core and designed for heat dissipation, with thin skin, minimal subcutaneous fat, and dense 
eccrine glands (473). In sum, humans experience a high degree of regional body temperature 
variation even under conditions of thermal comfort and thermoneutrality, and this variation is 
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exacerbated under conditions of cold stress. Heat stress can also result in increased whole-body 
temperatures, but this generally decreases regional temperature variation. However, many 
physiological conditions stemming from demographic factors, disease states, and voluntary 
behaviors can greatly impact human thermoregulatory mechanisms and cause abnormal variation 
in body temperature.       
1.4.4 Physiological factors affecting human body temperature 
1.4.4.1 Impaired circulation 
As body heat redistribution from core tissues to the periphery is centrally dependent on blood 
circulation and convective heat transfer, any condition leading to impaired peripheral circulation 
will reduce heat delivery to peripheral tissues and steepen the core-peripheral thermal gradient. 
Poor circulation, regardless of the underlying cause, results from narrowing or blocking of blood 
vessels, such that blood flow through those vessels decreases and blood pressure increases. 
Unsurprisingly, cardiovascular diseases such as peripheral artery disease and atherosclerosis in 
peripheral vessels, by definition, result in decreased blood circulation in peripheral tissues. Thus, 
people with certain cardiovascular diseases may experience symptoms such as pain, numbness, 
and coldness in tissues suffering inadequate perfusion, most prominently in the limbs and 
extremities. Aging is also associated with circulatory dysfunction, in no small part due to higher 
incidences of cardiovascular diseases in the elderly (474). However, thermoregulatory 
mechanisms also degenerate with age, which contributes to decreased thermal tolerance and a 
higher risk for temperature-associated injury (475). In older individuals, the vasoconstrictor 
response becomes blunted due to decreased synthesis and release of noradrenaline (475) and 
falling muscle mass and glucose uptake lead to reduced shivering capacity (476). Combined with 
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a slowing of resting metabolic rate and decreased capacity to sense their thermal environment, 
elderly individuals are at a greater risk of hypothermia even in a mild climate (477). 
Aging is not the only risk factor for poor circulation and cardiovascular disease. Smoking 
is strongly associated with deterioration of cardiac function and a primary risk factor for all 
manner of cardiovascular diseases, including atherosclerosis and peripheral artery disease (478, 
479). Smoking also causes acute changes in peripheral circulation, such as a peripheral 
vasoconstrictor response during and immediately after smoking a cigarette (480). Further, 
smoking can cause the development of Buerger’s disease, chronic inflammation of and 
thrombotic occlusions in the small and medium blood vessels, usually affecting the hands and 
feet, and starving these tissues of nutrition and heat (481). Additional disease states such as 
obesity, diabetes mellitus, and hypertension are also known to affect thermoregulatory cutaneous 
blood flow and may affect an individual’s ability to control core and peripheral tissue 
temperatures (482, 483). Finally, Raynaud’s syndrome is an example of peripheral vascular 
dysfunction that is not necessarily associated with underlying cardiovascular disease but can 
have profound effects on the temperature of the extremities. Individuals with Raynaud’s 
syndrome experience vasospasm in the small arteries of the fingers and toes in response to cold 
exposure, emotional stress, or other stimuli, causing excessive narrowing of these vessels and 
severely limited blood supply to the affected tissues (484). Over time, this can result in 
permanently thickened vessel walls, which further limits blood supply to the extremities. 
1.4.4.2 Fever 
Fever is the programmed physiological elevation of core body temperature and most often occurs 
in response to infection. When the body senses invasion by a pathogen, innate immune cells 
release inflammatory, pyrogenic (fever-inducing) cytokines such as interleukins 1 and 6 (IL-1 
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and IL-6) and tumor necrosis factor (TNF) into the bloodstream, which stimulate production of 
prostaglandin E2 (PGE2) in the brain (485). PGE2 induces fever by decreasing the firing rate of 
certain heat-sensing neurons in the hypothalamus, which in turn activates cold effector responses 
(486). In other words, PGE2 signaling makes the hypothalamus less sensitive to heat signals, 
triggering heat generation and conservation mechanisms to compensate for the perceived 
temperature reduction, even though none exists. The result is that cutaneous vasoconstriction, 
shivering, and behavioral heat-seeking results in a 2-4°C increase in core body temperature 
(486). Temperatures in the peripheral thermal compartment may initially drop due to the 
vasoconstriction, but may also rise as core temperature increases, although still remaining cooler 
than the body core (487). The immune advantages conferred by fever induction in response to 
infection will be covered in a later section. 
1.4.5 Intracellular responses to temperature change 
Just as endothermic organisms have whole-body and local responses to thermal stress, so too do 
their cells. Mammalian cells are equipped with specific responses to mitigate potential 
temperature-related damage and as an adaptive mechanism to maintain homeostasis during 
variations in temperature. However, much of what is known about temperature stress responses 
comes from studies of cultured cells, which may behave differently from cells in an organismal 
context. For example, there is evidence of heat shock protein expression (detailed below) on the 
cellular level that contributes to whole-body protection from hyperthermia, and due to the narrow 
range of elevated temperature survivable by endotherms, it is likely that the heat shock responses 
observed in vitro are similar to those that operate in vivo. Less clear is the relationship between 
the response of cultured cells and body cells to cold stress. Near-freezing temperatures in 
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cultured cells are poorly tolerated and typically result in significant apoptotic or necrotic cell 
death. Conversely, core temperatures at or below 0°C are routine for deep hibernating mammals, 
and rapid and sporadic rewarming events can occur multiple times in a single hibernation cycle 
without detriment to the organism (488). On the other hand, cultured cells rapidly adapt to mildly 
hypothermic temperatures (28-34°C) and can continue to grow and divide indefinitely, while 
body core temperatures this low kill non-hibernating mammals, including humans, within hours. 
However, as discussed above, many peripheral tissues and cell types in humans regularly exist at 
both hypo- and hyper-thermic temperatures and are subject to rapid changes in their thermal 
environments according to ambient temperature conditions. Thus, it is plausible that different 
body cell types are differentially sensitive to temperature variation, and that modeling these 
responses in immortalized cultured cell lines might not accurately reflect in vivo responses. 
Conversely, the thermal stress responses observed in cultured cells may represent the 
homeostatic baseline for body cells under constant temperature stress. 
1.4.5.1 Heat shock response 
Under conditions of even mild heat stress, cells face significant challenges posed by the heat-
labile nature of proteins. Heat-induced denaturation, misfolding of nascent proteins, 
entanglement, and nonspecific aggregation can deleteriously affect a vast number of cellular 
processes and, if left unmitigated, can lead to cell death (489). Cytoskeletal rearrangement and 
aggregation can cause incorrect localization of organelles and breakdown of proper cellular 
transport networks (490, 491). In the nucleus, ribosome assembly dysfunction in the nucleolus 
results in large granular deposits of ribosomal proteins and RNA (491). In the cytoplasm, 
mRNAs, translation initiation factors and ribosome components, and other proteins are 
sequestered in stress granules, which leads to a global decrease in protein translation (492). 
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Rising cellular temperatures can also cause damage to DNA and RNA, mitochondrial loss or 
dysfunction, fragmentation of the endomembrane system, and loss of plasma membrane integrity 
(493). The severity of these complications is directly related to the magnitude and duration of the 
heat stress (494). Severe (>42°C) or prolonged heat stress results in cell cycle arrest and eventual 
cell death by apoptosis (494, 495). However, typical heat stress, such as febrile-range 
temperatures, rarely reaches that critical point and cells can survive and recover through 
induction of the heat shock response. 
In a hyperthermic cell, changes in protein conformations and interactions, lipid 
membrane fluidity and permeability, and ion flux are sensed through various signaling events 
and trigger a coordinated stress response known as the heat shock response (HSR) (494). The 
HSR begins upon heat-induced activation of heat shock factor 1 (HSF1), which is constitutively 
expressed but is repressed in complexes with other regulatory proteins in the absence of heat 
stress (494). When rising temperature induces protein misfolding, those chaperones free HSF1 in 
favor of interaction with the misfolded proteins (496). Activated HSF1 is a homotrimer that 
translocates to the nucleus and binds to consensus heat shock elements (HSEs) in the promotors 
of heat shock genes and activates their transcription (497). Chief among heat shock responsive 
genes are the heat shock proteins (HSPs), which are protein chaperones involved in preventing 
protein misfolding and aggregation during thermal and other cell stresses. The HSP family 
consists of high molecular weight proteins (e.g. HSP70, HSP90) and low molecular weight 
proteins (e.g. HSP27), many of which are expressed in the absence of cellular stress to aid in 
protein folding and proper aggregation under normal conditions, but this function becomes 
paramount during heat stress (498, 499). Large HSPs such as HSP70 and HSP90 family 
members preferentially bind to hydrophobic regions of unfolded polypeptides and promote 
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proper refolding in an ATP-dependent manner (500), both in the cytoplasm and the nucleus 
(501). Small HSPs also act as molecular chaperones, but passively prevent aggregation of 
unfolded proteins under conditions of cell stress, rather than actively aiding in refolding (502). In 
addition to their role as chaperone proteins, HSPs can block apoptosis during heat stress through 
interaction with cytochrome c (HSP27) or through inhibition of downstream caspase-9 activation 
(HSP70/90) (503, 504). 
In addition to HSPs, there are many other heat-shock inducible proteins, including many 
not dependent on HSF1 (505), that carry out important functions for cell survival during heat 
stress. These include proteasome components for clearing misfolded and aggregated proteins 
from the cell, nucleic acid-modifying enzymes for repairing DNA and RNA damage, various 
signaling molecules and transcription factors involved in maintenance of the stress response and 
repression of other signaling and metabolic pathways, and cytoskeleton- and membrane- 
stabilizing proteins (489). Despite the large number of genes upregulated upon heat stress, an 
even greater number are repressed, leading to a net decrease in overall transcription (505, 506). 
In sum, repression of cellular macromolecular synthesis in combination with preferential 
upregulation of pro-survival proteins such as chaperones and other stabilizers puts heat-stressed 
cells into a sort of “holding pattern,” during which the cell is protected from further damage until 
the thermal stress is relieved. HSE is self-limiting as thermal conditions return to normal. As the 
challenge of unfolded and misfolded proteins wanes in response to normal cellular temperatures, 
the highly upregulated chaperones HSP70 and HSP90 become excessive and re-associate with 
HSF1, blocking its transcription factor ability and curtailing the response (507). 
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1.4.5.2 Cold shock response 
It has long been appreciated that under hypothermic conditions, cultured cells slow their growth 
rate, and with further temperature depression, enter cell cycle arrest and eventually die. At first 
this was attributed to generalized metabolic decline and cessation of vital cellular reactions. 
However, while metabolic slowing does indeed occur during cellular cold stress, it is in fact a 
part of a purposeful and carefully orchestrated set of responses. Like the heat shock response, the 
cold shock response in mammalian cells is designed to mitigate cellular damage that may occur 
in the wake of thermodynamic changes to cellular structures and processes under conditions of 
temperature stress. Cold shock rapidly and selectively induces the expression of a small group of 
cold responsive genes, and much of what is known about the cold shock response comes from 
studies on the functions of the two best-characterized cold-shock proteins, cold-inducible RNA 
binding protein (CIRP) and RNA binding motif protein 3 (RBM3). 
  CIRP and RBM3 are highly homologous, evolutionarily conserved glycine-rich RNA-
binding proteins (508) that are expressed under normal homeostatic conditions in various tissues 
(509) and are upregulated in response to a variety of cellular stresses, including hypothermia, 
hypoxia, and ultraviolet and ionizing radiation (510-513). Peak expression of CIRP and RBM3 
occurs at mildly hypothermic temperatures (28-34°) and further temperature reduction greatly 
decreases expression (510, 514, 515). Accordingly, both CIRP and RBM3 are highly expressed 
in mammalian testes, though in distinct cell types, where lowered temperatures are required for 
normal spermatogenic functions (516, 517). In warmer tissues, baseline levels of CIRP and 
RBM3 have a variety of functions and are involved in many processes, such as embryonic 
development, and their expression is tightly controlled both spatially and temporally (518). In 
adult humans, RBM3 expression is very low in most tissues except for actively proliferating 
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brain regions, where it is implicated in the maintenance of stemness, the ability to self-renew as 
well as differentiate, in neural progenitors (519, 520). Under conditions of cold stress, CIRP and 
RBM3 display some tissue-specific and cell-type-specific upregulation, indicating that different 
tissues may have distinct requirements for optimal responses to hypothermia (518). In 
hyperthermic conditions, expression of both proteins drops substantially (516, 521). 
Induction of CIRP upon cold stress is mediated at the transcriptional, post-transcriptional, 
and translational levels. At 32°C, an increase in Sp1 recruitment to the mild-cold responsive 
element (MCRE) in the CIRP promoter region was observed versus 37°C (522). Post-
transcriptionally, CIRP mRNA maturation is regulated by an alternative splicing mechanism 
wherein transcripts encoding the full-length CIRP are preferentially produced under hypothermic 
conditions, although the mechanism responsible for this preference was not identified (523). In 
addition, the cold-induced CIRP splice variants contain putative internal ribosomal entry sites 
(IRES) that may contribute to selective translation in the face of global translational slowing 
during cold stress (523). Much less in known regarding the cold-inducible properties of RBM3 
transcription. The subcellular localization of CIRP is primarily nuclear under homeostatic 
conditions, but a fraction can shuttle to and from the cytoplasm (514). Nuclear CIRP regulates 
gene expression at the post-transcriptional level by binding to the 3’ UTRs of certain target 
RNAs and stabilizing them (524). In addition, CIRP can contribute to alternative polyadenylation 
and splicing of certain genes (525, 526). CIRP targets often include other stress response genes 
and it can also enhance their translation through interaction with eIF4G after shuttling to the 
cytoplasm (527). However, CIRP has also been shown to reduce global translation through its 
binding to 3’ UTRs, so its exact role in translational regulation is not fully understood (528, 
529). 
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In addition to modulating gene expression, CIRP plays major roles in the promotion of 
cell survival and proliferation during hypothermia. Indeed, under the mild hypothermic 
conditions that induce maximal CIRP expression, cells continue to function and divide normally, 
albeit at a reduced rate. CIRP is intimately involved in preventing cell cycle arrest under mild to 
moderate cold stress, and has been shown to contribute to increased expression of cyclin E1 as 
well as prevent phosphorylation and inactivation of cyclin D1, which encourages progress 
through the G1/S checkpoint (530-532). In addition, CIRP is pro-survival in that it inhibits 
several apoptotic pathways and protects hypothermic cells from apoptotic death. In neurons, 
CIRP prevents cellular apoptosis by blocking mitochondrial apoptotic pathways (533, 534) and 
can also inhibit the activities of p53, Fas, and caspase-3 and their downstream pathways (535-
537). CIRP overexpression or hypothermia-induced expression has also been shown to 
dramatically reduce apoptosis in hydrogen peroxide-treated neuronal cultures, in which the 
formation of reactive oxygen species (ROS) drive cell death (534, 535), and reduce ROS 
formation in hypothermic hepatocytes (538). Perhaps unsurprisingly, constitutively elevated 
CIRP is a common feature of many cancers, presumably due to its proliferative and pro-survival 
activities (518). To summarize, mild hypothermia (28-35°C) within a typical physiological range 
fails to induce cell cycle arrest and apoptotic cell death due in part to the activities of the cold-
inducible CIRP. In contrast, severe hypothermia (<25°C) leads to dramatically decreased CIRP 
levels and does indeed result in cell cycle arrest and eventual apoptotic or necrotic cell death.  
Like CIRP, RBM3 binds RNAs in the nucleus to modulate gene expression at post-
transcriptional steps including alternative splicing and polyadenylation (525, 526). However, the 
most well-known impacts of RBM3 on gene expression are due to its effects on translation. At 
severely hypothermic temperatures, translation is arrested through the constitutive 
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phosphorylation of eIF2α, which prevents assembly of the initiation complex (539). When 
RBM3 is upregulated under mild hypothermia, it enhances global translation through several 
mechanisms that promote translation initiation, including preventing the phosphorylation of 
eIF2α (540, 541). Furthermore, RBM3 can promote cell cycle progression by facilitating the 
G2/M transition (542) and antagonize apoptosis. Hypothermia, like hyperthermia, can trigger ER 
stress and the unfolded protein response (UPR), which can lead to apoptosis through activation 
of the protein kinase RNA-like endoplasmic reticulum kinase (PERK), which arrests translation 
by phosphorylating eIF2α and stimulates apoptosis through induction of the transcription factor 
C/EBP homologous protein (CHOP) (514, 543). RMB3 can traffic from the nucleus to the 
stressed ER and inhibit the activation of PERK, which mitigates the downstream translational 
arrest and suppresses pro-apoptotic pathways (544, 545). 
Although CIRP and RBM3 are critical mediators of the cold shock response under mildly 
hypothermic conditions, other changes occur in cold stressed cells that appear to be independent 
of these proteins, and it is likely, as suggested above, that many functions of these proteins serve 
to prevent drastic changes to cell homeostasis that would otherwise occur, and indeed do occur 
with deeper hypothermia, in their absence. Common outcomes of mild cold stress observed in 
cultured mammalian cells include decreased oxygen and ATP consumption (slowed 
metabolism), attenuation of transcription and translation, increased mRNA stability and reduced 
degradation, extended doubling times, and prolonged viability (546). Some of these features, 
such as increased mRNA stability and prolonged viability, can be explained in part by the 
activities of CIRP and RBM3. Attenuation of global translation rates under mild cold stress was 
recently shown to be controlled at the elongation phase, rather than initiation, which is the target 
at lower temperatures, as discussed above (547). The molecular mechanisms leading to the other 
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changes are less clear, and may simply be attributable to the lowered temperature causing 
thermodynamic changes in macromolecule structure and interactions. However, if and how this 
assumed cold-induced, nonspecific slowing of cellular activity affects specific cellular 
components and processes is near completely unexplored. In addition, as nearly all studies of the 
cold-shock response in mammalian cells have been completed using cell culture models, the 
question of whether or not, and to what extent, these phenomena occur in cold-stressed cells in 
vivo remains open. Some studies in hibernating mammals under deep hypothermia have 
confirmed the metabolic, transcriptional, and translational arrest observed in cells under severe 
hypothermia, but without the accompanying apoptotic and necrotic injury (488). In addition, 
upregulation and functionality of CIRP and RBM3 have been noted in mouse testes (517, 548), 
indicating that these proteins are indeed inducible by mildly reduced temperatures in vivo. 
However, the effect of cold stress on the survival and functions other tissues, especially in 
humans, has yet to be extensively described. 
1.4.6 Effects of physiological temperature variation on immune responses   
1.4.6.1 Fever/hyperthermia 
Fever, the purposeful elevation of body temperature in response to infection or injury, is 
evolutionarily conserved among many diverse animal taxa, with fever achieved biochemically in 
endotherms and behaviorally in ectotherms and poikilotherms (485, 486). The febrile response 
likely evolved around 600 million years ago and was retained in many lineages despite the 
considerable metabolic costs of raising one’s temperature (486, 549-551), suggesting that 
hyperthermic body temperature is strongly pro-survival during infection. In 1927, Julius 
Wagner-Jauregg won the Nobel Prize in Physiology or Medicine for his successful treatment of 
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progressive neurosyphilis patients with malaria-induced fever, a strategy that built on the 
association between high fever and neurosyphilis remission known since Hippocrates’ time 
(552). In the time since Dr. Wagner-Jauregg’s discovery, the use of antipyretic medication to 
combat fever during infection has soared in popularity and become a staple of both at-home and 
clinical care for febrile patients (552). However, numerous studies have shown that the use of 
antipyretics has a detrimental effect on the patients’ ability to control and clear various 
infections, including rhinovirus, varicella, and influenza (553-555), and that the immune 
response to vaccination may be weakened by antipyretics in children (556). In addition, 
numerous lethal challenge models of bacterial and viral infections in host species including 
goldfish, lizards, and mice can be rendered nonlethal by increasing the host’s core temperature to 
a febrile range (486). Blocking fever with antipyretics in similar studies eliminated the survival 
benefit (486). However, there are some contexts in which fever or hyperthermia may be harmful 
to the host, such as during uncontrolled inflammatory states such as sepsis, or neural ischemic 
injury, when the proinflammatory effects of fever are no longer beneficial (557, 558). Together, 
these data argue for a host-protective role of fever in the context of many infections provided the 
febrile response and its downstream effects do not go uncontrolled and homeostasis can be 
restored. 
The mechanisms that mediate fever’s host-protective actions can be broadly categorized 
into anti-pathogen effects and pro-immune effects. In some cases, febrile-range temperature can 
directly inhibit a pathogen if the pathogen’s ability to survive and grow is reduced at higher 
temperatures. For example, poliovirus replication in mammalian cells was reduced over 200-fold 
at 40-41°C compared to 37°C (485). Fever-range temperatures have also been shown to increase 
the susceptibility of Gram-negative bacteria to serum-induced lysis (559). Many pathogens, 
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however, are largely unaffected by the 2-4°C increase in body temperature caused by fever. For 
these infections, the survival benefit of the febrile response comes from its immune-enhancing 
effects. Numerous studies have characterized the molecular and cellular immune processes that 
benefit from hyperthermia, namely, those involved in inflammation and lymphocyte trafficking. 
Some of the pyrogenic molecules involved in the induction of the febrile response, such as IL-6, 
IL-1, and TNFα, are also classical proinflammatory cytokines that are upregulated in response to 
a variety of infections, thus providing a crucial link coordinating the febrile response and 
inflammation (485). In addition, activation of the heat shock response mediator HSF1 at febrile-
range temperature (38-41°C) but not heat shock temperature (42-45°C) augments production of 
these cytokines (485) with mild activation of the heat shock response, indicating molecular 
crosstalk between the immune response to infection and pro-survival cellular responses to the 
heat stress (560). These are examples of feed-forward mechanisms driving both febrile and 
immune cytokine responses in a coordinated, complementary fashion. 
While the specific response to a given infection can vary widely depending on the nature 
of the invading pathogen, the general innate inflammatory response typically involves 
recruitment of innate immune cells such as neutrophils, NK cells, macrophages, and DCs to the 
site of infection followed by relocation of antigen-presenting cells (APCs) to the local lymph 
node to activate pathogen-specific T cells near the high endothelial venule, the major port of 
entry for tissue-resident immune cells into lymphoid organs (561-563). In mouse models of fever 
induced by either LPS injection or external whole-body heating, neutrophil recruitment into 
bacteria-infected tissues and the respiratory burst associated with their activation were found to 
be enhanced by elevated temperature compared to normothermia (564-566). Similarly, increased 
NK cell cytotoxic activity and recruitment into tumor tissues was augmented by febrile 
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temperatures in vivo (567). Macrophage function is also enhanced by febrile-range temperature. 
HSP70 induction in macrophages at febrile temperatures is associated with prolonged activation 
in response to LPS and also increases the production of nitric oxide and inducible nitric oxide 
synthase upon activation by LPS and IFN-γ (568). Under febrile heat stress, HSP70 can also be 
released from cells and act as a damage-associated molecular pattern (DAMP) to stimulate 
macrophages and DCs to produce proinflammatory cytokines (569, 570). Fever-range 
hyperthermia has also been shown to improve the phagocytic, pathogen-sensing, and antigen-
presenting abilities of DCs in part through heat-induced upregulation of TLRs and major 
histocompatibility complex (MHC) class I and II molecules (485). Trafficking of APCs from 
sites of infection to draining lymph nodes as well as extravasation of activated lymphocytes 
through endothelial gaps into sites of infection are also be improved by fever through more 
efficient chemotaxis (571, 572). Finally, T cell stimulatory function was enhanced in DCs under 
fever-range temperatures in an ex vivo assay (571). Together, these findings suggest that febrile 
temperatures can augment many functions of innate and adaptive immune cells and promote 
inflammatory responses to inflammation. However, most of these studies were completed in 
models of LPS-induced fever, and the specific mechanisms by which fever may enhance 
antiviral immunity, specifically the type-I IFN response, have not been extensively studied. 
1.4.6.2 Hypothermia 
Considerably less work has been undertaken on the effect of sub-normal temperatures on the 
immune response compared to fever-range temperatures. However, as alluded to above, there are 
certain situations in which hyperthermia becomes dangerous to the organism due to its 
contribution to uncontrolled inflammatory responses. In such cases as bacterial sepsis and 
neurologic injury, enhanced inflammation due to febrile temperatures can cause catastrophic 
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tissue damage, and therapeutic hypothermia have proven beneficial to patient outcomes in these 
contexts due in part to its anti-inflammatory effects in addition to induction of the pro-survival 
cold shock response (486, 573, 574). Hypothermia is generally considered to be immune-
suppressive. Solid tumors can benefit from a hypothermic microenvironment due to 
dysfunctional T cell responses (575) and intraoperative hypothermia has been associated with 
increased risks of postoperative infection (576). However, few studies examining the 
mechanisms underlying these observations exist. 
 Recently, the type-I IFN response was shown to be attenuated by hypothermic 
temperatures in an in vitro model of rhinovirus infection (577). This study built upon previous 
observations that other viruses capable of infecting hypothermic tissues, such as a bovine 
herpesvirus, which was shown to induce less IFN but replicate to higher titers in experimentally 
cooled skin temperatures versus normal skin on two sides of the same cow (578). In addition, 
IFN-β has been implicated as one of the proinflammatory cytokines whose activity is dampened 
by therapeutic hypothermia in models of cerebral ischemia (579). Collectively, these studies 
suggest that type-I IFN induction and antiviral activity may be less at temperatures below 37°C, 
however, the mechanisms resulting in this phenotype have not been delineated.  
1.5 HYPOTHESIS 
The IFN-α/β response is one of the most critical innate immune systems in the protection of 
vertebrate hosts against viral infection; however, accumulating evidence suggests that its efficacy 
might be temperature-dependent. Many human viruses replicate and cause disease in anatomical 
sites that vary in temperature, such as the skin and respiratory tract, which are nearly always 
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lower in temperature than the body core. Arboviruses traverse variable thermal environments in a 
human host throughout their pathogenic course from the skin into the deeper organs, and 
therefore may be subject to temperature-regulated innate immune environments. In addition, 
many viral infections are associated with the febrile response, which results in an elevated body 
temperature and is generally considered to be immune-enhancing, although the mechanisms 
through which fever exerts its protective effects are incompletely understood. A recent study of 
human rhinovirus (RV) found that the increased replicative fitness of RV at the low upper airway 
temperature could be partially explained by hypothermia-mediated attenuation of IFN-α/β 
responses (577). However, the molecular mechanisms leading to reduced IFN-α/β efficacy 
remain unknown. 
IFN-α/β is largely responsible for acute control of CHIKV and many other arboviral 
infections. CHIKV preferentially replicates and causes both acute and chronic arthritic/arthralgic 
disease in distal small joint tissues located in the extremities, such as those in the fingers, wrists, 
ankles, and toes. An underappreciated feature of these sites is their prominent role in whole-body 
thermoregulation in response to cold stress, which is constantly activated under room-
temperature conditions. Peripheral vasoconstriction and arteriovenous blood shunts in the hands 
and feet render these regions much cooler in temperature than core tissues, and their large 
surface area-to-mass ratio and thin adipose insulation do little to protect the deeper bone and 
muscle tissues from experiencing these reduced temperatures. Therefore, CHIKV infection in 
these regions likely often occurs under conditions of mild hypothermia. 
Overall, I hypothesized that the type-I IFN response against CHIKV and other 
arboviruses is less effective at subnormal temperatures and more effective at febrile 
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temperatures, compared to the normal 37°C mammalian core temperature. Specific aims for 
these studies were addressed in the following chapters:  
• In Chapter 2, I explored the relationship between temperature variation and the ability of 
IFN-α/β to inhibit arbovirus infection. I hypothesized that temperature variation 
influences the sensitivity of diverse arboviruses to IFN-α/β responses as the result of 
temperature-dependent differences in the production of IFN-α/β and ISGs. In addition, I 
hypothesized that reduced temperatures in vivo contribute to acute CHIKV replication 
and disease through attenuation of the IFN-α/β response. 
• In Chapter 3, I sought to better understand the factors that predispose CHIKV patients to 
developing chronic disease. One risk factor identified in human cohorts is the severity of 
acute phase viremia and disease. I hypothesized that body temperature reduction in the 
acute phase, chronic phase, or both could exacerbate chronic CHIKV infection in an adult 
wild-type mouse model as a result of its action on IFN-α/β-mediated viral control, 
dependent on the magnitude of viral replication during the acute phase. 
 
The results of these studies revealed the mechanisms by which temperature variation 
influences the efficacy of the IFN-α/β response. They also demonstrated the impact of this 
relationship on the course and severity of arthritogenic alphavirus infection and suggest the 
utility of local or systemic temperature modulation as a therapeutic option for CHIKV or other 
arboviruses. 
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2.0  EFFICACY OF THE INTERFERON-Α/Β RESPONSE VERSUS ARBOVIRUSES 
IS TEMPERATURE-DEPENDENT 
2.1 INTRODUCTION 
Type I interferon is a critical early protector of vertebrate hosts from overwhelming viral 
replication and disease [reviewed in (357)]. This role has been abundantly demonstrated with 
arboviruses and other viruses by infection of Ifnar1-/- mice that lack IFN-α/β signaling. In many 
cases, a completely benign localized infection of normal mice is rendered systemic and rapidly 
fatal by elimination of signaling through the IFN-α/β receptor (e.g., (97, 98, 190, 580)). Even 
minor changes in the characteristics of the IFN-α/β response greatly increase viral replication and 
disease (581).  
The IFN-α/β response consists of an inductive phase in which virus infection stimulates 
infected and possibly uninfected cells to produce and secrete IFN-α and IFN-β proteins that 
signal through the dimeric IFN-α/β receptor and cause the transcriptional upregulation of 
antiviral effector genes (279, 582). This leads to production of proteins in infected and 
uninfected cells that, together, constitute an “antiviral state.” This response is the primary 
protector of vertebrate hosts from overwhelming virus replication prior to development of the 
adaptive immune response and is also involved in the clearance phase of infection (583, 584). 
Subclinical infections with arboviruses and other viruses that normally only affect regional 
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tissues can be rendered systemic and catastrophic by the absence of this response (98, 580, 585). 
The type I IFN response is so effective that it can determine apparent tissue tropism for highly 
IFN-α/β-sensitive viruses (98). This suggests that even minor increases or decreases in the 
efficacy of this response could have dramatic impacts upon the outcome of virus infection.  
Previous studies have primarily focused upon the characteristics of IFN-α/β induction and 
effector phases in standard laboratory conditions mimicking mammalian core temperatures (e.g., 
37°C). However, temperatures in peripheral tissues of humans can range as much as 5 degrees 
below 37°C under normal room temperature conditions (466), and can become much lower 
under more extreme conditions (586). In addition, few studies have examined IFN-α/β responses 
in the febrile conditions under which they commonly act in vivo during pathogen infection. 
Indeed, core (rectal) temperatures can rise to 42°C during extreme febrile or hyperpyrexic 
episodes, and febrile responses to infection typically range between 38 and 40°C (587). 
However, two recent studies have suggested that IFN-α/β responses may be lesser in upper 
airway epithelia where temperatures are substantially below core (577, 588). This work 
complemented several historical studies that also suggested temperature-mediated effects on 
IFN-α/β efficacy in other model systems (578, 589-594). Other early studies, however, including 
with arboviruses, that identified temperature variation as a factor in IFN-α/β effectiveness 
implicated temperature-altered virus replication rather than the IFN-α/β response (595-606). 
Herein, we demonstrate that multiple arboviruses including alphaviruses, bunyaviruses, 
and flaviviruses, which have evolved to replicate at ambient temperatures in the invertebrate 
vector, are dramatically more resistant to the IFN-α/β system at temperatures below 37°C. 
Subnormal temperatures led to a considerable diminution of IFN-α/β efficacy and supranormal 
temperatures led to a modest enhancement of efficacy, possibly representing an evolutionary 
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mechanism for the febrile response. At the same time, induction of IFN-α/β was delayed and 
reduced at low temperatures and enhanced at higher temperatures in vitro. A primary mechanism 
underlying the temperature effect appeared to involve reduced rates of gene transcription at the 
lower temperatures. Furthermore, in a mouse model of chikungunya virus (CHIKV) infection 
and musculoskeletal disease (MSD), lowered temperatures induced in torpid or reserpine-treated 
mice resulted in exacerbation of virus replication and signs of MSD in an IFN-α/β response-
dependent manner. The results of these studies will have impacts upon the understanding of 
pathogenesis of all arboviruses as well as other viruses that replicate in sites with altered 
temperature (e.g., rhinovirus, influenza virus, coronavirus) as well as other therapeutic contexts 
in which IFN is used (e.g., oncology). This may lead to improved therapeutic modalities 
involving localized or systemic temperature modification. 
2.2 RESULTS 
2.2.1 Efficacy of IFN-α/β against arboviruses is reduced at subnormal temperatures  
To test the hypothesis that arboviruses are differentially sensitive to IFN-α/β treatment at 
different temperatures, we compared growth of wild-type strains from three distinct arbovirus 
genera, Alphavirus, Flavivirus, and Phlebovirus, in Vero cells treated with IFN-α/β at 
temperatures between 30 and 39°C with growth in temperature-matched untreated cells. Because 
Vero cells lack the IFN-α/β genes, they circumvent the potential confounding variable of 
temperature-dependent differences in IFN-α/β induction upon viral infection (577, 588). The 
arbovirus strains chosen, CHIKV La Reunion (CHIKV-LR), Sindbis virus TR339 (SINV-
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TR339), Venezuelan equine encephalitis virus ZPC738 (VEEV-ZPC738), Eastern equine 
encephalitis virus FL93939 (EEEV-FL93), Dengue virus 2 16681 (DENV2-16681), Yellow 
Fever virus Angola (YFV-Angola) and Rift Valley fever virus ZH501 (RFVF-ZH501), are wild-
type viruses that have undergone no or minimal passage in vitro, to limit potential selection for 
optimal replication under typical laboratory conditions, such as growth at 37°C. In the absence of 
IFN-α/β pretreatment in Vero cells, alphavirus growth was greatest at 37°C, the normal 
mammalian core body temperature, by 24 hours post infection (h.p.i.) compared to growth at 30 
or 39°C, which was comparable to 37°C or slightly attenuated. (Fig 7A; 8A). This was also true 
in baby hamster kidney (BHK) cells (Fig 8B). Thus, in the absence of IFN-α/β, departure from 
37°C conferred no advantage to alphavirus replication. Conversely, in cells pretreated with IFN-
α/β, incubation at 30°C near uniformly conferred significant advantage to virus growth compared 
to 37°C, while incubation at 39°C, representing a febrile-range temperature, significantly 
reduced SINV and CHIKV growth compared to 37°C (Fig 7B). Accordingly, the replication 
ability of three alphaviruses, EEEV, CHIKV, and SINV, in IFN-α/β-treated cells was found to be 
significantly correlated to increasing IFN-α/β treatment temperature (Fig 7C). These results 
indicate that IFN-α/β efficacy was lowest at 30°C and increased with rising temperature. No such 
correlation was observed with VEEV, which is much more IFN-α/β-resistant than the other 
alphaviruses and minimally inhibited in Vero cells at the IFN-α/β concentration used (116, 607), 
further supporting the idea that decreased inhibition at 30°C is due to effects on IFN-α/β activity.  
In addition, the EC50 of IFN-α/β against SINV, CHIKV, EEEV, and VEEV on Vero cells 
was significantly correlated with incubation temperature, with substantially lower concentrations 
of IFN-α/β effectively inhibiting these viruses as temperature increased (Fig 7D-E). Finally, 
analogous temperature-dependent IFN-α/β sensitivity was observed in experiments with YFV 
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and DENV as well as RVFV, demonstrating that this effect is relevant to multiple families of 
arboviruses capable of replicating across a broad temperature spectrum (Fig 7F-I). Similar results 
were obtained in NIH/3T3 Tet-Off murine embryonic fibroblasts (MEFs) and primary murine 
osteoblasts, cell types representative of in vivo targets common to many of these viruses (Fig 8B-
C). Collectively, these experiments suggest that the antiviral activities of IFN-α/β are most 
effective versus a variety of arboviruses at temperatures in the febrile range, and much less 
effective at subnormal temperatures in mammalian cells. 
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Figure 7. Efficacy of type I IFN against arboviruses is reduced at subnormal temperatures. 
A-C: Vero cells were treated overnight with 0 or 1000 IU IFN-α/β at 30, 34, 37, or 39°C and infected with the 
indicated alphaviruses at a M.O.I. of 0.1. Supernatants were collected at 24 h.p.i. and viral titers were determined by 
plaque assay on BHK cells at 37°C. A: Comparison of viral growth at 24 h.p.i. between temperatures with and 
without IFN-α/β treatment. B: Log10 fold-change in viral titer between IFN-α/β-treated and untreated cells at each 
temperature ± SD. *p<0.05, **p<0.01, ***p<0.001, ***p<0.0001, ns not significant by two-way ANOVA with 
Tukey’s multiple comparison test on log-transformed fold-change values. C: Significant linear correlation between 
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increasing temperature and viral growth inhibition by IFN-α/β pretreatment for IFN-α/β-sensitive alphaviruses. 
Pearson’s correlation p<0.02 for EEEV and CHIKV, p<0.07 for SINV. D-E: EC50 of IFN-α/β in Vero cells at 30, 34, 
37, and 39°C against the indicated alphaviruses was determined by IFN-α/β bioassay. D: Data are presented as log10 
mean IU/mL required to protect 50% of Vero cells from virus-induced cytopathic effect at each temperature ± SD. 
*p<0.05, **p<0.01, ***p<0.001, ***p<0.0001, ns not significant by two-way ANOVA with Tukey’s multiple 
comparison test on log-transformed IU/mL values. E: Significant linear correlation between increasing temperature 
and decreasing IFN-α/β EC50 was established using Pearson’s correlation on log-transformed IU/mL values (p<0.02 
for all viruses). F-G: Vero cells were treated overnight with 0 or 100IU IFN-α/β at 30, 37, or 39°C and infected with 
YFV or DENV at a M.O.I. of 0.1. 96 h.p.i. supernatants were assayed for viral titer by focus forming assay at 37°C. 
F: Comparison of viral growth at 96 h.p.i. between temperatures with and without IFN-α/β treatment. G: Data are 
expressed as mean fold-change in titer between IFN-α/β-primed and unprimed cells at each temperature ± SD. *** 
p<0.001 two-way ANOVA with Tukey’s multiple comparison test of log-transformed fold-change values. H-I: The 
procedure from (A) was repeated with RVFV at a M.O.I. of 5-10, using only 30 and 37°C temperature conditions. 
24 h.p.i. supernatants were assayed for viral titer by plaque assay. H: Comparison of viral growth at 24 h.p.i. 
between temperatures with and without IFN-α/β treatment. I: Data are expressed as fold-change in titer between 
IFN-α/β-treated and untreated cells at each temperature ± SD. * p<0.05 two-tailed Student’s t test of log-transformed 
fold-change values. All infections were performed in triplicate and data are representative of at least two 
independent experiments. 
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Figure 8. Efficacy of type I IFN against arboviruses is reduced at subnormal temperatures in additional cell 
types. 
A-B: Unprimed Vero (A) or baby hamster kidney (BHK; B) cells were infected in triplicate with the indicated 
alphaviruses at a M.O.I. of 0.1 and incubated at 30, 37, or 39°C. At the indicated times post infection, supernatants 
were harvested and viral titer was determined by plaque assay on BHK cells at 37°C. C: Osteoblasts cultured from 
adult CD-1 mice were treated with 1000 IU/mL IFN-α/β at 30 or 37°C overnight and then infected at a M.O.I. of 0.1 
with the indicated alphaviruses. 24 h.p.i. supernatants were assessed for viral titer by plaque assay at 37°C. Data are 
expressed as fold-change in titer between IFN-α/β-treated and untreated cells at each temperature. *p<0.001 using 
multiple two-tailed t tests with Holm-Sidak correction of log-transformed fold-change values. D: MEFs were treated 
overnight with 100 IU/mL IFN-α/β at 30, 37, or 39°C and infected with YFV-Angola at M.O.I. 0.1. 48 h.p.i. 
supernatants were assayed for viral titer by focus-forming assay on Vero cells at 37°C. Data are presented as fold-
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change in titer between IFN-α/β-treated and untreated cells at each temperature. *p<0.0001 one-way ANOVA with 
Tukey’s multiple comparison test of log-transformed fold-change values. 
2.2.2 ISG protein and mRNA levels are reduced at subnormal temperatures 
We hypothesized that the effect of temperature variation on IFN-α/β antiviral efficacy was most 
likely to result from differential expression levels of antiviral IFN-stimulated genes (ISGs). To 
test this, we treated cells with IFN-α/β at 30, 37, or 39°C for the time course indicated and 
performed western blots and qRT-PCR for protein and mRNA levels of several ISGs. STAT1, 
IFIT1, and ISG15 proteins were induced more slowly and to a lower peak expression level at 
30°C compared to 37°C, and their expression was, in several cases, significantly increased at 
39°C versus 37°C (Fig 9A-B, 10A-C). ISG mRNA expression patterns paralleled protein 
production at early timepoints, suggesting that temperature-dependent differences in ISG 
transcription efficiency contribute to differences in corresponding protein levels (Fig 9C 10D-E). 
However, ISG mRNA induced at 30°C did equalize to or surpass the levels induced at the higher 
temperatures at later times post IFN-α/β treatment, whereas protein levels did not. These data 
may suggest that both ISG transcription and subsequent translation are independently affected by 
cell temperature variation and that attenuation of both processes at 30°C contributes to the 
decreased magnitude of ISG production in response to IFN-α/β treatment. 
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Figure 9. At subnormal temperatures, ISG protein and mRNA levels are reduced. 
For all panels, Vero cells were treated with 1000 IU/mL IFN-α/β at 30, 37, or 39°C for 0-24 hours. A-B: 
Immunoblot of ISG protein levels (A) and corresponding densitometry quantification with ISG bands normalized to 
β-actin (B), presented as mean ratio of ISG to actin ± SD. C: qRT-PCR was performed on total cellular RNA with 
specific primers for the indicated ISGs. Data are presented as fold-change in 18S-normalized Ct values between 
IFN-α/β-treated and untreated cells at each temperature ± SD. Significance between groups is indicated with color-
coordinated asterisks. For example, red and green asterisks indicate significance of 39 and 37°C results, 
respectively, over 30°C. Two sets of same-colored asterisks stacked over a single data point indicate significance of 
the results at that temperature over both others at that time point. Statistics: *p<0.05, **p<0.01, ***p<0.001, 
***p<0.0001, ns not significant by two-way ANOVA with Tukey’s multiple comparison test. All experiments were 
done with triplicate samples and data are representative of at least two independent experiments. 
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Figure 10. At subnormal temperatures, ISG protein and mRNA levels are reduced in additional cell types. 
A-C: Primary CD-1 osteoblasts (A), MEFs (B), and HeLa cells (C) were treated with 100 IU/mL IFN-α/β at 30, 37, 
or 39°C for 6-24 hours. Lysates were analyzed for ISG protein production by immunoblot. Graphs display 
densitometry analysis of ISG bands at each temperature normalized to β-actin. D-E: The procedure from (A-C) was 
repeated and total cellular RNA was probed for ISG mRNA content by qRT-PCR. Data are presented as log10 fold-
change (D) or fold-change (E) between 18S-normalized Ct values for IFN-α/β-treated and untreated cells at each 
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temperature. Statistics: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns not significant by two-way ANOVA 
with Tukey’s multiple comparison test. 
To support this idea, we performed qRT-PCR for the gamma actin intron #3, as a proxy 
for basal transcriptional rate (116, 608), in cells incubated at different temperatures. We observed 
an approximate 2-fold decrease in intron transcript levels in cells incubated at 30°C compared to 
37°C; however, raising the temperature to 39°C did not appear to influence basal transcription 
(Fig 11A). To test whether or not basal translation rate was also affected by temperature 
variation separately from effects on basal transcription, we transfected MEF cells with in vitro-
transcribed RNAs expressing firefly luciferase (fLuc) and measured fLuc activity after 1 hour of 
incubation at 30, 37, and 39°C. At 30°C, fLuc reporter protein levels were slightly lower than 
those at 37°C, and fLuc activity was slightly increased at 39°C versus 37°C (Fig 11B). Beyond 1 
hour, fLuc activity at 30°C met and surpassed the higher temperatures, and continued to rise 
through 6 hours post-transfection, while activity at the higher temperatures peaked and waned, 
indicating a defect in reporter RNA and/or fLuc protein degradation at 30°C. We confirmed this 
result in MEF cells lacking Ifnar1 to rule out differential IFN-α/β responses to the reporter RNA 
at different temperatures accounting for this result (Fig 11B). To verify that basal translation 
rates vary with temperature in a native setting, we performed a [35S]-methionine and -cysteine 
incorporation pulse-chase experiment in MEFs incubated at 30, 37, and 39°C. Equal volumes of 
total protein lysates were quantified by SDS-PAGE followed by autoradiography and 
densitometry analysis of all visible protein bands. In agreement with the fLuc reporter results, we 
observed an approximate 2-fold reduction in new protein synthesis at 30°C compared to the 
higher temperatures after 1 and 12 hours of incubation (Fig 11C). These results indicate that both 
basal transcription and translation are affected by cellular temperature and likely contribute to 
the effect of temperature variation on ISG expression. 
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Figure 11. Temperature variation affects baseline transcription and translation rates. 
A: Total cellular RNA from MEFs incubated at different temperatures were assayed for gamma actin intron #3 using 
qRT-PCR. Data are presented as fold-change in 18S-normalized Ct values versus 37°C. B: Wild-type or Ifnar1-/- 
MEF cells were transfected with 5 µg of in vitro-transcribed firefly luciferase-expressing reporter RNA and divided 
among 30, 37, and 39°C temperature conditions for 1, 3, or 6 hours. Luciferase translation efficiency was quantified 
by luciferase activity assay and RLU values were normalized to total protein content determined by BCA assay.  C: 
MEF cells were incubated at 30, 37, or 39°C for 1 or 12 hours and new protein production was marked by [35S]-
labeled cysteine and methionine incorporation. Lysates were separated using SDS-PAGE and total protein was 
quantified using autoradiography followed by densitometry analysis of all visible bands in each lane. Graph: 
Quantification of (C). Data are presented as fold-change versus mean protein content at 37°C at each time point. 
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2.2.3 Suppression of type I IFN signaling pathways is not associated with early 
temperature effects 
In addition to the effects of temperature variation on global cellular transcription rates, we 
hypothesized that effects on one or more steps in the IFN-α/β signaling cascade may contribute 
to the temperature sensitivity of ISG transcription. IFN-α/β stimulates gene expression via 
activation of the JAK-STAT pathway, dependent upon the receptor tyrosine kinase activity of the 
IFN-α receptor complex (IFNAR1/2) and subsequent phosphorylation of primarily STAT1 and 
STAT2. It has been published previously that IFN-IFNAR binding characteristics do not vary 
significantly in the range of 30 to 37°C (609), so we decided first to examine the effect of 
temperature variation on the phosphorylation of STAT1 at Tyr-701. This step is mediated by the 
kinase Jak1 at the receptor complex and is required for assembly of the transcription factor 
complex ISGF3, which stimulates ISG transcription in the nucleus [reviewed in (325)]. Cells 
treated with IFN-α/β at 30, 37, or 39°C for 30 minutes showed similar levels of phosphorylated 
STAT1 (STAT1-p Tyr-701) by immunoblot (Fig 12A, 13A-B). By 60 minutes of IFN-α/β 
treatment, STAT1-p levels remained elevated in the 30°C samples but decreased at the higher 
temperatures (Fig 12A, 13B). Because phosphorylated STAT1 is required for ISG transcription, 
these findings did not fit with the attenuation of ISG transcription we observed at 30°C (Fig 9C, 
10D-E). We reasoned that despite efficient phosphorylation of STAT1 at 30°C, its nuclear 
translocation might be negatively affected and result in less activated STAT1 in the nucleus 
available for ISG transcription. To test this, we examined the efficiency of STAT1-p Tyr-701 
migration into the nucleus at different temperatures using confocal microscopy. In agreement 
with total STAT1-p levels, but in contrast to the observed effect on ISG transcription, IFN-α/β 
treatment of cells at 30°C resulted in significantly higher average content of STAT1-p per 
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nucleus compared to 37°C and 39°C by 30 minutes of IFN-α/β stimulation (Fig 12B, 13C). 
Furthermore, we noted similar levels of STAT1 phosphorylated at Ser-727, a modification 
required for maximal transcriptional activity of STAT1 that occurs in the nucleus, at all 
temperatures at 1-hour post-IFN-α/β (Fig 12C, 13D). Interestingly, late after IFN-α/β treatment, 
levels of STAT1-p Tyr-701 at 37 and 39°C were significantly increased over those at 30°C, 
indicating a potential mechanism for greater sustenance of the response at higher temperatures 
and (Fig 12D). This finding could perhaps be a consequence, in part, of the increased level of 
total STAT1 present at the higher temperatures compared to 30°C at this timepoint (Fig 9A-B). 
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Figure 12. Suppression of type I IFN signaling pathways is not associated with early temperature effects.  
A, C, and D: Immunoblot of STAT1 phosphorylated at Tyr-701(A and D) or Ser-727 (C) from Vero cells treated 
with 1000 IU/mL IFN-α/β at 30, 37, or 39°C and corresponding densitometry quantification with STAT1-p bands 
normalized to β-actin. Data are presented as mean STAT1-p/actin ratio ± SD. B: Vero cells treated with 1000 IU/mL 
IFN-α/β for 30 minutes at 30, 37, or 39°C were subjected to immunocytochemistry staining for STAT1-p (Y701). 
Confocal imaging shows phosphorylated STAT1 nuclear translocation. Graph displays average nuclear STAT1-p 
signal intensity per imaged nuclear area at each temperature. At least 199 cells/nuclei were analyzed in each 
temperature group. Statistics for A: **p<0.01, ****p<0.0001 two-way ANOVA with Tukey’s multiple comparison 
test. Statistics for B and D: ***p<0.001, ****p<0.0001, ns not significant by one-way ANOVA with Tukey’s 
multiple comparison test. All experiments were done with triplicate samples and data are representative of at least 
two independent experiments. 
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Figure 13. Suppression of type I IFN signaling pathways is not associated with early temperature effects in 
additional cell types. 
A, B, and D: MEF and HeLa cells were treated with 100 IU/mL IFN-α/β for 30 or 60 minutes at 30, 37, or 39°C and 
lysates were probed for STAT1 phosphorylated at Tyr-701 (A-B) or Ser-727 (D) by immunoblot. Graphs display 
densitometry analysis of STAT1-p bands normalized to β-actin at each temperature. Statistics for A and B: *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, ns not significant by two-way ANOVA with Tukey’s multiple comparison 
test. C: HeLa cells treated with 1000 IU/mL IFN-α/β for 30 minutes at 30, 37, or 39°C were subjected to 
immunocytochemistry staining for STAT1-p (Y701). Confocal imaging shows phosphorylated STAT1 nuclear 
translocation. Graph displays average nuclear STAT1-p signal intensity per imaged nuclear area at each 
temperature. ****p<0.0001 one-way ANOVA with Tukey’s multiple comparison test. 
2.2.4 Transcription of IFN response pathway genes is highly temperature-dependent 
Because the IFN-α/β signaling pathway upstream of ISG transcription was not attenuated by 
subnormal cellular temperature, we decided to focus more closely on the effect of temperature 
variation on ISG transcription. Specifically, we examined whether or not ISG mRNA induction 
was unique in its temperature sensitivity compared to other inducible and constitutively-
expressed genes, or if this phenotype might be solely attributable to a slowdown in global 
transcription rates. We performed direct mRNA quantification analysis via the NanoString 
platform on total RNA derived from MEF cells treated at 30, 37, or 39°C with IFN-α/β or 
lipopolysaccharide (LPS) for 3-12 hours. NanoString is a high-throughput mRNA quantification 
method that utilizes fluorescently-barcoded hybridization probes to simultaneously detect and 
count hundreds of distinct mRNA species in a given sample. Our multiplexed gene target panel 
included a variety of inducible genes from each stimulus, as well as signaling intermediates, 
feedback and regulatory genes, and cell homeostatic components such as transcription and 
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translation factors (see Table 2 for a complete list of target genes). Most constitutive genes were 
not appreciably affected by changing temperature or the addition of either stimulus (data not 
shown), including genes selected for normalization (Fig 14A). Expression of known 
temperature-responsive genes, including the cold-inducible CIRP and RBM3, and the heat-
inducible HSP70, displayed the expected temperature-dependent patterns, but expression was not 
influenced by IFN-α/β or LPS treatment (Fig 14B). Gamma actin intron #3 levels also followed 
the temperature-sensitive trend we observed in our qRT-PCR assays (Fig 14C). These results 
combine to validate the NanoString platform as a reliable method for quantitating the effect of 
temperature variation on gene expression. 
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Figure 14. NanoString analysis detects temperature-sensitive gene transcription. 
MEF cells were treated in with 100IU IFN-α/β or 250 ng/mL LPS, or were left untreated, at 30, 37, or 39°C for the 
time course indicated in duplicate samples. At each time point, total cellular RNA was harvested and subjected to 
direct mRNA quantification of 125 gene targets (see Table S2) using the NanoString platform. Raw mRNA counts 
in each sample were subject to background subtraction followed by normalization to the geometric mean of five 
normalization genes (B-actin, GAPDH, B-Tubulin, POLR2A, and eIF3a) in the same sample. A: Background-
subtracted mRNA count values of the five genes used for normalization, with IFN-α/β- or LPS-stimulated and 
unstimulated samples pooled at each temperature. B: Normalized expression profile of three known temperature-
responsive genes, with IFN-α/β- or LPS-stimulated and unstimulated samples pooled at each temperature. C: 
Gamma actin intron #3 expression. D: IL6 expression in LPS-treated MEFs in an independent experiment, 
quantified by qRT-PCR. E: Verification of expression of other LPS-responsive genes in MEFs at 3 hours post-LPS 
treatment in an independent experiment, quantified by qRT-PCR. 
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Figure 15A shows the fold-induction of IFN-α/β-responsive genes at 30, 37, and 39°C 
versus temperature-matched mock-treated samples at 3, 6, and 12 hours post IFN-α/β treatment, 
respectively. Panel B shows analogous results for LPS-treated cells. Only genes upregulated at 
least 2-fold over mock at any temperature are shown and included in subsequent analyses. After 
3 hours of stimulation with IFN-α/β or LPS, both IFN-α/β-induced and LPS-induced genes 
displayed similar patterns of temperature-sensitive expression in general, with optimal induction 
at 37°C or 39°C and dramatically reduced induction at 30°C (Fig 15A-B). Upon closer 
examination, however, differences became apparent. Most ISGs in our panel displayed decreased 
expression at 30°C compared to 37°C far below the 2-fold decrease in basal transcriptional rate 
that we observed (Fig 11A, 14C), indicating that the temperature sensitivity of ISG transcription 
may be attributable to additional mechanisms. Although this was also true of some LPS-
inducible genes, there were several examples (IKBA, NFKBIZ, and TNFAIP3) upon which 
temperature variation seemed to have little or no effect (Fig 15B). These results contrasted with 
the reliable temperature sensitivity of all ISGs in the panel. In addition, induction kinetics varied 
between ISGs and LPS-induced genes throughout the rest of the time course. For LPS-induced 
genes, apart from known ISGs also induced by LPS (GBP1, GBP2), expression in the 30°C 
group matched or exceeded expression at the higher temperatures by just 6 hours of LPS 
treatment (Fig 15B-C). At 30°C in IFN-α/β-treated cells, by contrast, ISG induction remained 
significantly lower than at higher temperatures until 12 hours of IFN-α/β treatment (Fig 15C). 
These differences in gene induction by LPS and IFN-α/β at different temperatures could indicate 
gene- or pathway-specific responses to changing cellular temperature beyond simple changes to 
basal transcriptional rates. 
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Figure 15. Transcription of IFN response pathway genes is highly temperature-dependent. 
NIH/3T3 MEF cells were treated in with 100IU IFN-α/β or 250 ng/mL LPS, or were left untreated, at 30, 37, or 
39°C for the time course indicated in duplicate samples. At each time point, total cellular RNA was harvested and 
 104 
subjected to direct mRNA quantification of 125 gene targets (see Table S2) using the NanoString platform. Raw 
mRNA counts in each sample were subject to background subtraction followed by normalization to the geometric 
mean of five normalization genes (B-actin, GAPDH, B-Tubulin, POLR2A, and eIF3a) in the same sample. A-B: 
Genes upregulated at least 2-fold in treated cells versus mock at any temperature are shown as log2 mean fold-
change of duplicate samples versus mock. Genes are ordered along the x-axis by log2 fold-change in expression at 
37°C. C: Bar graphs show geometric mean ± SD of ≥2-fold upregulated genes at each temperature at each time 
point. Statistics: **p<0.01, ****p<0.0001, ns not significant by Mann-Whitney rank test. 
2.2.5 Reduced temperature also affects type I IFN induction 
Thus far, our studies have focused on the effect of temperature variation on the signaling/effector 
phase of the IFN-α/β response. However, as the effector phase is preceded by the IFN-α/β 
inductive phase in response to infection in vivo, it is relevant to examine the effect of 
temperature in this context as well, as IFN-α/β efficacy in vivo depends concurrently on both 
phases. It has been published previously that IFN-α/β induction by rhinovirus is diminished at 
the subnormal temperatures of airway epithelial cells, which could contribute to enhanced 
rhinovirus fitness in the upper airways (577). To avoid temperature-dependent differences in 
viral replication that could influence IFN-α/β production, we electroporated poly-I:C into MEFs 
and then incubated the cells at 30, 37, or 39°C. We observed the earliest detectable IFN-α/β 
activity in cell supernatants from the 39°C samples, and IFN-α/β activity remained highest at this 
temperature throughout the time course (Fig 16A). IFN-α/β induction at 37°C was slightly but 
significantly reduced compared to 39°C at early time points, but still far exceeded levels of IFN-
α/β produced 30°C, which did not surpass the limit of detection until 8 hours post transfection 
(Fig 16A). We also performed qRT-PCR analysis for Ifna4, Ifnb, and Ifit1 mRNAs and found a 
similar trend in temperature dependent expression at early time points (Fig 16B). Interestingly, 
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while transcript levels of the IFN-α/β genes fell dramatically at the higher temperatures by 8 
hours post poly-I:C, they continued to rise at 30°C (Fig 16B); however, this did not correspond 
to increased secreted IFN-α/β at this temperature (Fig 16A), suggesting that translation 
suppression and/or attenuation of the secretory pathway may also play a role in temperature-
dependent IFN-α/β induction.  
The IFN-α/β genes are downstream targets of IRF3, which is activated in response to 
polyI:C, therefore, we examined IRF3 activation by western blot for IRF3 phosphorylated at Ser-
396 (IRF3-p). Temperature variation had no impact on levels of IRF3-p initially, but 
surprisingly, IRF3-p levels were maintained at 30°C through 6 hours post-stimulation, while all 
but disappearing at the higher temperatures (Fig 16C). In the same samples, however, IFIT1, 
which is directly IRF3-inducible (279), was much more highly expressed at 37 and 39°C 
compared to 30°C (Fig 16C). These results underline the discrepancy between activation of the 
IFN-α/β induction pathway and functional IRF3 responsive gene expression and highlight 
differences in gene transcription and translation as the major mediators of the effects of 
temperature variation on these pathways. 
The above experiments served to examine the effect of temperature variation on the 
cytosolic IFN-α/β induction pathway with equal initial stimulation of the pathway at all 
temperatures (i.e. an equal dose of the nonreplicating poly-I:C). However, this does not 
accurately represent the context of a viral infection, in which differences in viral replication rates 
at different temperatures could lead to variation in pathway stimulation and likely compound the 
effect of temperature on IFN-α/β induction that we observed with poly-I:C. To verify that viral 
infection at different temperatures also stimulates differential IFN-α/β induction, we infected 
cells at 30°C for the first hour to allow equal attachment and entry. After washing, infected wells 
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were divided among 30, 37, and 39°C temperature treatments for 12 to 24 hours, at which times 
supernatants were collected and assayed for IFN-α/β activity as described in Materials and 
Methods. Infections of MEF cells required the use of mutant viruses whose transcription and 
translation inhibitory mechanisms have been disabled (SINV-nsP2-726G (Fig 16D) and VEEV-
CD/nsP2-739L (Fig 16E)) (116). However, we also tested a wild-type alphavirus, SINV-TR339 
(Fig 5F), in the murine monocyte/macrophage RAW 264.7 cell line, which, unlike MEFs, can 
still produce IFN-α/β upon wild-type alphavirus infection. Unlike the results with poly-I:C, we 
observed greatest IFN-α/β activity from the 37°C infections, and IFN-α/β levels produced at 
39°C either did not differ from or were significantly lower than those observed from the 37°C 
treatment (Fig 16D-F). In agreement with the poly-I:C results, however, viral infection at 30°C 
resulted in greatly delayed and stunted IFN-α/β production (Fig 16D-F). Surprisingly, viral titers 
did not vary appreciably between temperatures, in general, indicating that differences in pathway 
stimulation may not have contributed much to differences in IFN-α/β output in this context. Viral 
growth at any temperature did not seem to be impacted by IFN-α/β induction by 24 h.p.i., which 
may be explained by the fact these viruses are competent for some inhibition of downstream 
IFN-α/β signaling in MEFs. The exception was SINV-nsP2-726G at 39°C, which did suffer 
some inhibition compared to the other temperatures, a possible indication of the increased 
efficacy of IFN-α/β at 39°C apparent against this virus. Importantly, these results demonstrate 
that IFN-α/β induction is also sensitive to temperature variation, and that a viral infection 
occurring at subnormal temperatures may benefit both from diminished detection and IFN-α/β 
induction, and from reduced ISG upregulation leading to a weakened antiviral state relative to 
higher temperatures. Combined, these two factors may create an environment in which the virus 
can replicate uninhibited by the IFN-α/β response long enough to produce IFN-α/β antagonists, 
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which could then combat subsequent IFN-α/β-mediated restriction, an interplay that could be 
particularly relevant in vivo. 
 
 
Figure 16. Reduced temperature also affects IFN-α/β induction. 
A-C: MEFs were transfected with 50µg polyI:C per million cells using electroporation. Pooled transfections were 
then divided among 30, 37, and 39°C temperature conditions. A: Supernatants were assayed for biologically active 
IFN-α/β as described in the Materials and Methods. Data are presented as log10 mean IU/mL ± SD.  B: qRT-PCR 
was used to quantify IFN-α/β and IFIT1 mRNA induction. Data are presented as mean fold-change in 18S-
normalized Ct values in polyI:C-treated versus untreated cells at each temperature ± SD. C: Immunoblot of IRF3 
phosphorylated at Ser-396 and IFIT1 from polyI:C-treated MEF lysates. D-F: Supernatants from virus-infected 
MEFs or Raw 264.7 cells were assayed for IFN-α/β as in A. IFN-α/β induction data are presented on the left Y-axis 
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as log2 mean IU/mL ± SD. Statistics: *p<0.05, **p<0.01, ***p<0.001, ***p<0.0001, ns not significant by two-way 
ANOVA with Tukey’s multiple comparison test of log-transformed IU/mL values. Viral titer data for (D) and (E) 
was determined by plaque assay on BHK cells at 37°C from the same supernatants assayed for IFN-α/β activity and 
is presented along the right y-axis of those panels, ± SD. # indicates the result was below the limit of detection of the 
assay. All experiments were done in duplicate or triplicate, and results shown are representative of at least two 
independent experiments. 
2.2.6 Lower temperatures in vivo suppress IFN-α/β responses 
To test the possibility that temperature variation might affect the pathogenesis and disease 
outcomes of a relevant infection in vivo, we adapted the C57BL/6 adult murine model of CHIKV 
infection and musculoskeletal disease (MSD) (183) to include systemic body temperature 
reduction. One of two strategies was used to achieve core temperature reduction depending on 
the experimental setup: either induction of metabolic torpor, a prolonged state of inactivity and 
energy conservation that attenuates heat-generating mechanisms (610), or administration of the 
small molecule reserpine (RES), which depletes peripheral monoamine neurotransmitters by 
antagonizing the vesicular monoamine transporter (VMAT), leading to dysregulation of 
temperature regulatory mechanisms (611, 612). Both methods effectively reduced mouse 
subcutaneous (scruff) temperature in both wild-type C57BL/6 (B6) and IFNAR1-/- (AB6) mice 
(Fig 18). For assessing the effect of reduced temperature on CHIKV-induced MSD, torpid and 
normal mice were infected in the left rear footpad and cross-sectional area was measured daily to 
track foot swelling. In wild-type mice, torpor induction resulted in significantly greater MSD 
between 6 and 8 days post infection, whereas in IFNAR1-/- AB6 animals, MSD was slightly 
reduced by torpor (Fig 17A). These results suggest that the effect of reduced body temperature 
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on CHIKV-induced disease signs manifests in an IFN-α/β-dependent manner, with low 
temperature leading to more severe disease only when functional IFN-α/β is present.  
Next, we used RES treatment to extend the duration of temperature reduction and 
examine viral growth kinetics using a nanoluciferase-expressing CHIKV (613) and in vivo 
imaging. In B6 mice, viral signal in both the infected (ipsilateral) and contralateral footpads rose 
similarly over time between RES-treated and normal animals until 3 days post infection, beyond 
which signal in the RES-treated group increased significantly over the signal in the warm group 
(Fig 17B). An opposite trend was observed in AB6 mice, with viral signal in RES-treated 
animals significantly lower than in the warm mice for the entire course of infection, until the 
mice were about to succumb to the infection (Fig 17B). In addition, viral titers from dissected 
tissues were not significantly different between normal and torpid B6 mice at 2 d.p.i., but 
remained high in the infected footpad and spleen of the torpid mice by 6 d.p.i., indicating 
dysfunctional viral clearance in those tissues at reduced temperature (Fig 17C). Finally, torpid 
mice failed to induce a robust serum IFN-α/β response at 2 days post-CHIKV infection 
compared to normal mice, suggesting that impaired IFN-α/β inductive pathways in vivo at low 
temperatures likely contribute to the observed effects on CHIKV infection (Fig 17D), although 
kinetic differences in virus replication brought on by the altered temperatures may have 
contributed to this result. 
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Figure 17. Lower temperature in vivo suppresses IFN-α/β responses. 
A: Core temperature reduction in 6-week-old C57BL/6 mice and Ifnar1-/- AB6 mice was achieved by induction of 
metabolic torpor. Torpid and normal mice were then infected in the left hind footpad with 1000 p.f.u. of wild-type 
CHIKV-LR (B6 mice) or the attenuated variant CHIKV-LR-E279K (AB6 mice). Virus-induced musculoskeletal 
disease was quantified daily by manual caliper measurement of footpad width and thickness to determine cross-
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sectional area. Data are presented as fold-change in infected footpad cross sectional area versus pre-infection area ± 
SEM. B: Mouse core temperature reduction was induced with intraperitoneal administration of reserpine 
approximately 3 hours prior to infection as in (A) with 1000 p.f.u of CHIKV-LR-nluc TaV and viral replication was 
tracked over time using in vivo imaging. Data are presented as the geometric mean of average footpad radiance in 
each group ± geometric SD. Statistics for A and B: *p<0.05 Mann-Whitney rank test at individual time points. C: 
Tissues from CHIKV-LR infected normal and torpid B6 mice were assayed for viral load by plaque assay at day 2 
and day 6 post infection. Data shown are mean viral titer ± SD. ****p<0.0001, ns not significant by two-tailed 
Student’s t test of log-transformed titer values. # indicates titer was below the limit of detection. D: Serum from 
CHIKV-LR infected normal and torpid B6 mice was assayed for biologically active IFN-α/β as described in the 
Materials and Methods. Data are shown as mean IU/mL ± SD. ****p<0.0001 by two-tailed Student’s t test. For all 
experiments, n = 3-6 mice per group and data are representative of at least two independent experiments. 
 
Figure 18. Torpor and reserpine treatment reduce mouse core temperature. 
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Mice were implanted subcutaneously in the scruff with temperature transponders (BMDS) prior to administration of 
reserpine (A) or induction of metabolic torpor (B) as described in the Materials and Methods. Temperature was 
monitored regularly throughout the course of all experiments, and graphs represent the typical temperature profiles 
of reserpine-treated or torpid animals versus normal. 
2.3 DISCUSSION 
Historically, studies of the IFN-α/β response have largely relied on genetic knockout strategies to 
examine the roles of individual mediators and effectors in various infection and disease models. 
However, there is a growing body of literature focused on intact innate immune mechanisms 
within the variable physiological contexts in which they operate in vivo and how this variability 
may affect efficacy (577, 579, 588, 591, 592, 594, 614-616). The results presented here indicate 
that ambient temperature can have broad impacts on the effectiveness of the mammalian IFN-α/β 
antiviral response. Many human pathogens, such as respiratory viruses, and other pathologies, 
such as certain malignancies (575), cause disease in tissues regularly exposed to temperatures 
below the normal core temperature of 37°C and may take advantage of a weakened innate 
immune environment. In these studies, we examined whether or not arboviruses, which are 
replication-competent across a wide range of temperatures due to their evolution in both 
arthropod vectors and mammalian or avian hosts, represented another type of pathogen capable 
of subverting IFN-α/β responses occurring at subnormal temperatures. In vitro, we found that 
arboviruses representing three distinct viral families had increased fitness at 30°C relative to 
37°C, but only when cells had been pretreated with IFN-α/β at each temperature. Without IFN-
α/β present, lowered temperature conferred no advantage to viral replication. These findings 
parallel trends observed with human rhinovirus (RV) and influenza virus (577, 588), although 
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the increased fitness of RV at low temperature is attributable to additional mechanisms as well 
(617). Uniquely, our studies demonstrate that temperature-dependent IFN-α/β efficacy alone is 
sufficient to alter arbovirus fitness and effectively overcome the small disadvantage posed to 
these viruses by low temperature in the absence of IFN-α/β. Collectively, these data suggest that 
the effect of temperature on IFN-α/β efficacy is widely applicable to any IFN-α/β-sensitive 
infection or pathology that occurs in a reduced-temperature environment. 
To examine the effect of temperature on the entirety of the IFN-α/β response, we 
examined both IFN-α/β gene upregulation and ISG upregulation phases. Mechanistically, it has 
been shown previously (577, 588) that several ISGs were less robustly induced at the mRNA 
level when cells are treated with IFN-α/β at temperatures below 37°C, but the mechanism(s) 
leading to decreased ISG transcription, as well as whether or not reductions in ISG transcript are 
functionally relevant to the antiviral state at the protein level, were not addressed. We found that 
activation of the Jak-STAT pathway resulting in phosphorylation, nuclear translocation, and 
nuclear phosphorylation of STAT1 to the transcription-promoting state was not attenuated by 
subnormal temperature. In fact, IFN-α/β signaling at 30°C resulted in more phosphorylated 
STAT1 present in the nucleus relative to 37°C. Thus, differences in IFN-α/β signaling efficiency 
were not responsible for the observed reduction in ISG transcript induction at subnormal 
temperature. Importantly, marked temperature-dependent differences in ISG expression were 
observed at the protein level, indicating that differences in ISG transcription and possibly 
subsequent translation result in differential functionality of the antiviral state at different 
temperatures. It is also possible that the activities of individual ISGs may be affected by 
temperature variation and that this could contribute to differences in their efficacy. If true, this 
idea may help explain the enhanced antiviral activity of IFN-α/β observed at 39°C versus 37°C, 
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when ISG protein levels were only modestly higher at this temperature. Moreover, enhanced 
induction of ISGs known to strengthen the IFN-α/β response, such as RIG-I or RNaseL, at higher 
temperatures may also contribute to increased efficacy versus lower temperatures, although this 
idea would presumably apply also to negative feedback ISGs, such as SOCS. Further studies will 
be needed to test this idea for individual ISGs and to determine the relative contributions these 
differences may have to immunity against specific pathogens. In sum, we conclude that 
transcription is the first step in both the IFN-α/β inductive and effector ISG inductive pathways 
affected by low cellular temperature that lead to attenuation of the antiviral activity of the IFN-
α/β response. 
Although detailed examination of the transcription factor activities for individual ISGs 
that account for the effect of temperature was beyond the scope of our current studies, our results 
comparing baseline transcriptional rate with ISG and LPS-responsive gene transcriptional 
efficiency did reveal some relevant trends. Transcript levels of the constitutively-expressed genes 
included in our NanoString analysis did not change appreciably upon temperature shift, while 
initial transcription of genes induced upon IFN-α/β or LPS treatment were highly affected by 
incubation temperature. We observed an approximate 2-fold reduction in basal transcriptional 
rate at 30°C versus 37°C by intron qPCR, and this may account for a portion of the reduction in 
inducible gene expression. However, it does not fully explain the dramatic differences in 
induction of all ISGs that were highly upregulated, nor does it account for the subset of LPS-
responsive genes whose expression was not temperature-sensitive. In general, these results point 
to a model in which inactive genes are much more susceptible to transcription attenuation by low 
temperature than genes actively being transcribed. Potentially, chromatin remodeling around 
inducible promotors and initial assembly of transcription machinery represent additional 
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obstacles to inducible genes being “turned on” that are absent from constitutively active genes 
(618). In addition, variation in the chromatin environments around different promotors, as well 
as in the transcription factors required for transcription of different genes, would allow for 
differential temperature sensitivity of inducible genes. Indeed, increased sp1 recruitment to a 
hypothermia-responsive element upstream of the cold-responsive RNA binding protein (Cirp) 
locus has been identified in the preferential upregulation of this gene at low temperature (522), 
indicating that temperature shift can impact transcription initiation at the chromatin level. In this 
view, the reliable temperature sensitivity we observed with ISGs is consistent with the 
presumption that ISRE-containing promotors reliant on similar transcription factors and 
chromatin modifications (619-621) would be subject to the same challenges of transcription 
initiation at subnormal temperatures, yielding the phenotype of temperature-sensitive ISG 
transcription. By contrast, the chromatin remodeling events and transcription factors required for 
LPS-responsive genes can vary considerably (618, 622), allowing for the possibility of different 
effects of temperature shift on individual genes or subsets of genes. Consistent with this idea, 
several genes that responded to both LPS and IFN-α/β treatment followed the same temperature-
dependent expression patterns regardless of the stimulus. Examination of additional signaling 
cascades with known repertoires of inducible genes, particularly those that stimulate distinct sets 
of transcription factors and co-factors to effect transcription of different gene subsets, will be 
helpful in elucidating gene-specific versus pan-regulatory effects of temperature variation. 
The initial lag in ISG transcription at 30°C was largely overcome by 12 hours post-IFN-
α/β treatment, and in some cases, ISG transcript levels at this temperature continued to increase 
as they began to stabilize or wane at the higher temperatures. Similarly, LPS-inducible gene 
transcript levels at 30°C also initially lagged behind those at higher temperatures on average, but 
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drew level by just 6 hours of LPS treatment, with many genes exhibiting greater expression at 
30°C by this timepoint. Although the mechanisms behind this temporal difference in ISG and 
LPS-induced gene regulation by temperature are unclear, this observation represents another 
piece of evidence that the effect of temperature on gene transcription is likely gene- and/or 
pathway-specific. That levels of gene transcripts induced at 30°C eventually met or exceeded 
peak expression at the higher temperatures and remained elevated over a longer period of time 
could be the result of a generalized increase in mRNA stability at subnormal temperatures (623-
625), and/or due to a defect in negative feedback pathways responsible for curtailing these 
signaling pathways. Regardless, there did not appear to be a functional consequence of ISG 
mRNA levels “catching up” at 30°C, as ISG protein levels remained reduced at this temperature 
compared to 37 and 39°C, even as late as 48 hours post-IFN-α/β treatment. It is likely that 
protein translation was also attenuated separately from transcription, accounting for this 
difference, as translational slowing is generally considered a hallmark feature of the cellular cold 
stress response (547, 624). This idea is supported by our in vitro RNA translation reporter and 
protein synthesis radiolabel assays (Fig 11). Differences in translational efficiency may also 
explain instances of enhanced ISG protein production at 39°C over 37°C when there was no 
difference at the transcript level. We conclude that general suppression of translation likely 
contributes to the suppression of ISG protein production at 30°C independently from effects on 
transcription. Whether or not ISG transcripts are specifically sensitive to temperature induced 
changes to translation efficiency, or if these effects manifest with all mRNAs, is still unclear.  
We also investigated the effect of temperature variation on IFN-α/β induction efficiency 
upon stimulation with either poly-I:C or viral infection. Poly-I:C, a non-replicating stimulus, was 
used for examination of IFN-α/β induction with equal RLR stimulation at each temperature. In 
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agreement with previous studies (577), poly-I:C treatment of cells at subnormal temperatures 
resulted in delayed and stunted IFN-α/β production compared to 37°C. That study attributed this 
difference to a modest reduction in the enzymatic activities of the cytosolic sensors Rig-I and 
MDA-5 at low temperature, as determined in in vitro ATPase assays (577). In contrast, we found 
that a downstream consequence of Rig-I/MDA-5 stimulation, the phosphorylation of IRF3, was 
not suppressed at the low temperature, suggesting that any effect on the enzymatic activity of 
these sensors is functionally inconsequential in this context. Rather, the effect of temperature on 
this pathway, as in the Jak-STAT pathway, likely manifests first at the level of transcription of 
responsive genes. We observed delayed transcription of IfnB, Ifna4, and Ifit1 genes, each 
primarily dependent on IRF3 in fibroblasts (279), at 30°C versus the higher temperatures at early 
time points, but levels surpassed those at the higher temperatures quickly thereafter. However, 
IFN-α/β protein release was drastically slowed and reduced at 30°C, both initially and well after 
mRNA levels had recovered, as was IFIT1 protein expression, indicating that efficiency of 
translation and/or secretory mechanisms also contributed to the reduction in IFN-α/β secretion at 
the lower temperature. Further studies are required to determine whether or not translation or 
secretory suppression by low temperature represents a universal effect or if different mRNAs are 
affected to varying degrees. Poly-I:C treatment at 39°C resulted in the highest induction of IFN-
α/β and IFIT1 proteins, indicating that enhanced IFN-α/β production may be an evolutionary 
aspect of the febrile response in vivo. As IFN-α/β is itself a pyrogenic cytokine, this relationship 
could be evidence of a feed-forward loop in which innate immune responses and fever co-
regulate to mount a more rapid response to infection. 
IFN-α/β induction was similarly temperature-dependent upon alphavirus infection, with 
the cells infected at 30°C resulting in delayed and diminished IFN-α/β production compared to 
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37°C. Interestingly, we did not observe the same enhancement of peak IFN-α/β production at 
39°C compared to 37°C that we did with poly-I:C treatment. It is reasonable to hypothesize that 
an enhanced downstream antiviral state at a febrile temperature could lead to more efficient 
control of the infection, possibly with lower peak IFN-α/β induction. Indeed, we did observe 
greater viral control of SINV-nsP2-726G at 39°C compared to 37 or 30°C in our MEF cultures, 
even with IFN-α/β levels well below those at 37°C. In contrast, at 30°C, IFN-α/β induction and 
subsequent effector phase are both delayed and attenuated. Because alphaviruses have evolved to 
grow efficiently at this temperature (and colder) in arthropods, virus replication largely resists 
the low-temperature environment, and initial replication proceeds largely uninhibited by IFN-
α/β. During this window, the virus can produce sufficient levels of IFN-α/β antagonists before a 
strong antiviral response can be mounted. IFN-α/β antagonism by most alphaviruses depends on 
the activities of nonstructural protein 2 (nsP2) or capsid proteins (116, 626, 627) and the viruses 
can also interfere with Jak-STAT signaling (119, 122, 607). 
In a murine model of CHIKV infection, we demonstrated that hypothermia can 
exacerbate virus replication and associated musculoskeletal disease, but only in the presence of a 
functional IFN-α/β response. In mice lacking IFNAR1, lowered body temperatures reduced both 
viral replication and disease signs, indicating that the effect of the reduced temperatures on the 
virus was acting through its effects on IFN-α/β, and serum IFN-α/β levels were much reduced in 
cold mice versus their warm counterparts. Surprisingly, differences in MSD in wild-type mice 
manifested several days after hypothermic mice had recovered to a normal body temperature, 
indicating that, as predicted from our cell culture models, influences of reduced temperature on 
viral infection occur at an early stage of the virus-host interaction, in the window before IFN-α/β 
can control the infection. As MSD in CHIKV infection is a complicated process driven by both 
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viral and host factors (183), it is tempting to speculate that subnormal temperatures early during 
infection allowed the virus to establish a more severe infection in the face of a weakened IFN-
α/β response, which then attracted increased immune cell infiltrates and induced greater 
inflammation at the site of infection. We did observe delayed viral clearance in the infected 
footpad and the draining lymph node of the hypothermic mice compared to the normal mice at 6 
d.p.i., which could help drive the exacerbated MSD at later timepoints. Together, these results 
demonstrate that CHIKV or other arbovirus pathogenesis and disease can be altered by variation 
in tissue temperature, with subnormal temperatures benefitting, and supranormal temperatures 
impairing, virus infection via effects on the IFN-α/β response. This suggests that local or 
systemic warming could represent a viable therapeutic for infection with CHIKV or other 
arthritogenic arboviruses if applied early after infection. However, other, off-target effects of 
reserpine treatment or torpor induction, such as systemic stress responses or altered hormone 
levels, may have contributed to our results through unknown mechanisms. Thus, future 
experiments using localized or external methods of temperature reduction may be useful for 
controlling for any off-target effects of reserpine or torpor. In addition, experiments involving 
external heating of reserpine-treated or torpid mice to mitigate temperature depression may be 
warranted to confirm the direct influence of temperature, and not other effects of reserpine or 
torpor, on viral phenotypes.  Finally, it is also worth noting that early studies of temperature and 
interferon responses focused on the establishment of persistent infection and its relationship to 
temperature-dependent interferon induction in vitro (628-632). It will be of interest to determine 
if temperature effects on the innate immune system influence the establishment of arboviral 
persistence in sites such as the testes (Zika (633-635)) and peripheral joints (CHIKV (180)) that 
may differ from core temperatures. 
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3.0  MODELING PERSISTENT CHIKUNGUNYA INFECTION IN MICE USING IN 
VIVO IMAGING 
3.1 INTRODUCTION 
The reemergence of Chikungunya virus (CHIKV) in previously endemic areas and expansion 
globally within the last 15 years has caused massive outbreaks affecting millions of people 
across the globe (33). Its 2004-2005 rampage across the Indian Ocean territories resulted in a 
new sublineage of the virus containing a mutation in its E1 envelope glycoprotein that was 
shown to confer enhanced fitness and transmissibility by a new species of mosquito vector, 
Aedes albopictus (165). This development is of major public health relevance because A. 
albopictus inhabits a much larger geographic range than the usual vector for CHIKV, Aedes 
aegypti, which is found only in tropical and subtropical regions (177). A. albopictus thrives 
across temperate climatic areas in Europe and North America as well as at equatorial latitudes 
across the globe, so its new role as a major vector for CHIKV puts an enormous number of naïve 
hosts at risk for infection, should the Indian Ocean Lineage CHIKV continue to expand its range 
(177). It has already been imported to southern Europe by infected travelers and seeded 
autochthonous spread by A. albopictus in multiple instances, however, it is not known to have 
established endemicity in these areas (168, 169). CHIKV made its way to the Western 
Hemisphere in 2013, when an Asian lineage virus caused an outbreak that started on St. Martin 
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island in the Caribbean and rapidly engulfed much of Central and South America, causing 
millions of suspected or confirmed cases (636, 637). Transmission during this outbreak was 
mediated by A. aegypti (636) and did not spread north of Florida (638), however, it did result in 
nearly 4000 traveler-associated cases reported in 49 states and the District of Columbia between 
2014 and 2016 (639), which suggests there is a real risk of CHIKV spreading into the greater 
United States, particularly if an A. albopictus-adapted virus emerges here. 
CHIKV causes an acute febrile illness characterized by intense and debilitating joint pain 
associated with direct cytolytic tissue damage and destructive inflammatory responses (153). In 
approximately half of acute CHIKV patients, arthritic/arthralgic symptoms will persist into a 
chronic disease phase after other acute symptoms have resolved and virus has been cleared from 
circulation (216). Chronic joint symptoms post-CHIKV infection may be persistent and 
unrelenting, or may reappear intermittently between periods of recovery. In either case, CHIKV-
induced chronic arthralgia is nontrivial and significantly decreases perceived quality of life in 
affected patients (220). Unlike acute CHIKV infection, during which any joint can be involved, 
chronic CHIKV-associated arthropathy is localized almost exclusively in the small, distal joints 
– ankles, wrists, fingers, and toes – and is usually polyarticular and symmetrical (33). Advanced 
age has been universally identified as one of the strongest risk factors for progressing to chronic 
CHKV disease (222, 229, 640). Other age-associated comorbidities such as cardiovascular 
disease, obesity, and diabetes are also independent risk factors, and may contribute to the 
strength of the association between chronic CHIKV and age (199). In addition, severity of acute 
disease strongly correlates with chronic CHIKV incidence, which may also be age-related, as 
elderly individuals account for a higher proportion of severe acute CHIKV cases than younger 
 122 
age groups (180, 231, 640). Smoking, female sex, and changing ambient temperature have also 
been identified as predictors of post-CHIKV chronic arthralgia or arthralgic episode (220, 223). 
In the previous chapter, we demonstrated that acute CHIKV replication in an arthritic 
mouse model was enhanced by systemic temperature reduction in both the inoculated and 
contralateral footpads of wild-type, but not Ifnar1-/- mice, indicating that lowered body 
temperature tempered the IFN-α/β response against CHIKV and contributed to increased viral 
fitness in vivo. It is known that adult wild-type mice can harbor CHIKV RNA, including 
negative-strand RNA, in joint-associated tissues as late as 4 months post-infection (202, 215). 
CHIKV RNA has also been detected in synovial biopsy samples from patients suffering chronic 
CHIKV-associated arthralgia, as well as one patient with CHIKV protein staining in synovial 
macrophages at 18 months post-infection (180). This study also found upregulated innate 
immune cytokines such as IFN-α, IL8, TNFα, and IL1β in PBMCs harvested from patients 
experiencing chronic CHIKV arthralgia, as well as in synovial fluid from one patient, indicating 
a persistent activation of innate immune responses that could be driving chronic inflammation 
(180). CHIKV antigen was also detected in muscle satellite cells in a quadriceps biopsy from one 
patient at 3 months post-infection (182). These findings suggest that CHIKV RNA capable of 
gene expression may persist in musculoskeletal tissues in humans. However, whether or not the 
viral RNA is a full-length conventional viral replicative entity, a dormant, infectious genome, or 
a defective replicative intermediate, are open questions. It is also unknown if all chronic CHIKV 
patients harbor the same type of persistent viral entity, or if persistent viral components differ 
between patients. Also, it is unlikely but possible that persistent virus infection is unrelated to 
chronic arthritis symptoms, which may reflect an autoimmune process originally stimulated by 
acute infection. Some studies have attempted to address these questions using mice deficient for 
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one or more components of the adaptive immune response to discourage viral clearance from 
joint-associated and lymphoid tissues and promote persistence, as viral clearance from 
circulation and most tissues is dependent on a strong neutralizing antibody response (251). 
CHIKV infection of Rag1-/-, Rag2-/-, or µMT mice results in higher initial viral burden in target 
organs that persists to chronic time points, a low-level serum viremia that in one study was found 
to last over 500 days, and infectious CHIKV virions recoverable from joint-associated tissues as 
late as 42 d.p.i. in Rag1-/- mice (202, 215, 233, 234, 251). Rag1-/- mice also showed histological 
signs of arthritis, metatarsal muscle inflammation and necrosis, and tendonitis at 12 weeks post-
infection, whereas these pathologies had resolved much earlier in wild-type B6 mice, although 
both strains still had synovitis at that time point (202). These results indicate that abrogation of 
adaptive immunity, particularly B cell responses, augments CHIKV and CHIKV RNA 
persistence and exacerbates chronic joint inflammation in ways that parallel human infections, 
but they have yet to address the underlying viral mechanisms that may be driving the 
inflammation and model the flaring of arthritis found in a large portion of humans suffering from 
chronic disease. 
In light of the established association between acute disease severity and risk of 
developing chronic CHIKV symptoms and the potential for virus replication as a driver of 
chronic and/or flaring disease, we hypothesized that factors that altered virus replication at acute 
or chronic time points might influence viral persistence and disease manifestations. To address 
this hypothesis, we have used a CHIKV expression vector newly developed in our laboratory 
that is similarly virulent to the unmodified parental virus and very stably expresses reporters of 
infection (613). 
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Initially, we used a wild-type CHIKV strain expressing nanoluciferase (nLuc) and an 
IVIS Spectrum CT in vivo imaging instrument (IVIS) to establish a sensitive method for tracking 
viral replication, spread, and persistence in adult wild-type C57BL/6 (B6) mice. We found that 
positive nLuc signal, a direct indicator of virus gene expression in this virus, was detectable 
throughout a 136-day experimental period. This is much longer than previously demonstrated 
and suggests that viral proteins are expressed in the mouse model during much, if not all, of the 
time viral genomes are present. Furthermore, to address the effect of the severity of acute 
infection upon subsequent chronic replication and disease, we have varied the intensity of initial 
replication by 1) reducing mouse core temperature during the first few days of disease, 2) 
infecting Irf7-/- transgenic mice that are more susceptible to initial virus replication and 3) 
infecting wild-type mice with a recently described CHIKV mutant (E2 K200R) that exhibits 
greater early replication and spread than normal CHIKV strains  (641). 
Temperature reduction caused by reserpine treatment during the first few days of 
infection was found to exacerbate CHIKV replication and spread at early time points and led to 
higher persistent viral signal compared to untreated mice at 30 days after infection. Similarly, use 
of innate-immune compromised Irf7-/- mice or the CHIKV 200R mutant enhanced initial virus 
replication and spread as measured by IVIS. Most notably, we observed that viral protein 
production at late time points could also be significantly increased by hypothermia induction 
during the chronic disease phase, potentially recapitulating a CHIKV infection “flare” and 
identifying temperature reduction as a potential driver of recurrent disease. Consistent with our 
hypothesis, the mice with the highest viral signal during the first two weeks of infection, either 
due to hypothermia at the time of infection or by genetic deletion of IRF7, tended to show the 
largest increases in signal upon temperature reduction later on, supporting the link between acute 
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disease severity and the risk of progressing to the chronic phase in humans. Studies of chronic 
infection with the CHIKV 200R mutant are in progress. 
To our knowledge, this is the first demonstration of active viral protein production during 
the chronic disease stage in any model, and it is suggestive that CHIKV can and does establish a 
bona fide persistent, productive infection in musculoskeletal tissues. This is also the first 
evidence that the “flaring” arthralgia phenotype observed in some human cases might be 
reasonably modeled in an animal and associated with potential viral reactivation events, possibly 
directly related to alterations in the efficacy of the IFN system as modulated by temperature. This 
is consistent with survey data of humans exhibiting chronic disease in that the most common 
factor associated with flaring disease was altered ambient temperature (220). Clearly, these 
initial observations come with many caveats and open questions, especially whether or not the 
persistent phenotypes in mice are analogous to those operating and driving persistent disease in 
human CHIKV patients. Further study and development of this model are necessary to address 
these questions. 
3.2 RESULTS 
3.2.1 High-sensitivity in vivo imaging reveals persistent CHIKV nLuc signal beyond four 
months post-infection 
Recent attempts to develop of a mouse model of chronic CHIKV infection have largely relied on 
the use of mouse strains deficient in various components of the adaptive immune system to delay 
or inhibit viral clearance from joint-associated (and other) tissues. This strategy is and will 
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continue to be valuable for understanding how CHIKV might establish persistence at various 
sites and especially whether or not chronic CHIKV represents a true, active persistent infection 
or retention of viral RNA or proteins in the absence of productive gene expression or replication. 
However, adaptive immunity plays a key role in viral clearance and protection from secondary 
infection. Thus, in its absence in these immunodeficient mouse models, CHIKV persistence 
phenotypes such as cell and tissue tropism may not accurately represent the situation in human 
patients. For example, antibody-deficient mice establish persistent, low-level viremia that lasts 
indefinitely, but this is not observed in human infections (202, 215). Therefore, we employed the 
use of wild-type adult C57BL/6 (B6) mice to establish an immunocompetent model of chronic 
CHIKV infection. It has been shown previously that CHIKV RNA is recoverable from the ankle 
joints of these mice at least 16 weeks post-infection, suggesting that this model does reflect some 
aspects of human infection (202). 
To maximize the sensitivity of CHIKV detection, we employed a strain of CHIKV-La 
Reunion (LR) expressing nanoLuciferase (Promega) for use with in vivo imaging (Fig 19A, 
(613)). The nLuc protein is fused in-frame between the capsid and pE2 proteins and gets 
autoproteolytically (amino terminus, capsid protease) and co-translationally (carboxy terminus, 
Thosea asigna viral 2A-like protease) cleaved from the structural polyprotein during virus 
replication. NanoLuciferase (nLuc) is a small, 19.1 kDa luminescent enzyme that exhibits 
enhanced stability and 150-fold greater luminescent output per molecule compared to firefly or 
renilla luciferases (642). Importantly, it also shows remarkable stability within the alphavirus 
genome and is less likely to be deleted from the genome than larger proteins, even over the 
course of a lengthy infection (613). Because nLuc was inserted into the CHIKV structural gene 
subgenomic region and was constructed as an in-frame fusion with the viral structural proteins, it 
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is produced concomitantly with viral proteins only after the synthesis of negative strand RNA. 
Therefore, its presence is suggestive of both productive viral gene expression and successful 
genome replication. Thus, our viral nLuc reporter system should reveal active viral replication 
and gene expression even when infection levels are very low or if relatively few cells become 
persistently infected during the chronic phase of CHIKV disease. Importantly, it should also be 
very sensitive to changes in chronic virus replication associated with altered host or 
environmental factors. 
To test the ability of the CHIKV-LR-nLuc reporter virus to persist in mice and our ability 
to detect persistence by in vivo imaging, we infected 5-week-old male B6 mice subcutaneously 
on the left rear footpad with 1000 pfu of CHIKV-LR-nLuc and imaged them regularly through 
136 days post-infection. Viral nLuc signal was highest in the inoculated (ipsilateral) rear footpad 
and the opposite rear (contralateral) footpad very early after infection (day 3 in our imaging time 
course) and decreased sharply over the first two weeks (Fig 1C-D). As expected from previous 
virus titrations and examination of musculoskeletal disease (93, 184), ipsilateral nLuc signal was 
always higher than contralateral. Interestingly, the primary footpad signal in both footpads at 
chronic time points was localized between the fibulare/intermedium bones and in the base 
metatarsal region adjacent to, but not in, the phalanges, and possibly not associated with a 
synovial joint (Fig 1B-C). In the ipsilateral footpad, viral signal at 14 days post-infection (dpi) 
was still over 2 logs above mock-infected background levels and remained well above 
background until very late time points, steadily decreasing throughout the rest of the time course 
(Fig 1C). In contrast, signal in the contralateral footpad was much lower and became 
indistinguishable from background signal by 58 dpi. Interestingly, similar localization of signal 
was observed regardless of whether or not the footpad was infected artificially (ipsilateral) or 
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through natural spread of the virus (contralateral). However, it is possible that the localization of 
signal within the footpad as well as footpad signal being prominent versus other sites on the 
mouse is related to technical aspects of IVIS imaging as well as precise sites of maximal virus 
replication. Indeed, other locations such as the snout, forelimbs, and popliteal lymph nodes can 
also become positive for viral signal, and signal may persist and flare at these sites as well (Fig 
20B, D; data not quantified). For the remainder of the chapter, I will focus on the footpad signal 
as an indicator of persistent virus replication that may well also be occurring at other sites as 
levels below the limit of detection of the IVIS instrument. 
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Figure 19. High-sensitivity in vivo imaging reveals persistent CHIKV nLuc signal beyond four months post-
infection. 
A: Diagram of the genome structure of CHIKV-LR-nLuc (adapted from [sun 2013]). B: 5-week-old male C57BL/6 
mice were infected in the ventral left hind footpad with 1000 p.f.u. CHIKV-LR-nLuc and viral replication and 
spread was tracked over time using in vivo imaging. C: Dorsal view of murine hind foot bone anatomy (diagram 
adapted from (643). D-E: Regions of interest encompassing the entire visible ventral foot were quantified for 
average radiant signal. 
3.2.2 Exacerbation of CHIKV acute phase replication via body temperature reduction, 
IRF7 deficiency, or a mutant CHIKV (200R) 
To test the hypothesis that the magnitude of CHIKV replication during the acute infection phase 
leads to higher viral signal during the chronic phase, we first tested three strategies aimed at 
increasing acute CHIKV replication versus a normal infection with CHIKV-LR-nLuc in B6 
mice: 1) reserpine (RES)-induced body temperature reduction during the first few days of 
CHIKV-LR-nLuc infection in B6 mice, 2) CHIKV-LR-nLuc infection of mice lacking IRF7 
(Irf7-/-), and 3) infection of B6 mice with a CHIKV strain containing a mutation that has been 
shown to increase virulence in mice versus the parental virus (641) (CHIKV-LR-200R-nLuc).  In 
addition, we infected another group with the related arthritogenic alphavirus Sindbis virus strain 
TR339 (SINV-TR339-nLuc) with the intent to evaluate the persistence phenotype of a related 
alphavirus that does not commonly cause severe or chronic arthritis. Each of these groups was 
infected with 1000 p.f.u. of either CHIKV-LR-nLuc, CHIKV-LR-200R-nLuc, or SINV-TR339-
nLuc subcutaneously in the left hind footpad on day 0 and viral replication, spread, and 
persistence was monitored by in vivo imaging. 
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As expected, reserpine treatment four hours prior to infection resulted in a period of 
hypothermic body temperature corresponding to the first few days of CHIKV infection (Fig 
20A), and these mice exhibited higher viral signal in the ipsilateral footpad than normal mice on 
days 3 and 9 post-infection (Fig 20B-C, *p<0.05 Kruskal-Wallis rank test). Similarly, both 
CHIKV-LR-nLuc-infected Irf7-/- mice and B6 mice infected with the 200R mutant CHIKV had 
significantly higher viral nLuc signal in the ipsilateral footpad than the LR-infected B6 control 
mice at 3 d.p.i. (Fig 20D-E, ***p=0.0008, *p=0.0424 unpaired two-tailed t tests of log-
transformed radiance values). Note that the same normal B6 + LR control group mice were used 
across all experiments in figure 20. The visual differences in the nLuc signal for these mice in 
figure 20 panels B and D reflect different ranges of the pseudocolor scales that were necessary to 
accurately depict differences in the experimental groups, which varied greatly in signal strength. 
These results validate all three of our methods for exacerbating acute CHIKV replication to test 
the effect of the magnitude of acute phase replication of chronic or persistent phenotypes. The 
experimental groups for two of these strategies, temperature reduction and IRF7 deficiency, were 
followed by in vivo imaging to approximately 1-month post-infection. Interestingly, ipsilateral 
footpad nLuc signal became significantly higher in the reserpine-treated B6 mice than the normal 
mice on day 30 after two weeks of insignificant difference, possibly resulting from a slower rate 
of signal diminution during this time (Fig 20C, *p<0.05 Kruskal-Wallis rank test). Ipsilateral 
footpad nLuc signal in Irf7-/- mice remained higher than that in B6 mice throughout the entire 
time course, although direct comparison at chronic time points was not possible because the 
groups were imaged on slightly different days (Fig 20F). SINV-TR339-nLuc signal was 
comparable to CHIKV-LR-nLuc at 3 d.p.i., but decreased more rapidly thereafter (Fig 20C). 
Surprisingly, SINV-TR339-nLuc signal was still detectable in the infected footpad at 30 d.p.i., 
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suggesting that this virus may have heretofore unrecognized potential to persist in host tissues, 
though it could be an artifact of undegraded nLuc that may remain active in tissues for a time 
after it is produced. No direct evidence exists for either of these possibilities, however, and it will 
be important to answer this question in the future. Collectively, these results indicate that 
increased acute CHIKV replication can lead to higher levels of persistent viral signal at a chronic 
time point. Studies with the 200R mutant are ongoing, but we expect that those results will lend 
further support to this conclusion. However, whether greater acute viral replication results in a 
greater number of persistently-infected cells compared to baseline or a similar number of 
infected cells that are producing more viral proteins on a per-cell basis is unknown and either 
possibility could underlie our findings. Future immunohistochemical/immunocytochemical 
analysis of persistenly-infected cell populations in these different experimental groups will be 
needed to resolve this question. 
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Figure 20. Exacerbation of CHIKV acute phase replication via body temperature reduction, IRF7 deficiency, 
or a mutant CHIKV (200R). 
5-6-week-old male C57BL/6 and Irf7-/- mice were infected in the left rear footpad with 1000 p.f.u. of nLuc-
expressing CHIKV strains LR or LR-200R, as indicated. A subset of the C57BL/6 mice were treated with reserpine 
four hours prior to infection with CHIKV-LR-nLuc. Viral replication and spread were monitored over the course of 
1 month by in vivo imaging on an IVIS-Ct machine. A: Subcutaneous (scruff) temperature profiles of reserpine-
treated and normal C57BL/6 mice during the first 8 days of infection. B and D: Pseudocolored IVIS images show 
nLuc signal strength and distribution in infected mice. C, E, and F: Average radiant signal was quantified from the 
ipsilateral hind foot region and compared between experimental groups. Statistics for C: *p<0.05 Kruskal-Wallis 
rank test. Statistics for E and F: *p<0.05, ***p<0.001 unpaired two-tailed t tests of log-transformed average 
radiance values.   
3.2.3 Temperature reduction during chronic CHIKV infection induces flaring of 
persistent viral nLuc signal 
CHIKV RNA persistence has been associated with chronic immune activation in humans and in 
animal models, evidenced by cellular infiltrates into musculoskeletal tissues and elevated levels 
of proinflammatory cytokines, including type-I IFNs (180, 215). Chronic IFN-α/β activation has 
been suggested to contribute to inflammatory tissue damage or adaptive immune suppression 
associated with several persistent viral infections (127, 644, 645), but it may also be playing a 
virus-suppressive role, and its role in chronic CHIKV infection and disease has not been defined. 
In addition, temperature change has been associated with the onset of chronic CHIKV arthralgia 
flare-ups in humans (220), and we have demonstrated that temperature reduction increases 
CHIKV fitness in vivo by suppressing IFN-α/β (previous chapter). Therefore, we hypothesized 
that temperature reduction during the chronic phase of CHIKV infection will cause a flare in 
viral nLuc signal in our mouse model, potentially through attenuation of IFN-α/β. To test this, 
 135 
we treated a subset of the CHIKV-LR-nLuc-infected B6 control mice from the previous 
experiment (Fig 20 group normal B6 + LR) with reserpine at 1-month post-infection and 
performed IVIS imaging one day before and four days after treatment to observe any changes in 
nLuc signal associated with the temperature reduction. Reserpine treatment caused the expected 
four-day period of hypothermia (Fig 21A) and resulted in modest but significant increases in 
ipsilateral footpad nLuc signal compared to signal one day before treatment (Fig 21B-C; group 
Normal B6 + LR RES d31; ***p<0.001 paired ratio t test). To our knowledge, this is the first 
demonstration of active changes in viral protein expression levels in a chronic CHIKV infection 
model. 
We also observed ipsilateral footpad signal flares post-reserpine treatment in the CHIKV-
LR-nLuc-infected B6 mice that had been treated with reserpine at the outset of infection (RES 
B6 + LR RES d31) and the reserpine-treated Irf7-/- mice (Fig 21B-C; RES B6 + LR RES d31 
**p<0.01 paired ratio t test; Irf7-/- + LR RES d32 – statistical analysis could not be performed 
due to n of only 2). Additionally, increases in nLuc signal were clearly visible post-reserpine 
treatment in other locations as well, such as the snout region, front footpads, and the popliteal 
lymph nodes (Fig 21B, white arrows). Curiously, a much smaller but significant ipsilateral 
footpad signal increase from pre- to post-reserpine was also observed in CHIKV-LR-nLuc-
infected B6 mice that had not received reserpine treatment at any point (Fig 21C; Normal B6 + 
LR *p<0.05 paired ratio t test). These mice were co-housed with reserpine-treated mice, and as a 
result, they suffered slight reductions (~1°C) in body temperature during this window potentially 
due to a dearth of shared body heat available to them (Fig 21A). This may underlie the small 
signal increases in this group, although it may also reflect the presence of naturally-occurring 
flares in viral activity in this model. Finally, we observed that the mice with the highest levels of 
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viral replication during the acute phase of CHIKV infection (B6 mice treated with reserpine on 
the day of infection and Irf7-/- mice) also had the largest fold-change in ipsilateral footpad nLuc 
signal post-reserpine treatment versus pre-reserpine at 1-month post-infection (Fig 21D). 
Reserpine-induced fold-change in viral signal in Irf7-/- mice was significantly higher than in the 
normal B6 group (p=0.006 two-tailed t test). While the fold-change in signal was not statistically 
different between the initially reserpine-treated B6 + LR group and the control B6 + LR group in 
this experiment, we are confident that significance will be achieved once more mice are tested, 
and experiments to address this are currently in-progress. In addition, two of the reserpine-
treated B6 + LR mice exhibited much larger signal flares than the others, which resulted in a 
high variance and contributed to the lack of statistical significance. In any case, these results 
support our hypothesis that acute infection severity is a determinant of chronic CHIKV 
persistence phenotypes. In sum, these data are highly suggestive of an active CHIKV infection 
persisting in multiple musculoskeletal and/or lymphoid tissue at least one-month post-infection 
and confirm that hypothermic temperature can influence both the establishment of chronic 
CHIKV infection and elicit flaring events. In addition, the data support an association of acute 
infection severity with the intensity of flaring disease, either via stochastic aspects due to 
differing infected cell numbers or the actual intensity of the viral gene expression increase. 
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Figure 21. Temperature reduction during chronic CHIKV infection induces flaring of persistent viral nLuc 
signal. 
A subset of the mice from each experimental group from Figure 20 were treated with reserpine at ~1-month post-
infection and changes in nLuc signal between pre- and post-reserpine were observed by in vivo imaging. A: 
Subcutaneous (scruff) temperature profiles of reserpine-treated and normal C57BL/6 mice. B: Pseudocolored IVIS 
images show nLuc signal strength and distribution in infected mice pre- and post-reserpine treatment at 1-month. 
White arrows indicate sites of visible signal increases other than the ipsilateral footpad. C: Average radiant signal 
was quantified from the ipsilateral hind foot region and compared between pre- and post-reserpine time points for 
each animal. *p<0.05, **p<0.01, ***p<0.001 paired ratio t test. D: Mean fold-change in ipsilateral footpad signal 
post-reserpine vs. pre- for each experimental group. P values reported are from two-tailed t tests. 
3.3 DISCUSSION 
3.3.1 Detection of a persistent infection 
Using a CHIKV that expresses an nLuc reporter within its structural proteins, we successfully 
detected positive viral protein signal over four months post-infection using in vivo imaging. As 
alphavirus structural proteins are produced from a subgenomic mRNA transcribed only after 
negative strand RNA synthesis and genome replication, nLuc signal in this context is highly 
suggestive of persistent, productive viral genome replication and protein production in the 
inoculated footpad and other sites where signal could be detected. However, a significant caveat 
exists in this interpretation that will need to be addressed before this chronic CHIKV model can 
be validated as evidence for a true, persistent CHIKV infection. Specifically, our experiments did 
not rule out the possibility that nLuc might be remarkably stable in mouse tissues, and the long-
term signal we observed was not due to new gene expression from the virus, but rather from 
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undegraded nLuc protein produced earlier in the infection. It is unknown how long nLuc protein 
can remain active in tissues once it is produced, and what the limit of detection of nLuc is on the 
IVIS, as no studies have addressed these issues so far. Direct injection of nLuc protein from a 
transfected cell lysate that gives an initial IVIS signal equivalent to CHIKV infection into the 
footpad and tracking how quickly its activity wanes via in vivo imaging might be a productive 
strategy for answering the question of in vivo nLuc stability, although presumably, the majority 
of injected protein would be extracellular as opposed to intracellular virus-produced protein and 
the clearance rates of these two groups may not be similar. Alternatively, the addition of a PEST 
sequence to the nLuc insert would theoretically speed up nLuc turnover and reduce its potential 
for giving a false positive signal. 
Infection of mice with SINV-TR339-nLuc did result in diminished nLuc signal compared 
to CHIKV-LR-nLuc at 30 d.p.i. despite similar signal strength at 3 d.p.i., but signal was still 
detectable in a subset of SINV-infected mice (Fig 20C). This experiment was intended to address 
the similarity or differences in persistent replication produced by a related alphavirus that causes 
a less severe manifestation of musculoskeletal disease (MSD) in humans. Along these lines, we 
have never detected swelling of the ipsilateral (or any) footpad when mice are infected with 
SINV in the same context as CHIKV, where we do see easily detectable increases in footpad 
cross-sectional area (93). The results we obtained suggest that SINV may also exhibit persistent 
genome replication and protein expression. Indeed, previous studies have demonstrated the 
capacity to RT-PCR amplify SINV sequences from the brains of infected normal mice for their 
lifetimes (646). Therefore, multiple alphaviruses may have persistent replicative cycles in 
vertebrates. However, the mechanisms underlying the differences in disease elicited by SINV 
versus CHIKV remain to be elucidated 
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Naturally, the most compelling evidence for a truly persistent CHIKV infection in our 
model would be isolation of infectious virus from persistently-infected sites such as the 
ipsilateral footpad. Although we did not attempt to culture live virus from a chronic time point in 
our studies, several unsuccessful attempts have been made in other studies using normal mice 
(201, 202, 215), Whether or not these failures reflect the scale of the persistent infection in the 
studies or the effects of neutralizing antibodies on the characteristics of persistent infection or the 
capacity to detect infectious virus is unclear. Since mice incapable of producing a neutralizing 
antibody response do yield infectious virus for long periods post infection (202, 215, 234, 251), 
it does appear that detection of viable virions at late times post infection of normal mice should 
be technically possible and that in the absence of clearance pressures exerted by antibodies, the 
virus infection can productively persist. We could approach these issues in antibody-competent 
mice by increasing the magnitude of acute disease through use of early reserpine treatment or 
IRF7-deficient mice or by reducing antibody responses at late times post infection through B cell 
and IgG depletions followed by sensitive co-culture of nLuc-positive tissues with susceptible 
cells. Alternatively, transplantation of an infected foot from a chronic timepoint onto a naïve, 
immunocompromised mouse, such as a Rag-/- or Ifnar-/-, may be a very sensitive method for 
determining if infectious virus persists in our model. Presumably, in the absence of these 
immune components, any infectious CHIKV would be able to replicate and spread uninhibited 
from the transplanted foot, and would be readily detectable in its new host by IVIS imagaing. 
Barring detection of cell-free virus, PCR could be used to amplify both the genome and 
antigenome from tissues showing persistent nLuc signal to confirm the presence of viral RNA 
and active replication. Deep sequencing could reveal whether the whole CHIKV genome is 
present in these tissues. If the intact CHIKV genome is not present, then that would strongly 
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suggest that infectious virions are not being produced during the chronic phase, and persistence 
of CHIKV RNA does not represent a true persistent or latent infection. In addition, it will be of 
interest to identify the cell type(s) that harbor persistent viral RNA or protein using 
immunohistochemistry on tissue sections from chronically-infected hindlimbs and feet. 
However, this has not been achieved previously, likely due to the limited number of infected 
cells or the low level of virus gene expression in cells subjected to antibody-mediated clearance 
pressure (647, 648). Indeed, only the high sensitivity of the nLuc/IVIS approach has allowed us 
to reproducibly detect chronic gene expression in normal mice. As indicated above, antibodies to 
viral proteins are insufficiently sensitive to detect persistent gene expression and no antibody to 
nLuc has been described. However, we are attempting to detect long-term virus gene expression 
by use of CHIKVs expressing fluorescent reporters of infection (e.g., GFP, mCherry, iRFP) 
followed by tissue cryosectioning and confocal microscopy. However, it remains to be 
determined if these approaches will yield the increased sensitivity required to detect virus gene 
expression in individual cells. Interestingly, the prevailing hypothesis is that synovial 
macrophages are the most likely cell type supporting persistent CHIKV infection (180, 181), but 
our IVIS images indicate that the most prominent viral signal may not always be associated with 
synovial joints at chronic time points. One of our hypotheses was that persistent viral nLuc signal 
could be enhanced by increasing the severity of acute CHIKV infection and replication. We used 
reserpine-induced hypothermia in B6 mice and IRF7-deficient mice as two distinct methods for 
achieving higher acute replication and spread than a typical B6 infection, and found that both 
strategies resulted in higher persistent signal at least one-month post-infection. In addition, we 
infected B6 mice with a mutant CHIKV strain, 200R, that exhibits increased pathogenicity in 
mice and found increased replication and spread versus the parental LR strain at 3 d.p.i. This 
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represents another strategy for exacerbating acute CHIKV infection, but the results pertaining to 
its effect on persistence are still pending. Effecting a more intense acute infection through one of 
these methods to enhance persistent infection/signal may improve the ability to detect individual 
cells or populations that are persistently infected, as those cells/populations are likely to be 
higher in number and/or viral antigens versus a typical infection. 
3.3.2 A flaring disease model 
We used reserpine treatment and the resultant reduction in body temperature to cause temporary 
flares in viral nLuc signal at chronic time points, however, the cellular and molecular 
mechanisms leading to the flare are unknown. Presumably, the low temperature caused by the 
reserpine treatment temporarily attenuated an immune mechanism that dampens viral gene 
expression during the chronic phase. It is possible that this mechanism is the type-I IFN 
response, as we have shown previously that temperature-sensitive IFN-α/β responses can alter 
acute CHIKV infection (Chapter 2). This would also make sense in the context of intracellular 
viral products driving continual stimulation of IFN-α/β inductive and effector pathways, as has 
been noted for other persistent viral infections and are proposed for CHIKV inflammatory 
arthritis (127). To test this, type-I IFN neutralizing antibody or a blocking antibody against the 
IFN receptor could be administered to chronically-infected mice to assess their effects upon 
nLuc signal flares either in normal mice or in those stimulated to undergo reserpine-induced 
flares. Similarly, other components of the immune system such as B cells, T cells, and NK cells 
could be systematically depleted during chronic CHIKV infection to determine which immune 
cell types contribute to the control or persistence of CHIKV. Effects of these depletions on the 
virus could be tracked over time using IVIS in normal mice and in mice with exacerbated acute 
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infections (e.g. reserpine-treated or IRF7-deficient). Presumably, flaring caused by any of these 
immune system modulations would be greater in magnitude following a more severe acute 
infection. 
Although temperature reduction at chronic time points resulted in flares in viral signal, 
we have not yet detected overt signs of MSD typical of the acute phase (i.e. visually evident foot 
swelling) in any mice, regardless of acute infection severity, although cross-sectional footpad 
area measurements would be needed to confirm or refute the presence of any swelling. 
Histological analysis of affected mouse tissues may reveal exacerbated MSD (e.g. edema, cell 
infiltration, inflammation damage, apoptosis) concurrent with a signal flare, but a model of 
chronic CHIKV arthritis/arthralgia with the obvious joint pain and swelling observed in humans 
would be useful in the future. To this end, we will be testing multiple factors that may affect the 
magnitude and duration of flaring signal as well as much more detailed assessment of the 
characteristics of the flare to determine if conventional signs of MSD (e.g. foot swelling, 
histological changes) become apparent in the chronic infection model, possibly dependent upon 
intensity of signal reactivation. Currently, mouse models of chronic CHIKV disease have been 
focused on the cellular and molecular underpinnings of viral persistence, and none have assessed 
disease symptoms such as pain. DigiGate analysis of chronic CHIKV-infected mice with and 
without viral signal flaring may reveal pain-associated alterations in gate (walking) attributable 
to chronic CHIKV disease, which would be a valuable parameter to measure 1) the relevance of 
a mouse model to human disease, and 2) the effectiveness of potential therapeutics aimed at 
treating CHIKV-associated chronic joint pain. 
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4.0  CONCLUSIONS 
Arboviruses such as CHIKV have evolved to tolerate a broad range of host tissue temperatures 
due to their transmission cycles through endothermic vertebrate hosts and ectothermic arthropod 
vectors. In a human host, these viruses encounter variable thermal environments throughout their 
pathogenesis from the skin into deeper tissues, and control of acute arboviral replication and 
spread is largely dependent on type-I IFN responses. As CHIKV is able to establish infection and 
cause chronic disease in distal joint tissues that are lower in temperature than the body core, we 
questioned whether or not the ability of type-I IFN to control CHIKV and other arboviruses was 
temperature-dependent. We found that the induction and antiviral efficacy of IFN-α/β was 
sensitive to changes in ambient temperature, and that transcription of inducible genes in these 
pathways, but not upstream signaling events, was the main cellular process regulated by 
temperature. In addition, we found that the interplay between temperature and the type-I IFN 
response could influence acute and chronic CHIKV infection in vivo. This work demonstrates 
that physiologically-relevant temperature variation can have meaningful impacts on innate 
immune pathways and potentially influence the severity of viral infections in humans. 
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4.1 TEMPERATURE-DEPENDENT EFFICACY OF TYPE-I INTERFERON 
In Chapter 2, we examined the effect of mildly hypothermic and febrile-range temperatures on 
the induction and antiviral efficacy of IFN-α/β, and the mechanism leading to observed 
differences. We conclude that diverse arboviruses are universally more resistant to the IFN-
induced antiviral state produced at sub-normal (30°C) temperatures compared to 37°C, and 
somewhat more sensitive to IFN-α/β treatment at a febrile-range temperature (39°C) in vitro. 
This finding can be explained by the delayed and blunted induction of ISG proteins we observed 
at 30°C versus 37°C, however, ISG levels at 39°C were modestly and non-uniformly higher than 
those at 37°C, indicating ISG expression alone may not underlie the enhanced antiviral activity 
of IFN-α/β at a febrile-range temperature. Both mRNA and protein levels of ISGs were affected 
by ambient temperature, but upstream JAK-STAT signaling steps including STAT1 
phosphorylation and nuclear translocation were not attenuated at 30°C. Thus, we conclude that, 
along the pathway of establishment of the antiviral state, ISG induction is initially temperature-
regulated at the transcription step. We obtained similar results for IFN-α/β gene induction, with 
bioactive IFN-α/β and IFN-α/β transcript levels both sensitive to ambient temperature, but not 
the upstream activation of IRF3. We also found that IFNs and ISGs may be somewhat unique in 
their temperature-sensitive transcription, as LPS-inducible genes did not reliably share the same 
temperature-regulated phenotype. Finally, we demonstrated that CHIKV replication and MSD 
can be exacerbated by reducing core temperature in an IFN-α/β-dependent manner in a mouse 
model of acute CHIKV arthritis. In sum, we conclude that low temperature associated with 
certain anatomical sites and tissues dampens IFN-α/β responses and provides an advantage for 
viruses such as CHIKV to replicate and cause disease there. These studies suggest that 
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exogenous heat application or tolerance of virally-induced fever may prove beneficial for 
controlling CHIKV or other infections through its enhancement of IFN-α/β. 
4.2 IMPACTS OF TEMPERATURE VARIATION AND ACUTE INFECTION 
SEVERITY ON CHIKUNGUNYA PERSISTENCE 
In Chapter 3, we extended our studies of the impact of reduced tissue temperature on acute 
CHIKV infection in vivo to possible effects on viral persistence. We established that adult wild-
type mice remain positive for CHIKV reporter protein (nLuc) expression in the infected footpad 
past four months post-infection using IVIS, indicating their use as a model for chronic CHIKV 
infections. In addition, we achieved higher persistent nLuc signal using temperature reduction 
during the acute phase as well as infections of IRF7-deficient mice, supporting the idea that the 
magnitude of viral replication during the acute phase is predictive of progression to chronic 
disease, as has been observed in human cases. Finally, we used temperature reduction at chronic 
time points to cause significant increases in persistent nLuc signal, reminiscent of the flaring 
chronic arthralgia common in CHIKV patients. We conclude that IVIS is a sensitive method for 
tracking chronic CHIKV phenotypes and will be useful for further developments of a chronic 
CHIKV mouse model. In adult wild-type mice, it is likely that CHIKV persists as a RNA entity 
capable of continued gene expression whose presence may be driving chronic inflammation, but 
it is unknown if this results in infectious virion production. 
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4.3 CONCLUDING REMARKS 
In conclusion, we have verified previous reports that IFN-α/β responses are attenuated at 
hypothermic temperatures and revealed that the mechanism of temperature regulation of these 
responses occurs at the transcription of the IFN-α/β genes and ISGs. We also showed increased 
efficacy of IFN-α/β against arboviruses at a fever-range temperature. In a mouse model of 
CHIKV, temperature reduction exacerbated viral replication during the acute phase and caused 
flares in viral reporter signal during the chronic phase, indicating that temperature variation can 
impact the pathogenesis of CHIKV in vivo. These studies contribute to our understanding of how 
environmental factors such as temperature can influence innate immune responses and impact 
viral infection. 
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5.0  MATERIALS AND METHODS 
Cell lines 
Baby Hamster Kidney (BHK-21) cells (ATCC; RRID CVCL_1915) and L929 murine 
fibrosarcoma cells (RRID CVCL_0462) were maintained in RPMI-1640 supplemented with 10% 
donor calf serum (DCS) and 10% tryptose phosphate broth (TBP). RAW264.7 murine 
monocyte/macrophage (RRID CVCL_0493), African Green Monkey Kidney (Vero; RRID 
CVCL_0059), and human cervical carcinoma (HeLa; ATCC; RRID CVCL_0058) cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf 
serum (FCS). MEF/3T3 Tet-Off murine embryonic fibroblasts (simply called MEFs throughout; 
Clontech; CVCL_KS91) and immortalized primary MEFs from Ifnar1-/- animals (MEF isolation 
and immortalization are described in (649)) were maintained in DMEM containing 10% FCS, 
100 mM HEPES buffer, 0.075% sodium bicarbonate, and 0.05 mg/mL G418 sulfate 
(Mediatech).  All media also contained 100 U/mL penicillin G sodium and 100 µg/mL 
streptomycin sulfate. Except for instances of experimental temperature variation, all cells were 
grown at 37°C in a humidified chamber with 5% CO2. 
 
Primary cell cultures 
Primary murine osteoblast cultures were generated from 3- to 5-day old suckling CD1 mice and 
maintained as described previously (117). Briefly, dissected calvaria were triply digested with 
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collagenase P and cultured for 5 days in AMEM containing 15% FCS at 37°C and 5% CO2 in a 
humidified chamber to allow osteoblast outgrowth. Osteoblasts were detached by trypsinization, 
strained to remove bone fragments, seeded into 150-mm culture dishes and allowed to expand 
under the same growth conditions as above. Upon reaching confluency, the osteoblasts were 
trypsinized and seeded into multiwell plates for experimentation. 
 
Virus stocks 
cDNA clones of SINV-TR339 (650), CHIKV-LR (651), EEEV-FL93-939 (626), and VEEV-
ZPC738 (652) have been described. Mutant viruses SINV-nsP2-726G (653), VEEV-CD-nsp2-
739L (116), and CHIKV-E2-79K (654) were generated by site-directed mutagenesis with 
appropriate overlapping primers and Quikchange kit (Agilent) according to the manufacturer’s 
instructions. The nanoluciferase-expressing CHIKV-LR-nluc-TaV and CHIKV-LR-E2-79K-
nluc-TaV viruses are described in (613). To generate virus stocks, infectious, capped RNA was 
generated by in vitro transcription from linearized clones (mMessage mMachine; Ambion) and 
electroporated into BHK-21 cells using a GenePulser II (Biorad) as previously described (655). 
Virus-containing supernatants were collected after 24 hours and titered on BHK-21 cells using a 
standard plaque assay. The DENV-2 strain 16681 was a gift from Jared Evans. Viral stocks were 
generated from a single passage on C6/36 mosquito cells and titers were determined by focus 
forming assay on human hepatocarcinoma Huh7 cells using anti-flavivirus D1-4G2-4-15 
antibody (ATCC). The YFV-Angola strain was a gift from Alan Barrett and stocks were made 
and titered as described (435). Experiments involving RFVF strain ZH501 (656) were conducted 
in the laboratory of Dr. Amy Hartman. Propagation and titration of this virus is described in 
(657). 
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Animals 
All experiments involving animals were carried out under approval of the Institutional Animal 
Care and Use Committee of the University of Pittsburgh and in accordance with the 
recommendations found in the Guide for the Care and Use of Laboratory Animals published by 
the National Institutes of Health. 5-6-week-old adult male and female C57BL/6 mice were 
purchased from Jackson Laboratories (RRID IMSR_JAX:000664) and 5-7-week-old adult male 
and female Ifnar1-/- mice on the C57BL/6 background were bred in-house. Mice were housed 
socially (maximum 5/cage for females and 4/cage for males) in SPF microisolator cages in our 
ABSL3 facility. Animals were kept on a 12-hour light/12-hour dark cycle with access to food 
and water ad libitum except in instances of experimental induction of metabolic torpor (detailed 
below). All mice weighed between 15 and 25 grams and were drug and test naïve prior to use in 
these studies. Prior to and upon initiation of experiments, all mice were weighed and checked for 
disease signs (lethargy, ruffled fur, hunching) daily to ensure maximal animal welfare in 
accordance with approved IACUC procedures. Animals of both sexes were divided randomly 
into experimental groups, such that experiments reflect pooled data from both sexes. 
  
Antibodies and other reagents 
The following antibodies were used for Western blotting and/or immunostaining: mouse anti-β-
actin (BA3R; Invitrogen; RRID AB_10979409), rabbit anti-STAT1 (M-22; Santa Cruz; RRID 
AB_632434), rabbit anti-ISG15 (H-150; Santa Cruz; RRID AB_2126309), rabbit anti-IFIT1 
(Invitrogen CAT# PA5-27907 for human/nonhuman primate samples; RRID AB_2545383), 
rabbit anti-IFIT1 (Invitrogen CAT# PA3-846 for murine samples; RRID AB_1958734), rabbit 
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anti-phospho-STAT1 (Tyr-701) (#9171; Cell Signaling Technology; used for Western blots; 
RRID AB_561284), rabbit anti-phospho-STAT1 (Tyr-701) (D4A7; Cell Signaling Technology; 
used for immunofluorescence; RRID AB_10950970), rabbit anti-phospho-STAT1 (Ser-727) 
(#9177; Cell Signaling Technology; RRID AB_2197983), rabbit anti-phospho-IRF3 (Ser-396) 
(#29047; Cell Signaling Technology). Anti-flavivirus group antigen D1-4G2-4-15 (ATCC HB-
112 hybridoma; RRID CVCL_J890) and mouse anti-YFV ascites fluid were used in flavivirus 
focus-forming assays. Human and murine IFNs α4 and β were prepared in-house as described 
(607). Lipopolysaccharides (LPS) from E. coli 0111:B4 were purchased from Sigma. Poly-I:C 
was purchased from R&D Systems. 
 
Treatment of cells with IFN-α/β, LPS, poly-I:C, and virus 
For experiments involving IFN or LPS treatment of cells, IFN-α/β (1:1 ratio of IFN-α4 to IFN-β; 
called IFN-α/β throughout) or LPS was applied directly to cells in media pre-warmed to room 
temperature or 30°C. IFN-α/β dosages selected for individual experiments represent the range of 
concentrations of IFN-α/β empirically determined to elicit robust ISG induction as well as 
observable dose-dependent anti-arboviral activity. The required dosage, then, necessarily varied 
according to the cell type used, the IFN-α/β sensitivity of individual viruses, murine vs. human, 
and the experimental aim. Dosages used for specific experiments are noted in the text and figure 
legends. LPS was used at a concentration of 250 ng/mL. After addition of the stimulus, cells 
were moved immediately to the appropriate temperature treatments and the stimulus was left 
until sample collection. For experiments involving poly-I:C treatment of cells, 50 µg poly-I:C 
was transfected into MEF cells using the Neon Transfection system (Invitrogen) at room 
temperature according to the manufacturer’s instructions and recommended settings. Pooled 
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transfections were then divided among temperature conditions. For experiments involving virus 
infection at different temperatures, all infections were performed for 1 hour at 30°C to minimize 
temperature-dependent variation in attachment and entry efficiency, unless otherwise noted. 
Cells were then washed in PBS and placed in fresh growth media before being placed in different 
temperature conditions. 
    
Viral growth curves 
Vero, MEF, or primary murine osteoblast cells were treated for 12-16 hours at 30, 37, or 39°C 
with 0 or 100-1000 IU/mL human (Vero) or murine (MEF/osteoblast) IFN-α/β, rinsed in room-
temperature PBS, and infected at a multiplicity of infection (MOI) of 0.1 as described above. 
Supernatants were harvested at the indicated time points and viral growth was determined by 
plaque assay on BHK-21 cells for alphaviruses, by focus-forming assay on Vero cells for 
flaviviruses, and by plaque assay on Vero cells for RVFV. All quantification assays were 
performed at 37°C. 
 
CPE inhibition assays 
Vero cells were treated for 12-16 hours at 30, 34, 37, or 39°C with 2-fold decreasing 
concentrations of human or mouse IFN-α/β in 96-well plates, beginning with 4000 IU. Cells 
were then infected at a MOI of 10 and returned to the original temperature condition for 96 
hours. The concentration of IFN-α/β necessary to inhibit 50% of cell death was determined 
visually by crystal violet staining. 
 
Western blotting 
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Protein lysates were taken in radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, pH 
7.4; 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 
1 mM EDTA, 1 mM EGTA) supplemented with protease inhibitors (1 mM 
phenylmethylsulfonyl fluoride, 1 µg/mL leupeptin, 1 µg/mL pepstatin), and a phosphatase 
inhibitor cocktail (Sigma). Protein concentrations were determined by bicinchoninic acid (BCA) 
assay (Pierce) according to the manufacturer’s instructions. Equal amounts of protein (15 µg) per 
sample were resolved by SDS-PAGE on a 10% polyacrylamide gel and proteins were transferred 
to a PVDF membrane (BioRad). Membranes were blocked in Tris-buffered saline with 0.1% 
Tween-20 (TBS-T) containing 5% milk for at least 1 hour. Primary antibody was diluted in TBS-
T containing 3% bovine serum albumin (BSA) and applied to membranes overnight at 4°C, then 
washed 4x in TBS-T (15 minutes per wash) and replaced with horseradish peroxidase (HRP)-
conjugated secondary antibody, diluted in a 2% milk/TBS-T solution. Secondary antibody was 
incubated at room temperature for at least 1 hour at room temperature or overnight at 4°C, then 
washed 4x in TBS-T, as above. Finally, membranes were exposed to Pierce ECL Western 
Blotting Substrate and signal was captured on x-ray film (GE Healthcare). Densitometry analysis 
was performed using ImageJ software (NIH).  
 
Quantitative PCR and NanoString 
Total cellular RNA was isolated from samples taken in TRIzol reagent (Ambion) per the 
manufacturer’s protocol using 1-Bromo-3-chloropropane (BCP) and isopropanol. For qRT-PCR, 
10 µg of RNA per sample was reverse-transcribed into cDNA using random hexamer primers 
and semi-quantitative PCR was performed using the Sybr Green method on an ABI 7900 Real-
Time PCR machine (Applied Biosystems) using gene-specific primers. See Table 1 for a 
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complete list of primer sequences. Ct values were normalized to 18S rRNA and compared using 
the ΔΔCt method (658).  
Table 1. List of primers used for qRT-PCR. 
Gene Name Sense (5’  3’) Antisense (5’  3’) 
Primate STAT1 CACGCACACAAAAGTGATGA ACATGTTCAGCTGGTCCACA 
Primate IFIT1 TCTCAGAGGAGCCTGGCTAAG CCACACTGTATTTGGTGTCTAGG 
Primate ISG20 CTCCTGCACAAGAGCATCCA CGTTGCCCTCGCATCTTC 
Primate ISG15 CACCGTGTTCATGAATCTGC CTTTATTTCCGGCCCTTGAT 
Murine Stat1 TTCAGAGCTCCTTCGTGGT TCGACTCTTGCAATTTCACC 
Murine Ifit1 TGGCTCACATAGAGCAGGA AGTTTCCTCCAAGCAAAGGA 
Murine Gbp2 TGAGAAGGGTGACAACCAGA AGCTCCGTCACATAGTGCAG 
Murine Isg20 GGCACTGAGACAGGGCTT CCATGGATGTTCACAATGCT 
Murine Il6 TTCCATCCAGTTGCCTTCTT CAGAATTGCCATTGCACAAC 
Murine Tlr2 ACAACTTACCGAAACCTCAGAC ACCCCAGAAGCATCACATG 
Murine Irf5 CACCTCAGCCGTACAAGATC GCCTGGTAGCATTCTCTGG 
Murine Ccl2 GTCCCTGTCATGCTTCTGG GCTCTCCAGCCTACTCATTG 
Murine Relb GCTGTACTTGCTCTGTGACA TGGCGTTTTGAACACAATGG 
Murine Cxcl10 TCAGCACCATGAACCCAAG CTATGGCCCTCATTCTCACTG 
Murine Nfkbiz GGAATAAGAGCCTGGTAGACAC AAGAGGCGAATGAGTTCCAG 
Murine Tnfaip3 ACAGGACTTTGCTACGACAC CTGAGGATGTTGCTGAGGAC 
Murine Gamma Actin 
Intron #3 ACAGAACGCAAGCAGAAACG TGGCATTTCCTCCCTGAAGC 
Murine Ifnb GAACATTCGGAAATGTCAGG ACTGTCTGCTGGTGGATGTC 
Murine Ifna4 CTGCTGGCTGTGAGGAAATA GAAGACAGGGCTCTCCAGAC 
18S rRNA CGCCGCTAGAGGTGAATTTCT CGAACCTCCGACTTTCGTTCT 
 
For NanoString, 100 ng RNA from each sample was subjected to fluorescent probe 
hybridization (see Table 2 for complete list of gene targets and probe sequences) and fluorescent 
barcodes corresponding to individual target mRNA molecules were counted automatically with a 
nCounter Analysis System (NanoString Technologies). All mRNA quantification steps were 
performed by the Genomics Research Core at the University of Pittsburgh. Raw mRNA counts 
for each target gene underwent background subtraction and housekeeping gene normalization 
using nSolver 2.6 software (NanoString Technologies). 
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Table 2. List of NanoString target genes and probe locations 
Gene Name Accession Number Probe Position 
β-Actin NM_007393.3 42-141 
γ-Actin ENSMUST00000071555.2 1090-1189 
ADAR1 NM_001146296.1 24-123 
AKT1 NM_001165894.1 899-998 
AKT2 NM_001110208.1 2505-2604 
ATF-1 NM_007497.3 1217-1316 
CCL2 NM_011333.3 416-515 
CCL5 NM_013653.1 166-265 
IKKα NM_001162410.1 223-322 
CIRP NM_007705.2 203-302 
CREB1 NM_001037726.1 2735-2834 
CREBBP NM_001025432.1 3771-3870 
CSE1L NM_023565.3 907-1006 
CXCL1 NM_008176.1 561-660 
CXCL10 NM_021274.1 116-215 
eEF2 NM_007907.2 1520-1619 
eEF2K NM_007908.3 1167-1266 
PKR NM_011163.4 407-506 
PERK NM_010121.3 503-602 
eIF2α NM_026114.3 666-765 
eIF3α NM_010123.3 755-854 
eIF4A1 NM_144958.4 1006-1105 
eIF4E NM_007917.3 697-796 
eIF4EBP1 NM_007918.3 555-654 
eIF4EBP2 NM_010124.2 236-335 
eIF4G1 NM_145941.3 1981-2080 
p300 NM_177821.6 4306-4405 
c-fos NM_010234.2 1331-1430 
GAPDH NM_008084.2 216-315 
GBP2 NM_010260.1 1997-2096 
GBP1 NM_010259.2 677-776 
HSP90ab1 NM_008302.3 1355-1454 
HSP70 NM_010478.2 2470-2569 
IFI27 NM_026790.2 167-266 
IFI44 NM_133871.2 991-1090 
IFI47 NM_008330.1 710-809 
IFIT1 NM_008331.2 891-990 
IFIT2 NM_008332.2 231-330 
IFIT3 NM_010501.1 1291-1390 
IFITM1 NM_001112715.1 413-512 
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IFNα4 NM_010504.2 262-361 
IFNAR1 NM_010508.1 1196-1295 
IFNAR2 NM_001110498.1 726-825 
IFNβ NM_010510.1 336-435 
IKKβ NM_010546.2 499-598 
IKKε NM_019777.3 619-718 
IKKγ NM_178590.2 526-625 
IL6 NM_031168.1 41-140 
IRAK1 NM_008363.2 952-1051 
IRAK4 NM_029926.5 251-350 
IRF1 NM_008390.1 366-465 
IRF2 NM_008391.2 441-540 
IRF3 NM_016849.4 527-626 
IRF5 NM_001252382.1 491-590 
IRF7 NM_016850.2 706-805 
IRF9 NM_008394.2 1406-1505 
ISG15 NM_015783.1 396-495 
ISG20 NM_020583.5 553-652 
JAK1 NM_146145.2 4081-4180 
c-jun NM_010591.2 2213-2312 
Importin α1 NM_008465.5 2671-2770 
Importin β1 NM_008379.3 5136-5235 
MEK NM_008927.3 1696-1795 
MAP2K3 NM_008928.4 1116-1215 
MAP2K6 NM_011943.2 321-420 
TAK1 NM_009316.1 823-922 
ERK2 NM_011949.3 1211-1310 
p38α NM_011951.2 1421-1520 
ERK1 NM_011952.2 826-925 
MCM5 NM_008566.2 2610-2709 
MKNK1 NM_021461.4 636-735 
MKNK2 NM_021462.3 2877-2976 
mTOR NM_020009.2 2433-2532 
MX1 NM_010846.1 2486-2585 
MX2 NM_013606.1 2096-2195 
MyD88 NM_010851.2 1596-1695 
IκBα NM_010907.1 941-1040 
Nfkbiz NM_030612.1 1306-1405 
OAS1a NM_145211.2 472-571 
OAS2 NM_145227.3 1149-1248 
PABP NM_008774.3 863-962 
PAP NM_011112.3 4117-4216 
PIAS1 NM_019663.3 1291-1390 
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PIAS3 NM_001165949.1 1137-1236 
PI3K p100α NM_008839.1 1256-1355 
PI3K p85 NM_001024955.1 5665-5764 
POLR2A NM_001291068.1 2769-2868 
PKCδ NM_011103.2 1266-1365 
PSMB9 NM_013585.2 541-640 
PTPN1 NM_011201.3 510-609 
SHP-2 NM_011202.3 3711-3810 
PTPN2 NM_001127177.1 1013-1112 
SHP-1 NM_013545.2 1692-1791 
Ran NM_009391.3 1756-1855 
RBM3 NM_001166409.1 537-636 
cRel NM_009044.2 1291-1390 
RelA NM_009045.4 646-745 
RelB NM_009046.2 2014-2113 
18S rRNA NR_003278.3 1019-1118 
RnaseL NM_011882.2 2387-2486 
RPS6 NM_009096.3 1196-1295 
S6K1 NM_028259.4 1079-1178 
Viperin NM_021384.4 341-440 
SOCS1 NM_009896.2 1021-1120 
SOCS3 NM_007707.2 586-685 
STAT1 NM_009283.3 1591-1690 
STAT2 NM_019963.1 363-462 
STAT3 NM_213659.2 2131-2230 
TBK1 NM_019786.4 441-540 
TBP NM_013684.3 71-170 
TRIF NM_174989.4 2160-2259 
TRAM NM_173394.2 1244-1343 
TIRAP NM_001177845.1 1109-1208 
TLR2 NM_011905.2 256-355 
TLR4 NM_021297.2 2511-2610 
TNFaIP3 NM_009397.2 233-332 
TRADD NM_001033161.2 563-662 
TRAF3 NM_011632.3 885-984 
TRAF6 NM_009424.2 981-1080 
β-Tubulin NM_009451.3 1820-1919 
Tyk2 NM_001205312.1 1533-1632 
USP18 NM_011909.2 1191-1290 
Exportin 1 NM_134014.3 1905-2004 
ZAP NM_028864.2 2586-2685 
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Biological interferon assays 
Concentrations of biologically active murine IFN-α/β was measured by bioassay as previously 
described (659). Briefly, supernatants or serum samples (200 µL) were acidified to pH 2.0 with 
2N HCl overnight at 4°C and then neutralized to pH 7.4 using 2N NaOH. Samples were serially 
diluted 2-fold across 96-well plates seeded with L929 cells and incubated at 37°C for 24 hours. 
Cells were then infected with 3x104 plaque-forming units (pfu) per well of encephalomyocarditis 
virus (EMCV) and incubated for an additional 24 hours at 37°C prior to fixation and staining 
with crystal violet. The concentration of IFN-α/β in each sample was calculated from the dilution 
required to protect 50% of cells from CPE, compared with a standard IFN-α/β dilution series of 
known concentrations. 
 
Immunofluorescence 
IFN-α/β- or poly-I:C-treated cells seeded on glass microscope slides were fixed in 4% 
paraformaldehyde at 4°C for at least 1 hour at the indicated times post-stimulation. Cells were 
permeabilized in 100% methanol at -20°C for 10 minutes and blocked in blocking buffer 
(phosphate-buffered saline with 3% BSA and 0.1% Triton X-100) containing 10% normal serum 
corresponding to the species of the secondary antibody for at least 1 hour at room temperature. 
Cells were then incubated overnight at 4°C with primary antibody diluted in blocking buffer, 
washed, and incubated with fluorescently-labeled secondary antibody and DAPI nuclear stain for 
1 hour at room temperature. Images were acquired on a Nikon A1 Confocal microscope or an 
Olympus CKX41 inverted epifluorescence microscope.  Image analysis was performed in NIS 
Elements v4.51.00. The DAPI channel was used to create a binary mask that identified both the 
nuclear location and individual cells. The intensity of the STAT-p channel for all pixels within 
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the nuclear mask was summed and then divided by the total number of pixels to produce the 
mean STAT-p signal per nucleus expressed as arbitrary fluorescence units (AFU). Mean STAT-p 
signal was plotted for individual cells. 
 
Protein radiolabel 
MEF cells were incubated at 30, 37, or 39°C for 1 or 12 hours. At each time point, growth media 
was replaced with labeling media (DMEM lacking cysteine and methionine (Cellgro) 
supplemented with 1% FBS and 1% Pen-Strep), and cells were returned to their temperature 
conditions for 15 minutes. Supernatants were then replaced with labeling media containing 
100µCi/mL [35S]-cys/met (MP Biomedicals) and plates were returned to their temperature 
conditions for another 15 minutes. Cells were rinsed in PBS and lysates were prepared with 
equal volumes of RIPA buffer. 20µL per sample was resolved on an 8% SDS-PAGE gel, which 
was then fixed and dried to allow for autoradiographic signal capture of x-ray film (GE 
Healthcare). Gels were exposed for 7 days at -80°C and resulting protein signal was quantified 
by densitomety analysis of all visible proteins in each lane using ImageJ software (NIH). 
 
Translation reporters 
Construction and production of host-mimic firefly luciferase-expressing mRNA translation 
reporter constructs have been described (385, 660, 661). MEFs or Infar1-/- MEFs were 
transfected with 5µg RNA reporter per reaction using the Neon transfection system (Invitrogen) 
according to the manufacturer’s instructions and recommended settings. Single transfections 
were divided among 30, 37, and 39°C temperature treatments for the appropriate time course and 
cell lysates were collected in passive lysis buffer (Promega). Firefly luciferase activity was 
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quantified using the Dual Luciferase Reporter assay kit (Promega) and light production measured 
on an Orion Microplate Luminometer (Berthold). Relative light unit (RLU) values were 
normalized to protein concentration in each sample, as determined by bicinchoninic acid assay 
(Pierce). Data are expressed at RLU/µg protein. 
 
Mouse core temperature reduction and infection 
5-6-week-old male and female C57BL/6 mice (Jackson Laboratories), Ifnar1-/- or Irf7-/- mice 
(bred in-house) were used for all experiments. For induction of metabolic torpor, mice were 
housed for 4.5 days in 24-hour low red light before torpor was induced by food withdrawal. Non-
torpid mice were also housed in red light but had access to food and water ad libitum. Food and 
normal light conditions (12h light/12h dark) were restored 48 hours after food withdrawal. For 
pharmacological temperature reduction, mice were given 300 µL intraperitoneal injections of 
1.5-2 mg/kg reserpine (U.S. Pharmacopeia Standard; Sigma) dissolved in 0.5% acetic acid. 
Reserpine solutions were prepared fresh by first dissolving the powder in 100% glacial acetic 
acid and then diluting to the desired concentration in sterile ddH2O. Final reserpine solutions 
underwent 0.22-micron filter sterilization before being injected into mice. Mice were given 0.5 
mg/kg booster doses as needed (when subcutaneous scruff temperature exceeded 30°C) to 
maintain core temperature reduction throughout an experiment. Control mice were given equal 
volumes of sterile 0.5% acetic acid only. Isoflurane-anesthetized mice were infected with 1000 
p.f.u. CHIKV-LR, CHIKV-LR-E2-79K, CHIKV-LR-E2-200R, SINV-TR339, or nanoluciferase 
(nLuc)-TaV viruses (described in (613)) in a 10 µL volume injected subcutaneously into the left 
rear footpad. For torpor experiments, infections took place 12 hours after food withdrawal. For 
reserpine experiments, infections were done 3 hours after reserpine treatment. All mice were 
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weighed and monitored for disease signs daily. Musculoskeletal disease in infected feet was 
quantified every 12 to 24 hours as described (93).  
On days 2 and 6 post-infection, groups of mice were sacrificed by isoflurane overdose 
and blood samples were collected by cardiac puncture before perfusion of tissues with PBS. 
Perfused tissues were extracted and homogenized, and viral load in each tissue was determined 
by plaque assay on BHK-21 cells. Serum was separated from whole blood samples using 
microtainer tubes (BD Biosciences) and IFN-α/β concentrations were determined by biological 
IFN-α/β assay, as described above. 
 
In vivo bioluminescence imaging 
Mice were anesthetized with a low-dose continuous stream of isoflurane using the Xenogen 
XGI-8 Gas Anesthesia System (Caliper Life Sciences). The nLuc substrate furimizine (Nano-Glo 
Luciferase Assay System; Promega) was diluted in sterile DPBS without Ca2+ and Mg2+ 
(Corning) and injected subcutaneously in the scruff (5 µL substrate in 500 µL total volume per 
mouse) and allowed to circulate for 4 minutes. After 4 minutes, bioluminescence was imaged 
using an IVIS Spectrum CT instrument (PerkinElmer). Exposure time was determined 
automatically according to signal strength using Living Image Acquisition Software 
(PerkinElmer). Resulting pseudocolored images, normalized for exposure time, were marked 
with regions of interest (ROIs) around the hind feet of each mouse, and luciferase signal was 
quantitated as average radiance (photons/sec/cm2/sr) in each ROI using Living Image software 
(PerkinElmer). 
 
Quantification and statistical analysis 
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Statistical significance for all experiments was determined using GraphPad PRISM software. 
Results were declared statistically significant when p was less than or equal to 0.05, for all 
statistical tests employed across experiments. Specific tests used as well as demarcations of 
additional levels of significance are detailed in the figure legends. All experiments were 
performed with at least two replicate samples per group, and all experiments were performed at 
least twice to confirm results, except for the NanoString analysis, which was performed once and 
select results were confirmed by qPCR. Data from single representative experiments are shown 
in the figures, and pooled data are presented as either mean ± SD or geometric mean ± geometric 
SD as appropriate. 
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APPENDIX A 
ABBREVIATIONS GLOSSARY 
AKT – protein kinase B 
APC – antigen-presenting cell 
AP-1 – activator protein 1 
Arbovirus – arthropod-borne virus 
C – capsid protein 
CARD – caspase recruitment domain 
CBP – CREB binding protein 
CCHFV – Crimean-Congo hemorrhagic fever virus 
CHIKV – chikungunya virus 
CIRP – cold-inducible RNA binding protein 
Crk – CT-10 regulator of kinase 
DC – dendritic cell 
DENV – dengue virus 
DLN – draining lymph node 
DPI – days post infection 
 164 
dsRNA – double-stranded RNA 
E1/E2/E3 – alphavirus envelope proteins 
ECSA – East/Central/South African 
EEEV – eastern equine encephalitis virus 
eIF – eukaryotic initiation factor 
GAS – gamma interferon activated site 
GCN5 – gene control non-derepressible 5 
HAT – histone acetyltransferase 
HDAC – histone deacetylase 
HIV – human immunodeficiency virus 
HMG – high mobility group 
HSP – heat shock protein 
IFIT – interferon-inducible protein with tetracopeptide repeat 
IFITM – interferon-induced transmembrane 
IFN – interferon 
IFNAR – IFN-α receptor 
Ig – immunoglobulin 
IKKε – inhibitor of NFκB kinase subunit epsilon 
IL – interleukin 
IOL – Indian Ocean lineage 
IRF – interferon regulatory factor 
ISG – interferon-stimulated gene 
ISG15 – interferon-stimulated gene 15 kDa 
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ISG20 – interferon-stimulated gene 20 kDa 
ISGF3 – interferon-stimulated gene factor 3 
ISRE – interferon-stimulated response element 
IVIS – in vivo imaging system 
JAK – Janus kinase 
JEV – Japanese encephalitis virus 
LACV – LaCrosse virus 
LGP2 – laboratory of genetics and physiology 2 
LPS – lipopolysaccharide 
MAPK – mitogen activated protein kinase 
MAVS – mitochondrial antiviral signaling protein 
MCM – minichromosome maintenance 
MCP – macrophage chemoattractant protein 
MDA5 – melanoma differentiation associated protein 5 
MOI – multiplicity of infection 
mRNA – messenger RNA 
MSD – musculoskeletal disease 
mTOR – mammalian target of rapamycin 
Mx – myxomavirus resistance protein 
MyD88 – myeloid differentiation primary response 88 
NFκB – nuclear factor kappa-light chain-enhancer of activated B cells 
NHP – nonhuman primate 
NK – natural killer cell 
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NLS – nuclear localization signal 
nLuc – nanoluciferase 
nsP – nonstructural protein 
OAS – oligoadenylate synthetase 
ONNV – o’nyong’nyong virus 
PAMP – pathogen-associated molecular pattern 
PI3K – phosphatidylinositol-3-kinase 
PIAS – protein inhibitor of activated STAT 
PKC – protein kinase C 
PKR – interferon-induced double-stranded RNA-activated protein kinase 
Poly-A – polyadenylate 
PRD – positive regulatory domain 
PRR – pattern recognition receptor 
qRT-PCR – quantitative reverse-transcription polymerase chain reaction 
RA – rheumatoid arthritis 
RAP1 – Ras-proximate 1 
RBM3 – RNA binding motif protein 3 
RdRp – RNA-dependent RNA polymerase 
RES – reserpine 
RIG-I – retinoic acid-inducible gene I 
RLR – RIG-I-like receptor 
RNaseL – ribonuclease latent 
ROI – region of interest 
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RRV – Ross River virus 
RVFV – Rift Valley fever virus 
Ser – serine 
SINV – Sindbis virus 
SOCS – suppressor of cytokine signaling 
ssRNA – single-stranded RNA 
STAT – signal transducer and activator of transcription 
TBEV – tick-borne encephalitis virus 
TBK1 – TANK-binding kinase 1 
TFIID – transcription factor II D complex 
TF – transframe protein 
TIR – toll/IL-1 receptor 
TLR – toll-like receptor 
TNF – tumor necrosis factor 
TRAF – TNF receptor-associated factor 
TRIF – TIR-domain containing adapter inducing interferon-β 
Tyk2 – tyrosine kinase 2 
Tyr – tyrosine 
USP18 – ubiquitin-specific peptidase 18 
VEEV – Venezuelan equine encephalitis virus 
Viperin – virus inhibitory protein, endoplasmic reticulum-associated, interferon-inducible 
WNV – West Nile virus 
YFV – yellow fever virus 
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ZAP – zinc finger antiviral protein 
ZIKV – zika virus 
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